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5. 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Immune‐mediated  adverse  drug  reactions  are  difficult  to  predict  and  can  be severe  in  nature.  Recently  observed  genetic  associations  highlight  the importance  of  specific  human  leukocyte  antigen  alleles  in  the  development  of certain  reactions.  The  mechanisms  underlying  antigen  formation  and subsequent  T‐cell  activation  require  further  investigation.  The  drugs  abacavir (HLA‐B*57:01)  and  ximelagatran  (HLA‐DRB*07:01  and  HLA‐DQA*02:01) represent compounds associated with skin and liver reactions respectively, for which a HLA association has been reported.  In  order  to  investigate  the  mechanism  of  HLA‐restricted  T‐cell  activation  a cohort of 400 healthy volunteers was established. Both functional lymphocytes and  DNA  were  isolated  and  stored.  Following  sequence‐based  HLA‐typing twenty‐six individuals expressing HLA‐B*57:01 were identified (1 homozygote, 25  heterozygotes)  and  101  individuals  (10  homozygotes,  91  heterozygotes) expressing HLA‐DRB*07:01 were identified.  T‐cells  from  these  volunteers were  utilised  in  in  vitro  assays.  The  first  assays employed  had  low  sensitivity  and were  unable  to  detect  any  drug‐specific  T‐cells either by proliferation or cytokine secretion. Seventy‐four CD8+ abacavir‐specific T‐cell clones however were generated from 3/3 volunteers expressing HLA‐B*57:01.  These  clones  secreted  an  array  of  cytokines  and  cytotoxic mediators  (IFN‐γ,  Granzyme  B,  perforin,  Fas  ligand)  in  response  to  drug incubation.   Chemically  reactive  metabolites  are  frequently  associated  with  adverse  drug reactions.  The  metabolism  of  abacavir  in  both  liver  and  immune  cell preparations  was  therefore  assessed.  In  human  liver  cytosol,  abacavir  was metabolised to three isomeric carboxylic acids (48±15% turnover at 20h). This reaction  proceeded  via  a  reactive  aldehyde metabolite  that  could  be  trapped with  methoxylamine.  Metabolism  was  blocked  by  the  addition  of  4‐methylpyrazole,  an  alcohol  dehydrogenase  inhibitor  (1000µM  =  91.7±3.9% inhibition; p<0.05). Low‐level carboxylic acid formation could be detected in an S9  fraction  (2%)  and  cytosol  (3.6%)  generated  from  antigen‐presenting  cells suggesting  that  T‐cell  clones  are  exposed  to  a  small  amount  of  the  aldehyde metabolite during cellular assays. The parent drug however is the predominant chemical entity present.  Cross‐reactivity  at  the  MHC‐TCR  interface  was  determined  with  a  number  of abacavir analogues.   The  interaction was  found  to be highly specific with only deuterated  abacavir  stimulating  T‐cell  clones  at  a  similar  level  to  abacavir. Dihydro abacavir only stimulated clones when used at high concentrations. The alternative enantiomer of abacavir  (1S,4R) and carbovir did not  stimulate any clones at any concentration investigated.      This work further highlights the involvement of T‐cells in drug hypersensitivity reactions  and  the  importance  of  previously  described  HLA  associations.  In addition, chemical restriction exists at the HLA‐TCR interface and is key to the activation  of  abacavir‐specific  T‐cell  clones.  The  metabolism  of  abacavir  to  a protein‐reactive metabolite can occur  in antigen‐presenting cells  therefore the potential  of  reactive  intermediates  to  activate  T‐cells  in  a  HLA‐restricted manner should be investigated. 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1.1 Introduction   Immune‐mediated  reactions  to  drugs  are  difficult  to  predict  and  can  be extremely  severe  in  nature.  Recent  genome‐wide  association  studies  have reported increased susceptibility to adverse drug reactions with the possession of  specific  human  leukocyte  antigen  (HLA)  alleles.  The  evidence  for  the involvement  of  drug‐specific  T‐cells  in  the  pathogenesis  of  many  of  these reactions  is  well  established  however;  the  molecular  basis  of  these  HLA associations is not fully understood.  
1.2 Adverse Drug Reactions 
1.2.1 Definitions  In  1972,  the  World  Health  Organisation  (WHO)  defined  an  adverse  drug reaction as follows:  “A  response  to  a  drug  that  is  noxious  and  unintended  and  occurs  at  doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological function” (WHO, 1972)  Though  still  relevant,  a more  comprehensive definition has been proposed by Edwards and Aronson (2000):  “An appreciably harmful or unpleasant reaction, resulting from an intervention related  to  the  use  of  a medicinal  product,  which  predicts  hazard  from  future administration and warrants prevention or  specific  treatment, or alteration of the dosage regimen” 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The  authors  suggest  that  the  latter  definition  is  more  useable  as  it  refers  to serious reactions, includes reactions caused by contaminants or excipients and includes reactions caused by prescription error.  
1.2.2 Impact and prevalence Adverse drug reactions (ADRs) represent a major clinical problem and a serious impediment  to  the  advancement  of  new  therapeutic  agents.  Despite  rigorous pre‐clinical and clinical testing strategies, approximately 3% of new compounds will  ultimately  be  withdrawn  from  the  market  due  to  safety  concerns, particularly in the first two years following approval (Lasser et al., 2002).   The  incidence  of  ADRs  and  their  associated  severity  identifies  them  as  a significant health issue worthy of investigation. In 2004, a prospective study of over  18,000  hospital  admissions  in  the  North‐West  of  England  found  that approximately  6.5%  were  attributable  to  an  adverse  drug  reaction (Pirmohamed et al., 2004).  Reactions were particularly prevalent in the elderly (median  age  in  ADR  group  =  76;  median  age  in  non‐ADR  group  =66)  and amongst women (59% in ADR group; 52% in non‐ADR group) (Pirmohamed et al.,  2004).  This  is  consistent  with  other  studies  in  which  data  from  multiple centres  in  the  UK  was  collated  (incidence  of  ADRs  12.9  per  10  000  patient months for males vs. 20.6 per 10 000 patient months for females)(Martin et al., 1998).  In  the majority  of  cases  patients  recovered  from  their  ADRs,  however 2.3% of ADRs were  classified  as  being directly  responsible  for patient  fatality 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(Pirmohamed  et  al.,  2004).   When  this was  put  in  the  context  of  the  cause  of death among all hospital patients, ADRs were associated with fatalities of up to 0.2%  (Lazarou  et  al.,  1998,  Pirmohamed  et  al.,  2004).  Based  on  this  estimate Lazarou  et  al.  suggest  that  ADRs  therefore  represent  between  the  fourth  and sixth leading cause of death in the US (Lazarou et al., 1998).   In  addition  to  the  direct  risk  to  patient  safety,  ADRs  have  serious  economic consequences.  Pirmohamed et al. estimated that ADRs cost the NHS more than £400  million  per  year,  representing  a  significant  financial  burden  (2004). Additionally,  pharmaceutical  companies  stand  to  lose  substantial  investment following  late  stage  withdrawal  of  a  compound.  Various  estimates  put  the financial cost of bringing a new drug to market at up to $800million (DiMasi et al., 2003).    
1.2.3 Classification Serious adverse drug reactions have been reported for a diverse array of drugs with varied indications and frequencies (Table 1.1). These reactions can largely be grouped  in  to  two major categories;  type A, on‐target  reactions and  type B off‐target reactions (Park et al., 1998).  Type  A  (on‐target)  reactions  are  generally  a  function  of  dose,  causing  an exaggerated  pharmacological  effect.  They  may  be  influenced  by  metabolism, drug  transporters  or  enzyme  induction/inhibition  by  co‐administered therapies. In most instances it is possible to control these types of reactions by careful  therapeutic  monitoring  or  through  dose  adjustment  based  on  the patient’s genetic background. Type A reactions represent the majority of ADRs. Type B (off‐target) reactions,  though  less  frequent are a  leading cause of drug 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• Type C‐ Chronic   These reactions are associated with long term use of a particular drug e.g iatrogenic  Cushing’s  syndrome  caused  by  raised  glucocorticoid  levels during treatment with prednisolone. 
• Type D – Delayed   These reactions may become apparent years after the end of treatment. For  example  secondary  tumours  associated  with  the  use  of  alkylating agents. This definition also applies to teratogenic drugs causing adverse effects  to  the  offspring  of  mothers  undergoing  drug  treatment  while pregnant e.g thalidomide and valproate are associated with birth defects. 











           










Rhabdomyolysis  <0.1%  2001  (Furberg and Pitt, 
2001) 





Isoniazid  Tuberculosis  Hepatotoxicity  10‐20%* 
1%§ 
Still in use  (Mitchell  et  al., 
1976) 
 




3%  2004  (Bresalier  et  al., 
2005) 




10‐16%  Still in use  (Wysowski  et  al., 
2007) 
Ximelagatran  Thromboembolism  Hepatotoxicity  7.9%*  2006  (Lee et al., 2005) + genotyping recommended  * elevated ALT    § overt hepatotoxicity  
1.2.4 Drug­induced liver injury Drug‐induced liver injury (DILI) is a rare but serious side effect and is a leading cause  of  withdrawal  of  newly  developed  drugs  from  the market.    Identifying potentially  hepatotoxic  drugs during  the development process  can be difficult due  to  limitations  in  the  experimental  systems  available  and  the  lack  of predictability of pre‐clinical animal models (Kaplowitz, 2005). This is especially relevant where the immune system is thought to be involved.  Idiosyncratic  adverse  reactions  occur  in  only  a  small  number  of  susceptible individuals at a  frequency thought to range between 1  in 10 000 and 1  in 100 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000  of  treated  patients  (Holt  and  Ju,  2006).  Consequently  many  of  these reactions cannot be detected during the development process and only become apparent when the drug is released to the wider population. This makes DILI a major  cause  of  post‐licensing  labelling  restrictions  and  drug  withdrawal (Watkins,  2005).  Careful  monitoring  is  required,  as  liver  injury  may  not  be apparent until weeks or months after the commencement of therapy and is not always confined to one area of the liver (Wilke et al., 2007).  During clinical trials a number of readouts are monitored in order to ensure the safety  of  participants.  Monthly  measurements  of  serum  liver  enzymes,  in particular  alanine  aminotransferases  (ALTs),  are  performed  routinely.  These enzymes are  released passively  from dying hepatocytes.  If mild elevations are recorded (i.e. 3 x ULN) sampling may be performed more frequently and severe elevations (i.e. 10 x ULN) are justification for immediate termination of the trial (Lee and Senior, 2005).   This can however mean that a  trial  is stopped before any overt symptoms of liver injury are actually observed and therefore the true hepatotoxic  potential  of  the  new  drug  may  not  be  fully  established.  The phenomenon of adaptation can also confound the situation as in some instances elevations  in ALTs are  transitory and resolve despite continuation of  the drug (Kindmark  et  al.,  2008).    The  mechanisms  responsible  are  not  widely understood,  although  the  down  regulation  of  metabolic  enzymes  has  been implicated in adaptation to repeated doses of paracetamol (Shayiq et al., 1999). It may also be the case that adaptation is dependent on the individual (Au et al., 2011).  
Chapter 1 – General Introduction 
  9 
Measurement of serum ALTs does not however give any indication of impaired liver  function.  For  this  reason  bilirubin  levels  are  commonly  measured alongside  ALTs.  A  build  up  of  bilirubin  in  the  serum  indicates  that  haem metabolism has  been  disrupted.   Much  smaller  fluctuations  in  bilirubin  levels are  tolerated  in  clinical  trials  (>2  x  ULN),  reflecting  the  severity  of  this  side effect.    The  combined  appearance  of  both  jaundice  (bilirubin  >2  x  ULN)  and heaptocellular injury  (ALT > 3 x ULN) is the basis of Hy’s law, which estimates that these cases are associated with 10‐50% mortality (Zimmerman, 1999).   Other tests used clinically include prothrombin time, which is a measure of the time taken for patient plasma to clot. A prolonged prothrombin time (INR ≥ 1.5) may  be  indicative  of  reduced  clotting  factor  synthesis  and  is  observed  during acute  liver  failure.    At  this  stage  it  may  be  necessary  to  consider  liver transplantation (Reuben et al., 2010).     Following observation of abnormal liver tests it can still be difficult to diagnose DILI  and  to  determine  causality.    The  number  of  patients  experiencing  a reaction  is  generally  low  and  so  it  must  be  confirmed  that  the  drug  is responsible and not another underlying disease state. A number of  ‘hallmarks’ of DILI can be used to aid diagnosis, these include: time of onset  (within a few weeks of beginning drug  therapy),  an  easing of  the  reaction when  the drug  is stopped,  and  a  more  severe  and  rapid  reaction  upon  rechallenge  (Lee  and Senior,  2005).  Diagnosis  can  however  be  confounded  by  the  use  of  multiple drugs,  hepatitis  infection and  congestive heart  failure.  Liver  tests may also be abnormal in obese or diabetic patients. 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1.3. Immunological Reactions Type B reactions can involve the immune system. ADRs with an immunological aetiology tend to be severe and are incredibly difficult to predict since there are few  preclinical  screens  capable  of  recapitulating  the  complex  nature  of  the immune system either in vivo or in vitro. These reactions will be the focus of the rest of this thesis. 
 


















































































cells ME = Maculopapular  exanthema,  BE  =  Bullous  exanthema,  PE  =  Pustular  exanthema. Adapted from (Pichler, 2003) 
 
1.3.2 Clinical Manifestations Skin  is  the  most  frequent  site  of  hypersensitivity  reactions.  The  severity  of symptoms depends on both the chemical agent administered and the individual. The  majority  of  cutaneous  ADRs  (>90%)  are  benign  exanthematous  or maculopapular eruptions (Hunziker et al., 1997) which first appear on the trunk and  upper  extremities,  before  becoming  widespread  (Roujeau,  2005).  They usually  begin  4‐14  days  after  beginning  drug  treatment,  although  sometimes may not appear until shortly after treatment has finished (1‐2days).   Drug  reaction  with  eosinophillia  and  systemic  symptoms  (DRESS)  is  a  more severe side effect.  It is associated with 1 in 10, 000 exposures to drugs such as antiepileptics  (e.g  lamotrigine)  and  sulfonamides  (e.g  sulfamethoxazole) 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(Roujeau, 2005). As the name suggests, this reaction commonly affects multiple organs  including  liver,  kidney  and  lungs  (Guillon  et  al.,  1992).  An  increase  in circulating  eosinophils  is  characteristic  and may  coincide with  an  increase  in circulating lymphocytes. Onset is generally later than other cutaneous reactions and may not be observed until 2‐6 weeks after first administration. DRESS has a mortality rate of about 10% (Roujeau, 2005), which can often be as a result of liver involvement. Viral reactivation is often observed during DRESS and can be used as  a diagnostic  criterion  (Suzuki  et  al.,  1998, Tohyama et  al.,  1998).  It  is currently  unclear  what  role  this  reactivation  has  in  the  pathogenesis  of  the disease  and  whether  it  is  a  cause  or  consequence  of  the  clinical  symptoms. Reactivation  of  human  herpes  virus  6  (HHV‐6)  is  measured  by  increases  in specific  IgG  and  viral  DNA.  This  however  is  often  not  detectable  until  several weeks after symptoms have commenced (Shiohara et al., 2006).  It  is  therefore possible that viral reactivation occurs as a result of T‐cell activation. It is not just HHV‐6 that has been implicated in DRESS. Transient increases in virus‐specific immunoglobulins  against  cytomegalovirus  (CMV),  HHV‐7  and  Epstein‐Barr virus (EBV) have also been observed (Aihara et al., 2001, Descamps et al., 2003). These elevations are thought to occur in a sequential manner though this order is not universal in all patients (Kano et al., 2006). Cells taken from skin lesions have been found to contain high levels of HHV‐6 DNA and express viral antigens at  an  early  timepoint  (Suzuki  et  al.,  1998).  Clinical  manifestations  could therefore be  caused by  the  expansion of  virus‐specific T‐cells  (Shiohara  et  al., 2006). 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Symptom  SJS  TEN  DRESS 
Mucous membrane  >90%  >90%  <30% 
Erosions  Several sites  Several sites  Mouth and lips 
Detachment of epidermis  Yes <10% of BSA  Yes >30% of BSA  No 
Hyperkeratosis/desquamation  No  No  Usual 
Neutropenia  No  30%  No 
Eosinophilia  No  No  90% 







Liver  Hepatitis 10%  Hepatitis 10%  Hepatitis 60% 
Heart  No  No  Myocarditis 
Lymph node enlarged  No  No  Usual 
Viral reactivation  Occasional  Occasional  Frequent  SJS=  Stevens‐Johnson  syndrome,  TEN=  toxic  epidermal  necrolysis,  DRESS=  drug reaction  with  eosinophilia  and  systemic  symptoms,  BSA=  body  surface  area,  ARDS= acute respiratory distress syndrome. Adapted from (Bachot and Roujeau, 2001) 
 
1.4 Immune activation 
1.4.1 Cells of the immune system The  immune  response  is  comprised  of  both  adaptive  and  innate  immunity. Innate  immunity  is  a  non‐specific,  generalised  response  often  as  a  result  of tissue damage/trauma or infection. Adaptive immunity is an acquired response, which specifically recognises antigens. A vast array of cell types are involved in both types of immunity. For the most part, immune cells have a short life span and are constantly replaced. All cell types originate from pluripotent stem cells found  in  the  bone  marrow  and  depending  on  various  stimuli,  including cytokines and hormones, a number of phenotypically different cell types can be generated. They can be divided into the following classes each with a specialised function: 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Lymphocytes  Lymphocytes constitute approximately 20% of the leukocytes found in blood. B, T and NK cell subsets are all derived  from lymphoid progenitor cells but have unique  functions  and  developmental  lineages.  B‐cells  initially  develop  in  the foetal liver before migrating to the bone marrow for further development. The general function of B‐cells is to produce and secrete antibodies. B‐cells express immunoglobulins,  which  serve  as  antigen  receptors.  Following  antigen encounter,  B‐cells  will  proliferate  and  differentiate  into  either  plasma  or memory cells. Plasma cells secrete antibodies with the same antigen specificity as  the  immunoglobulin  displayed  on  the  cell  surface.  These  antibodies  have several functions including the neutralisation or shielding of viral components, fixation of  complement  and opsonisation or  coating of  antigen  in order  to  aid phagocytosis. A  small number of  long‐lasting memory cells are also produced, which  circulate  in  a  resting  state  but  respond  rapidly  when  the  antigen  is encountered again. This is because memory cells express high affinity IgA or IgG molecules in contrast to the lower affinity Ig molecules expressed on naïve cells (Ig D and  IgM). Experimentally, B‐cells are  identified by  the expression of  cell surface  markers  such  as  CD19.  Specific  IgE  antibodies  are  associated  with immediate  hypersensitivity  reactions,  exemplified  by  the  β‐lactam  antibiotics (Torres et al., 2003).  T‐cells  develop  in  the  thymus.  It  is  the  T‐cell  receptor  (TCR)  that  determines antigen  specificity  and  each  T‐cell  will  only  express  one  TCR  hence  only recognising  a  small  number  of  antigens.    In  contrast  to  B‐cells  the  TCR  only recognises a small portion of the antigen, just a few amino acids. Upon exposure 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to an antigen, antigen‐specific T‐cells bearing the corresponding TCR will divide and differentiate to give a large population of effector T‐cells. Positive selection removes the vast majority (>95%) of newly developed thymocytes (Romagnani, 2006). T‐cells expressing TCRs that have no affinity for MHC‐peptide complexes die  of  neglect.  Surviving  cells  then  undergo  negative  selection  which  induces apoptosis in T‐lymphocytes expressing TCRs which have a high affinity for self peptides found on the surface of medullary epithelial cells (Romagnani, 2006).  Subsets  of  T‐cells  express  either  CD4  or  CD8  molecules.  Originally  this  was thought to suggest the effector function of T‐cells; CD4+ T‐cells were referred to as helper cells whereas CD8+ T‐cells were cytotoxic. However as some CD4+ cells can also have cytotoxic functions this distinction is no longer relevant (Marshall and Swain, 2011).   CD4+ T‐cells can also be divided according to the cytokines that  they produce.  Prior  to  antigen  exposure,  naïve  cells  are  known as  type 0 (Th0)  cells.  In  the  presence  of  IL‐2  activated Th0  cells will  become Th1  cells, whereas  in  the  presence  of  IL‐4  Th2  cells  will  be  produced.  Th1  cells subsequently produce IL‐2 and IFN‐γ whereas Th2 cells produce IL‐4, IL‐5, IL‐9 and  IL‐13  maintaining  differentiation  down  this  lineage  (Mosmann  and Coffman,  1989).  These  different  cytokine  profiles  then  influence  the  type  of immune response that occurs, Th1 cytokines promote cell‐mediated  immunity whereas Th2 cytokines promote a humoral  (B‐cell)  response. Th17 cells are a relatively newly discovered subset of T‐cells (Harrington et al., 2005) which are thought  to  have  a  role  in  diseases  such  as  rheumatoid  arthritis  and multiple sclerosis (Tesmer et al., 2008).  It  is thought that IL‐1β is a signal  for T‐cells to develop along this lineage (Acosta‐Rodriguez et al., 2007). 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Phagocytes  The main  function  of  phagocytes  is  to  engulf  pathogens  such  as  bacteria  and subsequently break them down.  This can be achieved in a number of ways and the different subsets of phagocytes will briefly be discussed here.    Monocytes develop from a myeloid progenitor cell. They circulate in the blood before migrating  into  tissues and differentiating  into macrophages. They have large numbers of lysosomes, which contain digestive enzymes that break down pathogens. In vitro, they are identified by the presence of CD14. Once matured, macrophages generally reside in tissues, however a small proportion will return to the circulation where they are also capable of presenting antigens to T‐cells. Kupffer cells are a specialised liver‐resident macrophage.  Neutrophils make up the majority of leukocytes found in blood (approximately 70%).  They  are  relatively  short  lived  in  the  circulation  and  migrate  to  the tissues  under  the  influence  of  chemoattractants  such  as  IL‐8.  They  are  a granular  cell  type  containing  several  different  types  of  granule.  These  include acidic  lysosomes  and  primary,  secondary  and  tertiary  granules  containing molecules  such  as  lactoferrin  and myeloperoxidase.  Neutrophils  are  activated during  local  tissue  damage  leading  to  degranulation  and  the  subsequent recruitment of other cell types.   
Accessory cells Accessory  cells  work  alongside  lymphocytes  in  order  to  initiate  an  immune response.  They  include  granulocytes  and  antigen‐presenting  cells  such  as dendritic cells. 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Eosinophils, basophils and mast cells have a granular morphology and release various mediators upon activation. A key constituent of eosinophil granules  is major  basic  protein,  a  cationic  molecule  capable  of  damaging  pathogens directly. The release of IL‐5 and eotaxin causes eosinophil recruitment to a site of inflammation. Eosinophils produce IL‐2, IFN‐γ, IL‐4, IL‐5 and IL‐10.  They also synthesise  leukotrienes  and  prostaglandins,  which  are  key  mediators  of  the inflammatory  response.  Basophil  granules  contain  inflammatory  mediators such  as  histamine,  IL‐4  and  leukotrienes.  Histamine  is  also  the  major constituent  of  mast  cell  granules.    Both  basophils  and  mast  cells  have  large amounts  of  IgE  on  their  outer membrane  and  antigen  engagement  and  cross‐linking of these molecules is likely to cause activation. Dendritic  cells  (DCs)  are  professional  antigen‐presenting  cells  and  specialised DCs resident in the skin are known as Langerhans cells. Circulating DCs have an immature  phenotype,  which  is  associated  with  low‐level  MHC  class  II  and costimulatory  molecule  expression,  high  endocytic  activity  and  low  T‐cell activation  potential.  Upon  encountering  antigen,  dendritic  cells  develop  a mature  phenotype  which  involves  increased  expression  of  MHC  class  II molecules,  reduced  endocytic  capacity  (Sallusto  et  al.,  1995),  expression  of costimulatory molecules e.g     CCR7, CCR1 and CCR5 (Sallusto et al., 1998) and secretion of IL‐12 (Cella et al., 1996). Other signals that promote dendritic cell maturation  include  toll‐like  receptor  signalling  by  bacterial  components  and pathogen  associated  molecular  patterns  (PAMPs)  such  as  lipopolysaccharide (LPS)  and  release  of  damage‐associated molecular  patterns  (DAMPs)  such  as HMGB1,  heat  shock  proteins  and  uric  acid  (Shi  et  al.,  2003).  The  mature phenotype is associated with migration to the lymph. DCs also have a key role in 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Extracellular  antigens  are  processed  via  a  second  pathway.  Only  specialised antigen‐presenting  cells  such  as  dendritic  cells  and  macrophages  process antigens  in  this  way.  Pathogens  are  phagocytosed  and  contained  within  an endosomal vesicle where enzymes digest the pathogen into peptide fragments. MHC  class  II  molecules  are  transported  from  the  endoplasmic  reticulum  in membrane‐enclosed  vesicles,  which  then  fuse  with  the  endosome,  allowing peptide loading to occur.   
1.4.3 Intracellular signalling following TCR activation Upon MHC‐peptide  engagement with  the TCR,  a  complex  signalling  cascade  is triggered  eventually  resulting  in  cellular  proliferation,  differentiation  and/or cytokine/growth  factor  release.  TCR‐triggering  i.e.  the  transfer  of  the  signal across  the  cell  membrane  is  a  complex  process,  which  is  still  not  fully understood.  Currently  proposed  models  suggest  either  a  conformational change, aggregation or  segregation of  the TCR‐CD3 complex  (Choudhuri et al., 2005).  Much  more  is  known  about  the  signalling  cascades  following  TCR triggering.  Induction of tyrosine protein phosphorylation by the Src kinases Lck and Fyn  is  an  early  event  in T‐cell  signalling  (Nel,  2002).    Phosphorylation  of immunoreceptor  tyrosine  based  activation  motifs  (ITAMs)  within  CD3  itself serves as a docking site for other proteins, in particular ZAP‐70 (Smith‐Garvin et al., 2009). In this way the TCR becomes a site for phosphorylation of a vast array of  substrates  initiating multiple  signalling pathways  that  ultimately  lead  to T‐cell activation. Targets of ZAP‐70 are transmembrane adapter protein linker for the activation of T‐cells (LAT) and SH2 domain‐containing leukocyte phospho‐
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protein of 76kDa  (SLP‐76). This begins  the  formation of  a  complex of  adapter and  effector  proteins  positioned  in  order  to  ensure  both  proximity  for subsequent  enzymatic  reactions  and  stability.  The  ultimate  consequences  of TCR  activation  include  enzyme  activation  (e.g  ERK,  JNK,  PKC),  production  of transcription factors (e.g NFAT, STAT3) and the release of signalling molecules such as Ca2+ and DAG.    
1.5 T­cell activation by drugs  The activation of the immune system by small molecules such as drugs presents an  interesting  dilemma  given  that  peptides  are  the  traditional  target  of  the immune  response.  A  number  of  mechanisms  by  which  small  molecules  can interact with  immune  receptors  have  been  proposed  and  are  outlined  below. These mechanisms are not mutually exclusive.  
1.5.1 Hapten hypothesis  Early studies dating back to the 1930s gave a first insight into the mechanisms underlying  T‐cell  activation  by  small  chemicals.  Landsteiner  and  Jacobs  were able  to  sensitise  guinea  pigs  to  low  molecular  weight,  chemically  reactive compounds  such  as  dinitrochlorobenezene  (DNCB)  and  hypothesised  that protein  conjugation  may  have  an  important  role  in  the  immune  response observed  (Landsteiner  and  Jacobs,  1935).  Low  molecular  weight  compounds such as drugs are unlikely to act as traditional antigens given their small size. It is  suggested  that  immune  recognition  only  occurs  following  the  irreversible binding  of  a  drug  to  host  proteins.  This  is  termed  the  hapten  hypothesis.  It 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Figure  1.2  The  hapten/pro‐hapten  hypothesis.  Drug  antigenicity  occurs  as  a  result  of metabolism and subsequent covalent modification of host proteins. Modified proteins are then processed within  the cell,  cleaved  into peptide  fragments and associated with MHC molecules prior to translocation to the cell surface. It is the MHC/peptide complex that is recognised by the T‐cell  receptor.  Antigens  generated within  the  cell  are  processed  via  a  proteasomal  pathway, associate  with  MHC  class  I  molecules,  and  elicit  a  CD8+  T‐cell  response.  Antigens  generated outside  of  the  cell  are  processed  via  an  endocytic  pathway,  associate  with  MHC  class  II molecules and elicit a CD4+ T‐cell response (see Figure 1.1).   
1.5.2 The pharmacological interaction (pi) concept The  ability  of  otherwise  inert  drugs  to  stimulate  an  immune  response  is somewhat at odds with the hapten hypothesis, and for this reason an alternative mechanism has been proposed. A direct, non‐covalent association between the drug, TCR and MHC is suggested.     This  is  known  as  the  pharmacological interaction (pi) with  immune receptors concept  (Pichler, 2002). A direct, non‐
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covalent association is thought to occur between the drug molecule, and either the TCR or MHC molecule (Figure 1.3). This is thought to be a labile association, which is readily reversible. T‐cells activated by a pi‐mechanism respond rapidly to  drug  incubation  as  evidenced  by  Ca2+  influx,  suggesting  that  processing pathways  are  bypassed  (Zanni  et  al.,  1998).    As  there  is  no  de  novo  antigen formation  it  is  hypothesised  that  stimulation  via  a  pi‐mechanism  therefore represents  stimulation  of  a  pre‐existing memory  cell  population  (Adam  et  al., 2011). 
 
Figure 1.3. The p‐i concept. A chemically inert drug is able to bind directly but non‐covalently either  to  an MHC molecule or  to  the T‐cell  receptor,  inducing  an  immune  response. This may include hydrogen bonds, Van der Waals  forces or hydrophobic  interactions. A peptide may or may not be present.  
1.5.3 Costimulation/danger hypothesis The danger model was proposed by Matzinger in 1994. It states that immunity is not a simple case of self vs. non‐self but rather  it  is  the context  in which an antigen is presented that determines whether an immune response is initiated (Matzinger,  1994).    Immune  activation  is  dependent  on  at  least  two  signals. 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Engagement  of  the  TCR with  an MHC‐peptide  complex  represents  signal  one.  This  alone  is  not  sufficient  to  stimulate  an  immune  response.  Signal  two  is derived from the interaction of various co‐stimulatory molecules expressed on the  antigen‐presenting  cell  (APC)  and  the T‐cell.  In  the  absence  of  signal  two, signal  one  leads  to  immune  tolerance.  The  danger  hypothesis  relates  to mechanisms by which signal 2 can be modulated. Both exogenous PAMPs  (e.g LPS,  peptidoglycan,  viral  RNA)  and  endogenous  DAMPs  released  from damaged/dead cells (e.g. heat shock proteins, HMGB1) can contribute to danger signalling.   A number of drugs have been found to induce danger signalling: 
• Sulfamethoxazole metabolites increase dendritic cell expression of CD40 (Sanderson et al., 2007).   
• Abacavir induces heat shock protein redistribution in antigen‐presenting cells (Martin et al., 2007).  
• Amoxicillin  drives  dendritic  cells  towards  a  more  mature  phenotype (Rodriguez‐Pena et al., 2006).  The potential of tissues to act as a source of danger signals or the local release of danger  signals  may  explain  why  some  reactions  are  confined  or  at  least commence in certain tissues.   
Chapter 1 – General Introduction 
  29 
1.5.4 Terms used to describe small molecules  The  following  terms  will  be  used  throughout  this  thesis  to  describe  the interactions of small molecules with the immune system: 
• Immunogen A molecule that can stimulate a cellular or an immune response 
• Antigen Any molecule that can bind specifically to an antibody or T‐cell receptor 
• Hapten A  small  molecule  that  only  induces  an  immunological  response  when bound to a larger macromolecule 
• Prohapten A  small molecule, which  following metabolism  is  able  to bind  to  larger macromolecules and induce an immunological response. 
• Co‐stimulatory molecule A molecule that can stimulate or polarise an immune response to various antigens. Any drug may exhibit several of these characteristics. 
1.5.5 Experimental approach to study drug hypersensitivity 
reactions A main focus of drug hypersensitivity research is the use of patient cells ex vivo. This  is  due  to  the  importance  of  host  factors  in  the  development  of  immune‐mediated  reactions  caused  by  drugs.  A  number  of  paradigm  compounds illustrating different mechanisms of T‐cell activation will be discussed. 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Nitrohalobenzenes Directly  protein  reactive  compounds  such  as  the  contact  sensitisers dinitrochlorobenzene  (DNCB)  and  trinitrochlorobenzene  (TNCB)  have  been utilised to explore the basis of the hapten hypothesis. These compounds belong to the larger class of nitrohalobenzenes, which all form the same dinitrophenol (DNP)  or  trinitrophenol  (TNP)  adduct,  regardless  of  the  substituted  halogen (Figure 1.4A). Covalent binding has been observed at both cysteine and  lysine residues (Maggs et al., 1986, Kitteringham et al., 1985) although it appears that protein modifications are selective, and dependent on the inherent reactivity of individual amino acids within a protein (Aleksic et al., 2007).      T‐cell  clones  can  be  isolated  from  sensitised  patients  and  are  both  CD4+  and CD8+ (Pickard et al., 2007),  indicating that antigens are formed both intra‐ and extracellularly.  The  T‐cell  response  is  however  processing‐dependent  and requires  the  presence  of  functional  antigen‐presenting  cells.  Confocal microscopy  has  revealed  that  extensive  binding  occurs  throughout  the  cell within  minutes  of  DNCB  incubation  (Pickard  et  al.,  2007).  Furthermore synthetic TNP‐modified peptides are able to stimulate T‐cells derived from mice originally  sensitised  to  TNCB  (Cavani  et  al.,  1995).  These  peptides  can  be derived  from  many  different  sources  (Kohler  et  al.,  1995),  though  the positioning of the modification within the peptide can alter the strength of the response  (Cavani  et  al.,  1995).  Importantly,  the  interaction  of  these  haptens with  MHC  molecules  has  also  been  investigated,  highlighting  that  these complexes can be recognised by T‐cells (Weltzien et al., 1996). However, given the multiple targets of hapten formation it is difficult to suggest what the major 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Sulfamethoxazole Hypersensitivity  reactions  to  sulfamethoxazole  occur  in  up  to  8%  of  patients   and are especially prevalent amongst cystic fibrosis and HIV patients (Lavergne et  al.,  2010,  Carr  and  Cooper,  1995).  The  availability  of  synthetic  protein‐reactive  metabolites,  which  are  known  to  be  formed  in  vivo,  has  aided  the elucidation  of  the  mechanisms  of  antigen  generation  (Figure  1.4B). Sulfamethoxazole undergoes CYP‐mediated oxidation to form a hydroxylamine (SMX‐NHOH) (Cribb et al., 1995). Reaction of SMX‐NHOH with molecular oxygen then  yields  nitroso  SMX  (SMX‐NO),  which  readily  binds  to  proteins.  Multiple mechanisms are thought to be involved in the T‐cell response and T‐cell clones isolated from hypersensitive patients reflect this. Distinct populations of T‐cell clones can be generated that are either parent drug specific, metabolite‐specific or  cross‐reactive  (Castrejon  et  al.,  2010).  T‐cell  clones which  are  activated  by the  parent  drug  respond  rapidly  (Zanni  et  al.,  1998)  and  in  the  absence  of antigen  processing  (Schnyder  et  al.,  2000)  (Castrejon  et  al.,  2010).    Washing antigen‐presenting cells pulsed with SMX  for 1h abrogates  the T‐cell  response (Castrejon  et  al.,  2010).  Metabolite‐specific  T‐cell  clones,  in  contrast,  are activated  rapidly  by  SMX‐NO,  but  require  longer  incubation  with  SMX.  This mirrors  the  time  required  for  the  formation of  irreversible protein  adducts  in 




Piperacillin Studies  involving  the  β‐lactam  antibiotic  piperacillin  illustrate  how  the combination of in vitro cell assays and advanced mass spectrometric techniques can  be  used  to  interrogate  the  mechanisms  of  antigen  formation  and presentation. The involvement of T‐cells in penicillin allergy is well established. Drug‐specific  T‐lymphocytes  can  be  detected  in  the  peripheral  blood  of hypersensitive  patients  via  both  LTT  and  cytokine  secretion  (Romano  et  al., 2004) (Rozieres et al., 2009)  (El‐Ghaiesh et al., 2012).  T‐cell clones can also be isolated, providing a platform through which the mechanisms of activation can be investigated.   There is long‐standing evidence of β‐lactams covalently binding to proteins and in  particular,  lysine  residues  (Levine  and  Ovary,  1961,  Jenkins  et  al.,  2009) (Padovan et al., 1997)(Figure 1.4C). This is due to the inherent reactivity of the β‐lactam ring, which opens following nucleophilic attack. Stable protein adducts are  subsequently  formed.  The  penicilloyl  product  is  the  major  antigenic determinant. Adduct formation is time‐dependent, with extensive modifications to  lysine  residues  on  human  serum  albumin  detectable  following  overnight incubation (El‐Ghaiesh et al., 2012, Jenkins et al., 2009).  Synthetic piperacillin‐albumin conjugates can stimulate T‐cell clones from hypersensitive patients in a concentration  dependent  manner  (El‐Ghaiesh  et  al.,  2012).    Furthermore, antigen‐presenting  cells  incubated with  piperacillin  for  16  hours  followed  by 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extensive  washing  are  capable  of  stimulating  T‐cell  clones  to  proliferate  and secrete  cytokines.  Some  clones  will  respond  after  pulsing  for  4  hours,  but pulsing for 1 hour will not stimulate clones (El‐Ghaiesh et al., 2012), These time‐points coincide with the in vitro formation of protein adducts.  A key finding of this work is that the synthetic adducts formed in vitro are also clinically relevant. Piperacillin‐modified albumin could be detected in all of the patients  undergoing  therapy,  irrespective  of  whether  they  had  experienced  a reaction  or  not  (Whitaker  et  al.,  2011).  Protein  modification  occurred specifically  at  lysine  residues  as  expected  following  in  vitro  incubation  of albumin with the drug. Given that these protein conjugates were detected in all patients  it  seems  clear  that  additional  host  factors  must  determine  the susceptibility of an individual to DHRs. 
1.6 Drug Metabolism As stated previously, the formation of chemically reactive metabolites can result in the haptenation of proteins and subsequent immune recognition. In order to fully  understand  the  mechanisms  underlying  T‐cell  activation  by  drugs  it  is therefore  important  to  investigate  drug  metabolism  alongside  and  in  the context of cellular responses. This can be achieved through characterisation of the metabolising capacity of the different cell types utilised in in vitro assays and determination of  the cellular  fate of drugs and/or  their metabolites. The basic principles  of  drug  metabolism  and  the  sources  of  chemically  reactive metabolites will therefore be discussed here. 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In order for a drug to reach intracellular compartments and its site of action, it must be lipophillic. However, lipophillic species are not readily eliminated. Drug metabolism is required to assist the effective excretion of drugs from the body and to prevent unwanted accumulation. Enzyme catalysed reactions convert the drug into a more water‐soluble  form, which can then be safely excreted in the urine. The  liver  is  the main site of drug metabolism reactions although almost all cells are metabolically active.  
1.6.1 Phase I drug metabolism reactions Phase  I  drug  metabolism  reactions  are  catabolic  and  introduce  or  reveal functional  groups  such  as  hydroxyl,  amino  or  thiol  groups  for  subsequent conjugation in phase II. This is a process often known as ‘functionalisation’. The  most  common  phase  I  reaction  is  oxidation.  Reduction  and  hydrolysis reactions  may  also  occur  but  are  less  frequent.  If  the  product  of  phase  I metabolism is sufficiently polar it may be excreted at this point.   
Oxidation Cytochrome  P450  enzymes  (CYPs)  are  a  superfamily  of  haem  containing proteins  which  play  a  major  role  in  oxidative  phase  I  metabolism.  There  are dozens of CYP isoforms which are grouped into families i.e. CYP1, CYP2 etc. and subfamilies  e.g  CYP1A,  CYP1B  etc.  based  on  their  homology  and  sequence similarity  (Nebert  et  al.,  1987).  Substrate  specificity  varies  between  isoforms though may  be  shared  by  subfamilies. Molecular  oxygen,  NADPH  cytochrome P450  reductase  and  NADPH  are  required  for  CYP‐mediated  metabolism.  A 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Alcohol oxidation    Ethanol Compiled from (Gibson and Skett, 2001)   Though  liver  is  the  main  site  of  drug  metabolism  some  CYPs  are  specifically expressed  in  other  organs.  These  include  CYP2J2  which  is  heart‐specific  and CYP4A11 which is kidney‐specific, though these isoforms are not known to have any  significant  contribution  to  drug metabolism.  Lymphocytes,  dendritic  cells and  keratinocytes  express  some  CYP  isoforms,  in  particular  from  the  CYP1 superfamily  (Sanderson  et  al.,  2006).  The  presence  of  these  enzymes  is important  to  consider  when  discussing  chemically  reactive  metabolites  that 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might  only  need  to  be  formed  in  low  levels  in  target  organs  to  generate antigenic determinants that activate an immune response (see 1.6.4).  Other  enzymes  involved  in  phase  I  oxidative  reactions  include  alcohol  and aldehyde dehydrogenases, aromatases, amine oxidases and xanthine oxidase.  
Reduction and hydrolysis Reduction reactions can occur at nitro, keto or sulfoxide groups. Some reactions may  involve  CYP  enzymes  however  molecular  oxygen  is  not  required.  Hydrolysis reactions often occur in the plasma. They may be catalysed by tissue esterases or  in some circumstances occur spontaneously. This  is  the case with acetylsalicylic  acid  (aspirin).  Groups  particularly  susceptible  to  hydrolysis reactions include esters, which are hydrolysed to an acid and alcohol.  
1.6.2 Phase II drug metabolism reactions Phase II reactions are anabolic reactions. They often occur subsequent to a prior phase  I  reaction and result  in a more polar, hydrophilic  species, which can be effectively  excreted  in  the  bile  or  urine. As  phase  II  reactions  are  conjugation reactions  they  generally  require  the  formation  of  an  energy‐rich  donor molecule.  The  most  significant  phase  II  reaction  is  glucuronidation  which  is catalysed  by  UDP  glucuronyl  transferase  (UGT)  located  in  the  ER.  Glucuronic acid must  first  be  activated  via  conjugation with  uridine  diphosphate.  This  is then  attached  to  the  substrate.  This  is  a  major  route  of  metabolism  for carboxylic  acid  containing  drugs,  which  subsequently  form  acyl  glucuronides (Miners and Mackenzie, 1991). Some acyl glucuronides have been implicated in 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drug toxicity due to their ability to bind covalently to protein in vitro, however whether these are the causal chemicals in vivo remains uncertain (Regan et al., 2010).  Some  phase  I  reactions  will  result  in  the  formation  of  potentially  damaging electrophilic  species.  Reduced  glutathione  (GSH)  is  an  important  protective compound which is involved in the detoxification of these chemicals (Forman et al.,  2009).  It  is  a  nucleophilic  tripeptide,  consisting  of  glycine,  cysteine  and glutamate  residues.  The  cysteine  residue  contains  a  sulfhydryl  group  (‐SH), which in its reduced state is able to donate an electron to electrophilic species. This  reaction  is  catalysed  by  glutathione‐S‐transferase.  Though  glutathione conjugates may  be  directly  excreted  in  the  urine  further metabolism may  be required in order to yield a more hydrophilic product   
1.6.3 Bioactivation and chemically reactive metabolites As  alluded  to  previously,  the  metabolism  of  some  chemical  compounds  can result  in  the  formation  of  chemically  reactive metabolites  (CRMs).  These may have  direct  toxic  effects  through  binding  to  specific  ‘critical’  proteins  e.g enzymes or transporters (Park et al., 2005a).   The two main types of CRM are electrophiles and free radicals (Williams et al., 2002)  Electrophiles  lack  electrons  and  hence  react  with  electron‐donating nucleophiles. Both electrophiles and nucleophiles can be ‘hard’ or ‘soft’ and this determines  the kinds of  reactions  they will be  involved  in  (Jacobs, 1997). Soft electrophiles  have  a  low  energy  unoccupied  molecular  orbital  and  are  often uncharged. Targets of  soft electrophiles  include  thiol groups  found  in cysteine 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residues.  Hard  electrophiles  have  a  high  charge  densitiy.  Hard  electrophiles react with hard nucleophiles such as basic groups  in DNA and  lysine residues. Metabolites with unpaired electrons are known as free radicals. Free radicals do not  usually  form  covalent  bonds,  but  rather  abstract  hydrogen  molecules (Williams et al., 2002). This can lead to chain reactions and lipid peroxidation.  The  ability  of  a  compound  to  form  CRMs  is  investigated  during  drug development  and may  influence whether  a  candidate  is  continued  through  to clinical trials (Park et al., 2011). These studies can be performed via two main methods.  Covalent  binding  experiments  can  be  performed  with  radiolabelled compound  either  in  vitro  or  in  vivo  (Park  et  al.,  2011).  Adducts,  in  particular thioether or glutathione conjugates can also be detected via mass spectrometry. Incubations are performed in vitro with either microsomes or whole cell/tissue preparations  or  analysis  of  serum  or  urine  following  in  vivo  dosing  can  be achieved. Protein binding is however not always predictive of ADR risk. Indeed the  formation  of  glutathione  conjugates  is  indicative  of  bioinactivation,  hence their detection suggests the efficient detoxification of CRMs in vivo. 
 
1.6.4 Local production of chemically reactive metabolites  Though the liver is the main site of drug metabolism most cells in the body can be metabolically active. The  local  formation of chemically reactive metabolites may explain the organ‐specific toxicity of some drugs and chemicals (Sanderson et al., 2006). A significant number of drug metabolising enzymes are expressed in  skin  and  it  is  thought  to  be  the  site  of  bioactivation  for  many  chemicals associated with contact dermatitis (Merk et al., 2007, Bergstrom et al., 2007, Ott 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1.7 The major histocompatability complex Individual  variation  is  a  key  aspect  of  drug  hypersensitivity  research. Polymorphisms  in  drug  metabolising  enzymes  can  impact  upon  the susceptibility of certain individuals to experiencing an adverse reaction. Recent work however also suggests a role for genes within the MHC region.  
1.7.1 Location and variation The MHC  region  comprises  a  cluster  of  genes  spanning  around  3.4Mb  on  the short  arm  of  chromosome  6.  Genes  in  this  region  have  a  key  role  in  both adaptive and innate immunity.  Strong linkage disquilibrium extends across the entire region such that groups of alleles may be inherited as haplotypes (Daly et al.,  2001).  The  MHC  region  is  the  most  polymorphic  region  in  the  human genome. Traditionally,  this high  level of polymorphism in this region has been attributed  to  the  increased  viral  protection  offered  by  heterozygosity (heterozygote  advantage)  (Doherty  and  Zinkernagel,  1975).  Classical  MHC genes  encode  a  diverse  array  of  cell  surface  glycoproteins  involved  in  the presentation of antigens to T‐cells (see 1.4.2). In humans, the MHC class I and II genes  are  specifically  known as human  leukocyte  antigen  (HLA)  class  I  and  II genes.  
1.7.2 MHC Class I   MHC class I molecules are expressed by almost all nucleated cells. They include the  HLA‐A,  HLA‐B  and  HLA‐C  loci.  Class  I  molecules  consist  of  one  gene 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encoding a polymorphic light chain (α) and share a common β‐chain (β2m) the gene  for  which  is  not  located  in  the  MHC  region  (Figure  1.5).  β2m  is  not membrane bound but plays a key role  in transporting newly synthesised MHC molecules  to  the  cell  surface.  The  peptide‐binding  groove  accommodates peptides  of  between  9  and  11  amino  acids  in  length  and  is  restricted  at  both ends. Hydrogen bonds and Van der Waals forces secure the peptide in place.  
1.7.3 MHC Class II In  contrast  to  the  class  I  molecules,  class  II  molecules  are  only  expressed  by specialised antigen‐presenting cells such as dendritic cells, macrophages and B‐cells. They are encoded by the HLA‐DR, HLA‐DQ and HLA‐DP loci. The genes for both the α and β chains are located within the MHC region. Longer peptides can be  accommodated  in  the  peptide‐binding  groove  of  class  II molecules  as  they are open at both ends. 
 








1.7.5 HLA nomenclature The  vast  diversity  of  HLA  alleles  could  not  have  been  anticipated  when  they were first discovered, for this reason many changes have been made to the way in which they are named. Early work in the field was based on the observation that  serum  taken  from patients  that  had  received multiple  blood  transfusions caused  the  in  vitro  aggregation  of  platelets  (Dausset  et  al.,  1952).  This  was originally  attributed  to  the  presence  of  an  antibody  directed  against  the platelets.  HLA‐A  and  HLA‐B  antigens  were  identified  shortly  afterwards (Dausset, 1958). The HLA‐C locus was not discovered until 1970 (Thorsby et al., 1970).  The  first  class  II  alleles were  identified  eight  years  later  (Albert  et  al., 1978).  Initially naming was assigned based on serological typing. This was performed using  the  microlymphocytotoxicity  assay  of  Terasaki  et  al  (1964).  T  and  B‐lymphocytes  were  isolated  from  the  patient  and  exposed  to  a  selection  of antisera containing antibodies to individual HLA molecules. Antibody reactivity was used to identify the antigens expressed at the cell surface. Gene sequencing however,  now means  that  differences  in  single  amino  acids  that  could  not  be identified by serologic techniques are now detectable. This necessitated a new method of naming alleles and it is this system that is still in use today. Figure 1.6 details  the  current  system  of  naming  HLA  alleles.  The  letter  immediately succeeding  HLA  e.g  A,  B,  C  etc.  identifies  the  locus.  The  asterix  immediately following signifies that the allele has been assigned based on molecular typing techniques.  This  is  followed  by  a  series  of  numbers.  The  first  two  digits 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1.7.6 HLA associations in adverse drug reactions Recent  genome‐wide  association  studies  suggest  that  one  of  the  additional factors required for drug immunogenicity may be the genetic background of the patient, in particular, the possession of specific human leukocyte antigen (HLA) alleles. A  first clue  that genetic  factors may be  involved  in  the development of drug  hypersensitivity  reactions  was  a  case  of  carbamazepine‐induced mucocutaneous  syndrome  observed  in  monozygotic  twins  (Edwards  et  al., 1999).  An  association  between  HLA‐B*57:01  and  abacavir  hypersensitivity syndrome was reported in 2002 (Mallal et al., 2002, Hetherington et al., 2002) and  since  then  a  number  of  genetic  markers  have  emerged  for  both  skin reactions  (e.g  carbamazepine  (Chung  et  al.,  2004,  McCormack  et  al.,  2011), allopurinol  (Hung  et  al.,  2005)  and nevirapine  (Martin  et  al.,  2005))  and  liver reactions (e.g lapatinib (Spraggs et al., 2011), lumiracoxib (Singer et al., 2010), ximelagatran  (Kindmark  et  al.,  2008)  and  flucloxacillin    (Daly  et  al.,  2009)) (Table  1.5).    Associations  are  not  confined  to  any  particular  clinical manifestation  or  any  class  of  compound. However,  the  associations  described 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for  liver  reactions  have  to  date  been  weaker  than  those  observed  for  skin reactions. To further complicate the issue some associations can be confined to a particular ethnic group (Lonjou et al., 2008, McCormack et al., 2011) although this may reflect the different frequency of risk alleles in different populations.    The  strength  of  a  genetic  association  can  be  determined  by  calculation  of  an odds ratio (OR). This value compares the frequency of the risk allele in affected and unaffected groups (i.e. patients that have experienced an adverse reaction and  those  that  have  not)  and  can  be  calculated  by  generating  a  2  x  2  table (Figure 1.7). It gives an indication of effect size. 
                     
























































































The utility of screening for these alleles prior to prescription is dependent on a number of considerations, including the positive and negative predictive values, prevalence of the allele and transferability across different populations (Phillips and Mallal,  2010).  In  a  recent  study of  flucloxacillin  induced  liver  injury,  over 80% of patients carried the HLA‐B*57:01 allele compared to 6% of the controls (Daly et al., 2009). However, despite this strong association only 1 in 500 to 1 in 1000  individuals with  the  risk  allele  are  likely  to  develop  DILI, meaning  that were  prospective  screening  to  be  introduced  a  high  number  of  patients  who would not develop a reaction would be denied treatment (Daly et al., 2009). It has been estimated that over 13,000 patients would need to be tested in order to  prevent  one  case  of  flucloxacillin‐induced  liver  injury,  compared  to  just  13 patients  in  abacavir  hypersensitivity  (Phillips  and  Mallal,  2010).  It  would therefore  seem  that  the  allele  is  required  for  the  toxicity  to  develop  but  that other  factors  are  also  involved.  This  may  include  the  immune  status  of  the individual, history of infection or other concurrent mediations. In this case HLA‐typing may serve as more of a diagnostic rather than predictive marker.  Genetic screening prior to prescription is now recommended for both abacavir and  carbamazepine  (in patients  of Asian  ancestry)  and has been  successful  in reducing  the  incidence  of  DHRs  to  these  drugs  (Phillips  and  Mallal,  2009) (Rauch  et  al.,  2006).  As  described  previously  the  physiological  role  of  HLA molecules is to present peptides derived from pathogens at the cell surface to T‐cells.  The  observed  genetic  associations may  therefore  represent  a  functional consequence of polymorphism within the peptide‐binding groove. With this  in 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mind  in  vitro  assays  utilising  cells  from  a  known  genetic  background  are required and have been developed in this thesis.  The  drugs  abacavir,  carbamazepine,  flucloxacillin  and  ximelagatran  will  be discussed further. 
1.8 Abacavir 























1.8.4 Hypersensitivity and HLA association Hypersensitivity  reactions  to  abacavir  were  observed  early  in  clinical development  (Saag et  al.,  1998).    Symptoms were  typical of HSS and  included fever,  nausea  and  skin  rash  within  6  weeks  (median  =11  days)  of  starting treatment  (Hetherington  et  al.,  2001).  In  2002,  two  groups  independently reported  an  association  with  HLA‐B*57:01  and  susceptibility  to  abacavir hypersensitivity  (Hetherington  et  al.,  2002,  Mallal  et  al.,  2002).  Following  a large‐scale  double‐blind  randomised  prospective  study,  the  effectiveness  of genetic screening for the risk allele prior to prescription was established (Mallal et al., 2008) and has since been introduced on a global scale, effectively reducing the incidence of the reaction (Phillips and Mallal, 2009).  Epicutaneous patch testing, whereby the drug is applied to a small area of skin     has improved the identification of true abacavir hypersensitivity (Phillips et al., 2002) and has also improved the predictivity of HLA‐B*57:01 testing (Mallal et al., 2008). This  is particularly  important given  that  in  some  instances patients were diagnosed with HSS despite the fact that they were not receiving the drug (DeJesus et al., 2004, Gulick et al., 2006).  Over estimation of the clinical problem may  also  be  the  reason  for  concerns  having  been  raised  regarding  the transferability of the genetic marker across ethnicities (Hughes et al., 2004).  The immune basis for the adverse event is well established. Abacavir stimulates the  specific  release  of  pro‐inflammatory  cytokines,  including  interferon‐γ (Almeida  et  al.,  2008)  and  TNF‐α  (Martin  et  al.,  2004)  from  peripheral  blood mononuclear cells (PBMC) of hypersensitive patients ex vivo. Skin biopsies from 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inflamed skin of hypersensitive patients show a marked infiltration of CD8+ T‐cells,  suggesting  that  tissue  damage  develops  as  a  result  of  cytotoxic  T‐cell activity (Phillips et al., 2002). The activation of antigen‐presenting cells through redistribution  of  Hsp70  following  abacavir  exposure  has  also  lead  to  the suggestion  that  the  drug may  induce  signalling  pathways  leading  to  effective drug antigen presentation in individuals with the HLA‐B*57:01 allele (Martin et al., 2007).  Innovative studies by Chessman et al. (2008) recently defined the role of HLA‐B*57:01  in  the  disease  pathogenesis.  Abacavir‐specific  T‐cell  responses  were detected  in  vitro  using  lymphocytes  from  healthy  volunteers  expressing HLA‐B*57:01, but not other closely related HLA alleles (Chessman et al., 2008). The fine  specificity  of  the  abacavir  MHC  interaction  was  mapped  to  the  B*57:01 antigen‐binding F pocket where a serine residue at position 116 was important for drug antigen presentation.  
1.9 Other adverse drug reactions with HLA associations  
1.9.1 Carbamazepine Carbamazepine  (Figure  1.12A)  is  an  anticonvulsant  used  in  the  treatment  of epileptic seizures. Its action is caused by the blockade of voltage‐gated sodium channels, which  causes  a  reduction  in  the  propagation  of  action  potentials.  It can also be used in the management of nerve pain and bipolar disorder. 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Carbamazepine  is  a  substrate  for CYP3A4 and can be oxidised at  a number of positions.    Chemically  reactive  metabolites  have  been  identified  including  an arene  oxide  (Madden  et  al.,  1996)  and  a  quinone  (Ju  and  Uetrecht,  1999) however  they have yet  to be directly  implicated  in cellular damage. The 10,11 epoxide  (Figure  1.12B)  is  an  active metabolite  and  is  further metabolised  via epoxide  hydrolase  prior  to  excretion.    Interestingly  carbamazepine  is  also  an inducer  of  CYP  enzymes,  meaning  that  it  increases  its  own  clearance  after repeated doses. This can also lead to unfavourable interactions with other drugs such as the oral contraceptive.  
Figure 1.12 Chemical structures of carbamazepine (A) and its 10,11 epoxide metabolite (B).  A  range  of  cutaneous  adverse  reactions  have  been  associated  with carbamazepine use, from the relatively mild MPE, increasing in severity to HSS and SJS/TEN. An  immune pathogenesis has  long been  suggested based on  the characterisitics of the reaction including time of onset and increased severity of the  symptoms upon  rechallenge  (Leeder,  1998).  Furthermore, PBMCs  isolated from  hypersensitive  patients  proliferate  when  exposed  to  carbamazepine  in 
vitro  (Naisbitt  et  al.,  2003),  indicating  that  T‐cells  are  important  in  the  recall response.  The  generation  of  T‐cell  clones  has  also  provided  a  means  to 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investigate  the  phenotype  and  specificity  of  responding  cells.  Both  CD4+  and CD8+  T‐cell  clones  were  identified,  which  also  expressed  the  skin‐homing receptors  CTLA  and  CCR10  (Wu  et  al.,  2007).    Incubating  the  clones  with analogues  and  metabolites  of  carbamazepine  revealed  a  mixture  of  highly specific and cross‐reactive T‐cells (Wu et al., 2006).     In 2004, a case‐control study performed in Taiwan found that the HLA‐B*15:02 allele  was  present  in  all  of  the  patients  with  SJS  (44/44)  but  only  3%  of carbamazepine‐tolerant controls (3/101). The authors reported an odds ratio of 2504,  a  figure  that  remains  one  of  the  strongest  HLA  associations  to  be reported. A follow‐up study however revealed that the genetic association only applied  to  SJS/TEN  and  not  some  of  the milder  reactions  (Hung  et  al.,  2006). Attempts  to  replicate  the  genetic  association  in  other  study  populations  have also  met  with  mixed  results.    Studies  performed  with  patients  from  a  Han Chinese background have echoed the findings of the original study (Man et al., 2007, Locharernkul et al., 2008).  In European studies however, the association with HLA‐B*15:02  has  not  been  repeated  (Lonjou  et  al.,  2008,  Alfirevic  et  al., 2006). It has been suggested that this disparity could reflect both the increased frequency of SJS  in Han Chinese populations compared  to Caucasians  (8 cases per million person years vs. 2‐3 cases per million person years)  (Chung et al., 2004) and the reduced frequency of the risk allele in Caucasians. The strength of the  association  in  Han  Chinese  populations  warrants  prospective  genetic screening  in  patients  of  this  background  and  this  is  now  reflected  in  drug labelling (Phillips and Mallal, 2010). 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More  recently  a  second  genetic  association has  been  reported  from groups  in both  Japan  and  Europe  suggesting  that  HLA‐A*31:01  is  a  risk  allele  in  these populations  (McCormack et  al.,  2011, Ozeki  et  al.,  2011). This  association was considerably weaker  than  the  original  study  but  relevant  to  all  forms  of  drug reaction  and  transferable  across  ethnicities.  It  is  unclear  what  this  suggests about the underlying pathogenesis of the reaction however, as it is unlikely that different routes of antigen formation and presentation are present in patients of different ethnicities.  





A  5‐hydroxymethyl  metabolite  formed  via  CYP3A4  metabolism  has  been identified  as  toxic  to  human  biliary  cells  in  vitro  (Lakehal  et  al.,  2001). When media from hepatocytes pretreated with flucloxacillin was added to cultures of biliary  epithelial  cells  a  significant  increase  in  lactate  dehydrogenase  release was observed in 50% of preparations. Neither flucloxacillin nor the metabolite was  directly  toxic  to  hepatocytes.  This  does  not  however  explain  why  only certain individuals develop liver injury.  In  2009  a  GWAS  study  highlighted  that  84%  of  patients  (43/51)  with flucloxacillin‐induced  liver  injury carried  the HLA‐B*57:01 allele,  compared  to just  5%  of  the  population  controls  (Daly  et  al.,  2009).  Interestingly  the  HLA allele  (B*57:01)  identified  is  also  associated  with  abacavir  hypersensitivity reactions. The association may  therefore  indicate a possible  role  for T‐cells  in the  pathogenesis  of  the  reaction.  Indeed  positive  LTTs  to  flucloxacillin  have previously been recorded (Maria and Victorino, 1997). The reasons why liver is targeted  however  are  unclear  although  a  role  for  drug  metabolism  could  be hypothesised.  Both  flucloxacillin  and  the  5‐hydroxymethyl  metabolite covalently bind to HSA and at very similar positions within the protein (Jenkins et al., 2009). This has been shown both in vitro and also in vivo, where modified peptides  could  be  detected  in  the  plasma  of  all  patients  examined  (8/8),  this may therefore implicate hapten formation in the adverse reaction. 
1.9.3 Ximelagatran The  novel,  direct  thrombin  inhibitor  ximelagatran  was  withdrawn  from  the market in 2006 following the observation of raised liver transaminases 3 x ULN 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Recently observed HLA associations suggest a key role  for specific cell surface antigens  in  the  pathogenesis  of  immune‐mediated  adverse  drug  reactions.  In 
vitro assays incorporating this genetic variation are required in order to account for  allele‐specific mechanisms.  The  aims  of  the work  presented  in  this  thesis were therefore to; 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2.1 Introduction Human  leukocyte  antigen  (HLA)  molecules  are  cell  surface  molecules  that present  peptides  to  T‐cells.  If  these  peptides  are  derived  from  an  invading pathogen  immune  recognition  will  occur.  Recent  genome  wide  association studies  have  also  suggested  a  key  role  in  the  development  of  drug hypersensitivity  reactions.  For  both  abacavir  (Chessman  et  al.,  2008)  and carbamazepine  (Ko  et  al.,  2011)  the  associated  HLA  molecule  has  been suggested  to  have  a  direct  role  in  the  presentation  of  drug/drug‐modified peptides to T‐cells. In order to study the mechanisms of T‐cell activation in vitro, cells bearing  these molecules must  therefore be used. A cohort of 400 healthy volunteers  has  been  established  in  order  to  provide  a  source  of  genetically characterised lymphocytes.   HLA Typing The involvement of specific HLA alleles in adverse drug reactions and in tissue rejection  makes  reliable  HLA  typing  key  to  improving  drug  therapy  and preventing graft vs. host reactions. There are several methods currently in use to identify patient genotype.   
Serological HLA typing techniques  The  first  methods  routinely  used  in  HLA  typing  were  based  on  the microlymphocytotoxicity  assay  of  Terasaki  et  al  (Terasaki  and  McClelland, 1964).  T  and B‐lymphocytes were  isolated  from  the  patient  and  exposed  to  a selection of antisera containing antibodies to individual HLA molecules. Fixation 
Chapter 2 – HLA‐typed cohort 
  69 
of complement and subsequent cytotoxicity were used as a measure of antibody reactivity  and  hence  to  identify  the  antigens  expressed  at  the  cell  surface. Serological techniques can however be limited by the quality and availability of antisera for specific HLA alleles (Otten et al., 1995). Antibodies directed at HLA molecules  generally  only  recognise  differences  at  the  surface  of  the molecule, making it difficult to characterise HLA molecules that only differ at a couple of residues,  particularly  when  these  are  located  in  the  peptide  binding  cleft (Shankarkumar  et  al.,  2008)  and  as  such  only  low  resolution  typing  can  be performed  (Williams,  2001).  This  method  is  also  compromised  in  situations where  disease  states  affect  the  expression  of  antigens  at  the  cell  surface (Williams,  2001).  Otten  et  al.  (1995)  found  that  discrepancies  between serological  and  genotyping  techniques  were  increased  in  patients  compared with healthy volunteers.  Genotyping techniques have since been developed which can identify HLA type at  the  gene  level,  and  can  be  performed  on  any  source  of  genomic  DNA (Susskind, 2007).  
Sequence­specific oligonucleotide probe hybridization (SSOPH) Primers complementary to the conserved 5’ and 3’ flanking regions of the locus of interest are designed. Amplified products are then incubated with a range of sequence‐specific  oligonucleotide  probes,  and  an  allele  is  called  based  on  any resulting hybridization. A vast number of oligonucleotides are required due to the number of alleles that have currently been identified, and this can impact on the  costs  of  the  assay  (Williams,  2001). These methods  are not dependent  on 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surface  expression  of  the  antigen  and  the  ability  to  discriminate  single  base changes  between  alleles  means  that  a  much  greater  degree  of  resolution  is achieved.  Additional  oligonucleotides  can  be  designed  as  new  alleles  are discovered.  
Sequence­specific primer polymerase chain reaction (SSP­PCR) Primers are designed  to  the polymorphic region of  the allele, meaning  that,  in this  instance  an  allele  can  be  assigned when  amplification  occurs,  as  only  an allele  that  is  perfectly  aligned  with  the  primer  will  be  amplified  (Williams, 2001). These products  can  then be separated by electrophoresis  to determine whether  amplification  occurs,  or  real  time  PCR  methods  can  be  employed (Williams, 2001). 
 Large amounts of DNA are  required  to  fully  characterize patient HLA  type via this  method,  due  to  the  number  of  reactions  that  must  be  performed  and primers used (Susskind, 2007). However the implementation of whole genome amplification  techniques has  aided  this method,  so  that  a mouth  swab  can be sufficient  for  repeated  typing  experiments  (Gillespie  et  al.,  2000).  SSP‐PCR  is useful in typing at a standard equivalent to serology (Williams, 2001). Both SSP‐PCR and SSOPH‐PCR can be performed in 4‐5 hours (Susskind, 2007).  
Direct DNA sequencing PCR  amplification  of  genomic  DNA  followed  by  sequencing  of  the  amplified regions  is  currently  the  most  comprehensive  HLA  typing  technique,  yielding high‐resolution  allelic  discrimination  (Shankarkumar  et  al.,  2008). 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Fluorescently  labelled nucleotides are employed  to determine  the sequence of the amplified regions, base by base (Williams, 2001)(see 2.3.2).   However, interpretation of sequence‐based typing results is more difficult than in  other  methods.  Specialist  software  and  a  skilled  operator  are  required  in order to make allele calls (Sayer and Goodridge, 2007). Sayer et al. (2007) found both  inter‐ and  intra‐  laboratory variation exist  in sequence‐based techniques, and  that  this  was  largely  due  to  operation  rather  than  specific  reagents  or equipment.  Direct  sequencing  is  also  a  much  more  time  consuming  process, sometimes  taking  a  number  of  days  (Susskind,  2007).  Genotyping  techniques can give conflicting results when null alleles are present (Elsner and Blasczyk, 2004). These null alleles that are not present at the surface can still be detected by  PCR  techniques,  a  factor  that may  be  important  in  transplantation  (Elsner and Blasczyk, 2004).  Though undoubtedly useful, genotyping techniques can be expensive and time‐consuming processes, requiring specialist equipment and complicated analysis. Following  the  characterization  of  linkage  disequilibrium  throughout  the MHC region a number of tagging single nucleotide polymorphisms (tSNPs) have been identified (de Bakker et al., 2006). These  tSNPs offer an alternative method of predicting HLA types, which can be performed in most laboratories without the need for specialised equipment.    The MHC region is organized into a series of distinct haplotype blocks (Daly et al.,  2001)
Chapter 2 – HLA‐typed cohort 
  72 








Individuals responsible: Jane Evely and Giovanna Bretland (CDSS nurses)  Ethics  for  this  study  were  obtained  from  the  Liverpool  Research  Ethics Committee and all participants gave written informed consent. Advertisements were placed in local newspapers, on the University of Liverpool website and the Royal  Liverpool  University  Hospital  bulletin.  Volunteers  were  eligible  to participate in the study if aged between 18 and 60 years, healthy and willing to donate  one  or  more  blood  samples.  The  following  exclusion  criteria  were applied and volunteers were not recruited if:  
• they had donated blood to the transfusion service in the last 4 months;  
• they had any medical problems  including  asthma, diabetes,  epilepsy or anaemia;  
• they were on any medications;  
• they  had  taken  any  recreational  drugs  in  the  past  6  weeks  (including cannabis, speed, ecstacy, cocaine, LSD etc.).  
• Women were excluded if pregnant.  400 healthy volunteers were recruited from the North West of England between August 2009 and April 2010. This sample size was based on the frequency of the HLA‐DRB*07:01  allele,  associated  with  ximelagatran‐induced  liver  injury (Kindmark et al., 2008). Based on an allelic frequency of 0.165, a cohort of 400 volunteers was therefore expected to identify more than 110 heterozygotes and around 10 homozygotes. 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Blood  was  taken  at  the  Royal  Liverpool  and  Broadgreen  Hospital  Clinical Research  Facility.  Confidentiality  was  maintained  throughout  the  study  by several  mechanisms:  firstly,  only  clinically  trained  personnel  had  access  to participant’s  personal  data which  are  stored  in  password‐protected  computer files;  secondly,  coding  of  DNA  and  cells  used  in  functional  assays  were performed;  thirdly,  subjects  were  identified  only  by  their  assigned  number. Participants were given the right to withdraw from the study at any time. In that case,  any  identifiable  data  or  tissue  would  be  anonymised  and  retained  or otherwise disposed of if specified by the participant.   A  total  of  100ml  of  blood  was  collected  for  both  DNA  and  peripheral  blood mononuclear cell (PBMC) isolation. Careful consideration was paid to ensuring that  the  amount  of  blood  collected  would  enable  the  intended  experimental strategy  without  asking  too  much  from  volunteers.  Further  donations  may however  be  requested  at  a  later  date  in  order  to  replenish  cell  stocks.  All samples were processed within 4 hours of collection.    
2.3.2 Extraction of genomic DNA and sequence­based HLA 
typing 
Individuals responsible: Vivian Platt  Genomic DNA was extracted  from whole blood using  the automated Chemagic magnetic  separation  system  (Chemagen,  Baesweiler,  Germany).  Firstly,  cells were  lysed.  Lysis  buffer  (7.5ml)  and  protease  (20µl) were  added  to  3‐5ml  of whole blood and  incubated  for 5 minutes at room temperature. The Chemagic 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magnetic separation module (Chemagen, Baesweiler, Germany) was then run on a lysis cycle for 30 minutes. Following lysis of the cells 19.5ml of binding buffer was  added  along with  0.5ml magnetic  beads.  The magnetic  beads  are  able  to bind DNA with a high affinity allowing the transfer of the beads from one buffer to  another  when  the  electromagnetic  field  is  turned  on.  Resuspension  of  the nucleotides  is  achieved  when  the  magnet  is  turned  off  through  high‐speed rotation of the rods allowing efficient washing. The DNA was washed in 10 ml of five separate wash buffers followed by 0.5 ml of two elution buffers as provided by Chemagen. DNA concentration was determined by measuring absorbance at 260nm  (A260)  using  the  Nanodrop  spectrophotometer  (Labtech,  East  Sussex, UK).  High‐resolution  sequence‐based  HLA  typing  was  performed  at  the Histogenetics  laboratory  (Histogenetics  New  York,  USA)  at  the  following  loci; HLA‐A, B, C, DRB1 and DQB1. Samples were sent for HLA‐typing in two batches of  200.  Methods  were  as  described  in  detail  in  Lucena  et  al.  (2011)  and  are briefly  summarised  here.  Sequencing  was  performed  on  the  PCR  products generated from exon 2 of HLA‐A, B, C, DRB1 and DQB1. Exon 3 was additionally sequenced for the class I alleles. Sequencing was performed on both strands via cycle  sequencing  with  BigDye  V3.1  (Applied  Biosystems,  Warrington,  UK).  Analysis  of  the  resulting  data  was  performed  using  Histomatcher  and HistoMagic software developed at Histogenetics (New York, USA).  Alleles were assigned  based  on  the  latest  version  of  the  IMGT/HLA database  (release  date April 2008). 
 Long‐term  storage  of  DNA  from  all  volunteers  is  provided  by  SmaRTStore,  a DNA  archive with  integrated  robotics  (at  ‐20˚C).  Samples  can  be  tracked  and 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monitored  by  means  of  the  electronic  laboratory  management  system, STARLIMS. A small amount of whole blood was also retained and stored at ‐80˚C should  further DNA need  to be  extracted. Blood  spots were  also prepared  for each volunteer. 
2.3.3 Isolation and storage of volunteer lymphocytes 








2.4.1 Volunteer demographics 400 volunteers were recruited, however only 385 were able to donate sufficient blood  to  enable  both  DNA  and  lymphocyte  isolation.  Of  these  400  volunteers 64% were  female  and 36% were male. The average age of  volunteers was 29 years  (±10  years  range  18‐60)(Figure  2.1).  Given  that  a  high  number  of university  students were  recruited  there  is  a  higher  proportion  of  volunteers below the age of 30.  Recruitment of volunteers began in August 2009 and was completed in April 2010.     
 
Figure  2.1  Age  distribution  of  volunteers  recruited  to  the  HLA‐typed  cohort  by  CDSS  nurses (n=400).   Volunteers  from varied ethnic backgrounds were particularly  sought,  in order to  increase  the  allelic  diversity within  the  cohort.  It  is well  known  that  some HLA associations have only been observed  in  certain populations  (Alfirevic  et 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2.4.2 Allele frequencies In  our  cohort  43  different  HLA‐A  alleles  were  present,  the  most  frequent  of these  being  HLA‐A*02:01  which  was  expressed  by  176  individuals  (23 homozygotes, 153 heterozygotes). As expected the HLA‐B locus was the most 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2.4.3 Availability of volunteers for secondary donations In  August  2010  a  small  cohort  of  volunteers  was  approached  on  a  second occasion  in  order  to  obtain  a  further  blood donation  to  replenish  lymphocyte stocks. Of 19 individuals that were recalled 15 (79%) were able to donate again. From the 4 that were unable to donate, 2 were pregnant and therefore ineligible to donate at that time, and 2 could not be contacted. This suggested that should further  samples  be  required  from  particular  individuals  there  was  a  good chance  of  volunteers  being  willing  to  donate  again.  It  is  however  anticipated that given the size of the cohort there are sufficient numbers of individuals with interesting  HLA  alleles  in  order  that  alternative  donors  with  the  required genotype  could  be  selected  if  necessary.  In  a more  recent  study  conducted  in Summer 2012, only 18 out of 64 volunteers were contactable (28%) indicating that the recall rate has fallen considerably over time. 











Figure  2.3  Allelic  discrimination  of  rs2395029  in  23  volunteers.  Positive  controls  represent individuals previously typed by sequence‐based techniques. Negative control contains no DNA.  
2.5 Discussion  Immune‐mediated adverse reactions to drugs are incredibly difficult to predict, and  much  still  remains  to  be  established  regarding  their  underlying mechanisms. Recently observed genetic associations have focussed attention on the MHC region and have implicated specific HLA alleles in the development of adverse reactions to certain drugs (Tables 2.1 and 2.2).  A  number  of  hypotheses  have  been  proposed  to  explain  the  ability  of  small molecules  such  as  drugs  to  initiate  an  immune  response  against  host  cells. Nevertheless,  each  of  these  mechanisms  highlights  that  a  unique  interaction between  drug,  T‐cell  receptor  and  MHC  molecule  is  a  key  factor  in  the development of  immune‐mediated adverse  reactions  and as  such  the  study of 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HLA  alleles  represents  a  logical  route  to  study  the  genetic  basis  of  such reactions.  In order to further study these HLA‐linked reactions in vitro it will therefore be important  to  work  with  genetically  characterised  cells.  Immune  cells  bearing these HLA types can be utilised in functional assays to determine the propensity of small molecule drugs to initiate T‐cell responses. This approach has already shown  some  success  with  regard  to  reactions  to  abacavir.  Drug‐specific secretion  of  interferon‐γ  can  be  detected  in  lymphocytes  isolated  from  HLA‐B*57:01  positive  abacavir‐naïve  healthy  donors,  following  a  short  priming period  (Chessman  et  al.,  2008).  The  creation  of  a  DNA  and  cell  archive  will therefore be a valuable tool in further exploring the role of HLA molecules in the development of adverse drug reactions in certain susceptible individuals.  The  current  study has been  successful  in  creating a biobank of both DNA and lymphocytes  from  400  healthy  volunteers  in  order  to  study  HLA‐associated ADRs. These volunteers are drawn from the North‐West region and encompass a  range  of  ethnicities.  This was  important  to  the  study  given  that  some HLA‐associations  are  confined  to  specific  ethnic  groups  (Alfirevic  et  al.,  2006).  In order  to  be  able  to  study  the  involvement  of  rare  alleles  it  was  therefore important to recruit individuals from some of these backgrounds.  Advertisements  were  placed  in  local  newspapers  and  on  both  university  and hospital electronic announcement systems. In recruiting volunteers it was also important to ensure that volunteers would be contactable in the future. For this 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reason  the  cohort  is  composed of  individuals  from  the hospital  staff  and  local residents in addition to university students who may not remain in the North‐West once they have finished their studies.  The  cells  stored  in  our  cell  bank  will  be  utilised  in  functional  assays  to determine  the  propensity  of  different  drugs  to  elicit  a  T‐cell  response  in lymphocytes from volunteers with a known genetic background. For most HLA‐associated adverse drug reactions it has not yet been established that the HLA allele is indeed the causative allele.  Where a prevalent HLA allele is reported to be associated with a reaction it is unlikely that this alone is responsible for the toxicity observed.  It  is  likely  that an extended haplotype exists  in which other genes may be implicated.  The complex interplay between these genes can only be replicated in systems where these haplotypes are present. Humanised animal models,  in  which  specific  human  HLA  alleles  can  be  inserted  into  the mouse genome have previously been used to model autoimmunity (Shultz et al., 2007). However,  given  the  great  complexity  in  the  MHC  region  in  which  linkage disequilibrium can confound the discovery of genetic associations and the likely role  for  specific  HLA  haplotypes,  it  is  unclear  how  successful  this  approach would  be  in  studying  adverse  drug  reactions.  Through  the  use  of  human lymphocytes  in which  these  haplotypes  remain  intact  it  is  hoped  that  a more complete  picture  of  the mechanisms  underlying  drug  immunogenicity will  be created.        For many of the genetic associations observed it is likely that other factors will be  involved  in  determining whether  an  individual  experiences  a  reaction  to  a 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particular  drug.    Even  for  the  strongest  associations  there  is  not  100% correlation  between  genotype  and  phenotype.  In  the  case  of  abacavir hypersensitivity  only  55%  of  patients  expressing  the  HLA‐B*57:01  allele  will develop a reaction if exposed to the drug (Mallal et al., 2008). Other factors, both genetic  and environmental  e.g  viral  infection,  immune  status of  the  individual are  likely  to  be  involved.  Some  of  these  environmental  factors  may  not  be reproducible  in  vitro,  however  it  is  hoped  that  the  experimental  strategy  that has been adopted will be successful in detecting drug‐reactive T‐cells.   The availability of high‐quality DNA from volunteers that have been HLA‐typed by  sequence‐based  methods  also  provided  an  opportunity  to  investigate  a recently  discovered  tagging‐SNP  for HLA‐B*57:01.  This  technique  exploits  the linkage  disequilibrium  displayed  between  HLA‐B*57:01  and  a  T  to  G substitution located 100kB centromeric of the HLA‐B locus allowing rapid PCR‐based  genotyping.  A  number  of  studies  have  been  performed  in  order  to determine whether  this  assay would  be  useful  in  assigning  patient  genotypes prior  to  abacavir  prescription,  with  varying  results.  Colombo  et  al.  (2008) performed HCP5 SNP genotyping in 1103 individuals that were also HLA‐typed by  sequence‐based  techniques.  All  HLA‐B*57:01  positive  individuals  (n=98) were  found  to possess  a  copy of  the HCP5 SNP  (Colombo et  al.,  2008). Out of 1005 HLA‐B*57:01 negative  individuals,  999 were  also negative  for HCP5.  Six individuals however tested positive for the HCP5 SNP but were not carriers of HLA‐B*57:01. The authors suggest that though there is some discrepancy in the findings  the  relative  cost  and  speed  of  genotyping  by  this  method  warrants further  investigation,  particularly  for  use  in  situations where  sequence‐based 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The  involvement  of  drug‐specific  T‐cells  in  hypersensitivity  reactions  is  well established.  There  are  a  number  of  methods  currently  available  to  detect  or indeed prime drug‐specific T‐cell responses in vitro.   The  lymphocyte  transformation  test  (LTT)  is  commonly  used  to  detect  drug‐specific  T‐cell  responses  ex  vivo  (Pichler  and  Tilch,  2004).  Proliferation  of peripheral  blood  mononuclear  cells  (PBMCs)  isolated  from  hypersensitive patients  in  response  to  drug  treatment  signifies  prior  sensitisation  and hence expansion  of  a  memory‐cell  population.  This  proliferation  does  not  occur  in PBMCs  from  tolerant  patients.  The  assay  can  be  modified  in  order  to  reveal more  information about  the responding cells  through the use of CFSE staining coupled  with  antibodies  directed  at  cell  surface  markers  e.g  CD4  and  CD8, CD45RO and CD45RA (Hanafusa et al., 2012).  It can however be more difficult to  detect  circulating drug‐specific T‐cells  in  cases  of  drug‐induced  liver  injury where the LTT is positive  in  just 26% of cases (Maria and Victorino, 1997).  In addition to proliferation, cytokine secretion can also be detected and quantified. Amoxicillin induces the secretion of interferon‐γ from PBMCs of hypersensitive patients but not tolerant controls (Rozieres et al., 2009). Cytokine readouts may be  more  appropriate  where  CD8+  T‐cells  are  implicated.    Gene  expression analysis  can  also  reveal  the  presence  of  drug‐specific  T‐cells.  Previously,  cells isolated  from PPD‐  allergic  volunteers were  found  to  express  an  array of Th2 type genes compared to a regulatory gene profile in tolerant controls (Coulter et al.,  2010).  These  changes were  detectable  following  just  24h  incubation.  This type of study may therefore be more applicable to a high‐throughput setting. 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In naïve individuals a different approach must be taken. Primary stimulation of naïve  cells  requires  multiple  rounds  of  restimulation  with  the  drug  and autologous antigen‐presenting cells  in  the presence of  interleukin‐2 (Engler et al., 2004). Activation can be further enhanced by the provision of co‐stimulatory signals  such  as  CD40  during  the  priming  period  (Sanderson  et  al.,  2007). Priming  assays  utilising  dendritic  cells  as  antigen‐presenting  cells  have  also recently been developed (Faulkner et al., 2012). These assays have all utilised the drug metabolite sulfamethoxazole nitroso (SMX‐NO) for which no individual susceptibility factors have yet been identified. The priming assay could however be extended to HLA‐associated DHRs through the use of genotyped cells.  Chessman  et  al.  (2008)  detected  abacavir‐specific  secretion  of  IFN‐γ  from PBMCs of drug‐naïve HLA‐B*57:01 positive donors. PBMCs were incubated with abacavir in the presence of IL‐2 for 14 days and subsequently rechallenged with the  drug.    Cells  isolated  from  donors  expressing  HLA‐B*57:01  secreted  IFN‐γ and  killed  target  cells  in  a  dose‐dependent manner. When  antigen‐presenting cells  expressing  other  HLA‐B  alleles  were  substituted  into  the  assay  the response was blocked. The relatively short incubation time and seemingly high precursor  frequency  led  the  authors  to hypothesise  that  these  cells were pre‐existing  in  individuals possessing  the HLA risk allele. No evidence of any viral cross‐reactivity  was  observed  and  TCRs  were  polyclonal.  This  may  therefore represent a unique mechanism of activation in reactions where a HLA molecule is  strongly  associated  with  immunogenicity.  This  is  supported  by  similar findings  when  PBMCs  isolated  from  HLA‐B*15:02  positive  volunteers  were treated with carbamazepine (Ko et al., 2011). 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• Utilise  genotyped  cells  to  determine  the  propensity  of  ximelagatran, flucloxacillin and abacavir to elicit T‐cell responses 
• Investigate  gene  expression  changes  associated  with  abacavir  and flucloxacillin treatment in cells from HLA‐B*57:01 positive and negative individuals  
3.3 Methods 
3.3.1 Chemicals and reagents Human  AB  serum  was  obtained  from  Innovative  Research  (Michigan,  USA). Foetal bovine serum (FBS) was obtained from Invitrogen, Paisley, UK. Tetanus toxoid (TT) was bought  from the Statens Serum Institut, Copenhagen, Denmark. RNeasy  mini  kit  and  RNase‐free  DNase  kits  were  purchased  from  Qiagen, Crawley, UK. Custom‐designed codesets and other NanoString reagents were all sourced  from  NanoString  technologies,  Seattle,  USA.  The  RNA  6000  Nano  kit was purchased from Agilent technologies, Stockport, UK. TaqMan primers were bought  from Applied Biosystems, Warrington, UK, as were other PCR reagents including mastermix and reverse transcription reagents.  Interferon‐γ,  interleukin‐13,  interleukin‐5,  granzyme  B  and  perforin  ELISpot kits including antibodies and substrate solution were purchased from Mabtech, 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Stockholm,  Sweden.  The  Fas  ligand  ELISpot  kit  was  bought  from  Abcam (Cambridge,  UK).  CD4‐PE  and  CD8‐FITC  antibodies  were  purchased  from  BD Biosciences,  Oxford,  UK.  T‐cell  receptor  antibodies  were  obtained  from  AbD Serotec,  Oxford,  UK.  Bio‐Plex  Pro  Human  Cytokine  Th1/Th2  Panel  was purchased from Bio‐Rad, Hertfordshire, UK. Recombinant human interleukin‐2 (rhIL‐2)  was  supplied  by  Peprotech,  London,  UK.  [3H]‐Thymidine  was purchased from Moravek (California, USA). Multisort bead separation kits were bought from Miltenyi Biotec, Surrey, UK.  Abacavir  sulfate  and  ximelagatran  were  kind  gifts  from  GlaxoSmithKline  and AstraZeneca respectively. Flucloxacillin was obtained from the Royal University Hospital,  Liverpool.  All  other  reagents  were  obtained  from  Sigma‐Aldrich, Dorset, UK.  
3.3.2 Cell culture medium 
T­cell medium was comprised of RPMI 1640 supplemented with 10% human AB serum,  25mM  HEPES,  1000U/ml  penicillin,  0.1mg/ml  streptomycin,  2mM  L‐glutamine and 25µg/ml transferrin.   















HLA‐A  HLA‐B  HLA‐C  HLA‐DRB1  HLA‐DQB1 
001  01:01/02:01  51:01/57:01  06:02/07:02  15:01/07:01  03:03/06:02 
002  11:01/24:02  27:02/57:01  05:01/06:02  14:01/07:01  03:03/05:03 
003  01:01/03:01  14:02/57:01  06:02/08:02  13:02/07:01  03:03/06:09 
004  01:01/01:01  57:01/57:01  06:02/06:02  04:03/07:01  03:02/03:03 
005  24:02/26:01  40:06/44:03  07:01/15:02  07:01/07:01  02:01/03:03 
006  03:01/11:01  27:05/57:01  01:02/07:02  01:01/07:01  03:03/05:01 
007  01:01/02:01  07:02/58:01  03:02/07:02  13:02/04:01  03:01/06:09 
008  01:01/26:01  38:01/40:01  03:04/12:03  07:01/08:01  02:01/04:02 
009  02:01/03:01  07:02/15:18  04:01/07:02  04:01/07:01  02:01/03:01 
010  11:01/74:03  07:02/44:03  01:02/04:01  15:01/07:01  02:01/06:02 
011  03:01/32:01  07:02/14:01  07:02/08:02  01:01/07:01  02:01/05:01 
012  01:01/11:01  40:06/57:01  06:02/15:02  15:01/14:04  05:03/06:01 
013  01:01/02:01  07:02/40:01  03:04/07:02  07:01/08:01  02:01/04:02 
014  03:01/11:01  07:02/35:01  03:04/04:01  01:01/04:04  03:02/05:01 
015  02:01/03:01  07:02/27:02  02:02/07:02  01:01/15:01  05:01/06:02 
016  01:01/31:01  07:02/37:01  06:02/07:02  15:01/15:01  06:02/06:02 
017  02:01/68:01  40:01/44:02  03:04/05:01  15:01/13:01  06:02/06:03 
018  03:01/03:01  07:02/07:02  07:02/07:02  15:01/03:01  02:01/06:02 
 
3.3.3.2 Lymphocyte transformation test (LTT) The lymphocyte transformation test is designed to detect the presence of drug‐specific  memory  T‐cells  in  the  peripheral  blood  of  hypersensitive  patients. PBMCs  (1.5  x  105,  100µl)  were  incubated with  abacavir  (0‐250µM,  100µl)  or ximelagatran  in  triplicate  wells  for  six  days.  Tetanus  toxoid  (0.5µg/ml)  was included as a positive control.  [3H]‐ Thymidine (0.5µCi/well) was added for the final  16  hours  of  culture.  Plates  were  harvested  and  proliferation  was determined by scintillation counting. Stimulation indexes (SIs) were calculated by  comparing  proliferation  in  drug  treated  vs.  control wells  (SI=  cpm  in  drug treated wells ÷ cpm in control wells). An SI> 2 was considered a positive result (Pichler and Tilch, 2004).  
3.3.3.3 Lymphocyte stimulation The method  of  Chessman  et  al.  (2008) was  used  to  expand  and  detect  drug‐reactive T‐cells. Volunteer  lymphocytes were quickly  thawed, washed  in HBSS and  resuspended  in  complete  T‐cell  medium.  Cells  were  seeded  in  a  24  well plate  (2  x  106;  1ml)  with  abacavir  (35µM),  ximelagatran  (100µM)  or  tetanus toxoid  (0.5µg/ml).  Tetanus  toxoid  was  used  as  a  positive  control  as  it  is  a peptide  antigen  that  most  of  the  UK  population  will  have  been  immunised against. Cultures were supplemented with IL‐2 (10U/ml) on days 3, 6, 9 and 11. On  day  14  cells  were  harvested,  counted  and  resuspended  in  fresh  medium. Antigen  specificity  was  determined  via  proliferation  assay  and  cytokine secretion as described below. 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3.3.3.4 Proliferation assay Following lymphocyte stimulation 1 x 105 responder cells (50µl) were added to autologous  irradiated  PBMCs  from  frozen  stocks  (5  x  104,  50µl),  which  were used  as  antigen‐presenting  cells.  Responder  cells  were  restimulated  with  the same antigen as originally used during the 14‐day stimulation (abacavir 10 and 35µM,  ximelagatran  50  and  100µM,  TT  0.1  and  0.5µg/ml).  [3H]‐Thymidine (0.5µCi/well) was added after 48h and proliferation measured by  scintillation counting.  Dividing  cells  incorporate  the  radiolabelled  thymidine  into  newly synthesised DNA. Stimulation  indexes were calculated as described previously (see 3.3.3.2).  
3.3.3.5 Enzyme­linked immunospot (ELISpot) assay A schematic representation of the ELISpot assay is shown in Figure 3.1. On day 13 MultiscreenHTS filter plates (Millipore, Watford, UK) were coated overnight at 4˚C  with  interferon‐γ  capture  antibody  (15µg/ml).  The  following  day,  wells were  washed  five  times  with  PBS  and  blocked  with  T‐cell  medium  (200µl, 30min, room temperature). Responder cells (2 x 105, 50µl) were added to wells with  autologous  irradiated  PBMCs  as  antigen‐presenting  cells  (1  x  105,  50µl) and the antigen (100µl). Plates were incubated at 37˚C in 5% CO2 and developed after  48h,  according  to  the  manufacturers  instructions.  At  the  end  of  the incubation cells were discarded and wells were washed  five  times with 200µl PBS. Biotin‐labelled detection antibody was diluted to 1µg/ml in PBS containing 0.5%  FBS  and  added  to  the  wells  (100µl).  The  plate  was  incubated  at  room temperature  for  2  hours  before  wells  were  washed  five  times  with  PBS. Streptavidin‐ALP was diluted 1:1000 in PBS containing 0.5% FBS and added to 
Chapter 3 – In vitro assays 
  99 
wells  (100µl,  1h,  room  temperature). Wells were washed  five  times with  PBS (200µl)  and  spots  were  visualised  by  the  addition  of  BCIP/NBT  substrate (100µl,  15  min).  The  plate  was  counted  on  an  AID  ELISpot  reader  (Cadama Medical, Stourbridge, UK) when thoroughly dried.  
         
 







HLA‐A  HLA‐B  HLA‐C  HLA‐DRB  HLA‐DQB 
004  01:01/01:01  57:01/57:01  06:02/06:02  04:03/07:01  03:02/03:03 
019  01:01/02:01  08:01/57:01  06:02/07:01  03:01/03:01  02:01/02:01 
020  02:01/11:01  44:02/57:01  05:01/07:01  04:02/07:01  03:02/03:03 
021  01:01/02:01  07:02/08:01  07:01/12:03  15:01/03:01  02:01/06:02 
022  02:01/66:01  15:03/44:02  05:01/12:03  03:01/03:01  02:01/02:01 
023  01:01/02:01  08:01/44:02  05:01/07:01  03:01/04:01  02:01/03:01  
3.3.4.2 T­cell stimulation Peripheral  blood  mononuclear  cells  (PBMCs)  were  freshly  isolated  from  the blood of  three HLA‐B*57:01 positive  and  three HLA B*57:01 negative healthy volunteers via density centrifugation (as described in 2.3.3).   Abacavir (50µM), flucloxacillin (1mM) or  tetanus toxoid (5µg/ml) was added to PBMCs cultured in  T‐cell  medium  (final  volume=  2ml;  5  x106  cells/condition).  Cells  were harvested at 2, 24 and 72h. After washing in HBSS, cell pellets were frozen and stored at ‐80˚C until RNA was isolated.  
3.3.4.3 RNA isolation Total  RNA was  extracted  using  the  RNeasy mini  kit.  Lysis  buffer  (350µl) was added  to  the  cell  pellet.  The  lysate  was  passed  through  a  21g  needle  and  an equal volume of 70% ethanol was added. After gentle pipetting the  lysate was 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Total  RNA  (150ng)  was  incubated  with  the  reporter  and  capture  probe  sets overnight  at  65˚C. Twelve  samples  can be  analysed on  each  run. A mastermix comprising 130µl reporter probe and 130µl hybridisation buffer was prepared. A 12‐tube strip of PCR tubes was labelled and 20µl of the mastermix was added to each tube. RNA (5µl) was then added and mixed by gently flicking the tubes. Finally the capture probe (5µl) was added to tubes and mixed. The tubes were then immediately transferred to a heat‐block set at 65˚C.  Both probes are specific for the gene of interest. Each reporter probe is coupled to  a  unique  colour‐coded  sequence  at  the 5’  end  and  the  capture probe has  a biotin  label  at  the  3’  end.  The  following  day  a  number  of  washes  to  remove excess  unbound  probes  are  performed  in  an  automated  prep  station.  Where hybridisation has occurred a tripartite complex  is  formed comprising reporter probe,  target  mRNA  and  capture  probe.  These  tripartite  complexes  are immobilised on streptavidin‐coated slides. An electric current is applied to the slides in order to orientate the fluorescent labels and facilitate counting. Slides are imaged and counted on the nCounter digital analyser.   The unique fluorescent  label of each gene is quantified  in each sample. Counts for  each  gene  are  then downloaded  for  subsequent  analysis. Normalisation  to spiked‐in  positive  controls  is  first  performed  in  order  to  account  for  any differences in hybridisation efficiency. Data was further normalised for amount of RNA based on  the  expression of  the housekeeping  genes GUSB, RPL19  and HPRT1. All  analyses were performed  in nCounter  software. The  expression of each gene was compared between control vs.  treated samples  in HLA‐B*57:01 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positive  and  HLA‐B*57:01  negative  groups.  Fold  change  between  averaged treated and control samples was also determined.  
3.3.4.5 TaqMan real­time PCR In order to further validate these data, a smaller subset of 5 genes was selected for  confirmatory  real‐time  PCR  (CCL3,  CXCR3,  IL‐1R1,  IL‐6,  IL‐8).  Genes were selected  based  on  the  results  of  the  NanoString  assay.  Genes  were  selected where a fold change of greater than 2 was observed between averaged control and  treated  values.  The  24‐hour  time‐point  was  selected  for  further investigation.  Unlike  the NanoString,  TaqMan  real‐time PCR must  be  performed with  cDNA. RNA (900ng) was therefore reverse transcribed using the high capacity RNA to cDNA   mastermix. The mastermix contains all of  the components  required  for efficient  reverse  transcription  (MgCl2,  dNTPs,  RNase  inhibitor,  reverse transcriptase,  random  primers  and  oligo(dT)  primers).  Mastermix  (6µl;  total volume 30µl) was added to the RNA and heated to 25˚C for 5 minutes. This was followed by 30 minutes at 42˚C and 5 minutes at 85˚C.   Each  PCR  reaction  contained  the  following:  1.7µl  cDNA,  10µl  gene  expression mastermix,  1µl  gene  expression  assay  and  6.3µl  DNase‐free  water.  Reactions were performed in a 384 well plate and all samples were run in duplicate. Blank water  samples  were  included  for  each  gene  analysed.  Thermal  cycling  was performed on an ABI 7900HT machine (Applied Biosystems, Warrington, UK). Reactions were heated to 95˚C for 10 minutes. This was followed by 50 cycles of 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Figure 3.2 Purity of cell  fractions  following magnetic bead separation. A positive selection for CD8+ cells was performed given the HLA class I association.  Separated cells were  then cloned by  serial dilution using established methods (Wu et al., 2006). Cells were seeded in 96‐well plates at densities of 0.3, 1 and 3 cells/well and restimulated with allogenic irradiated PBMCs (5 x 104 cells/well), PHA (1µg/ml) and IL‐2 (60U/ml). Well‐growing clones were transferred to new plates  and  split  as  required.  Clones  were  restimulated  every  14  days  as described above in order to maintain T‐cell proliferation.  




3.3.5.3 Antigen­specificity of T­cell clones  At least 28 days after the serial dilution, abacavir‐specificity was assessed by the addition  of  autologous  irradiated  EBV‐transformed B‐cells  (1  x  104/well)  and abacavir (50µM) to T‐cell clones (5 x 104/well; 200μl). [3H]‐Thymidine (0.5µCi) was  added  after  48h  and  proliferation  measured  by  scintillation  counting. Clones with a stimulation index of greater than 2 were expanded by repetitive mitogen stimulation  in  IL‐2 containing medium for  further analysis. The effect of  drug  concentration  on  the  T‐cell  response  was  measured  by  incubating clones (5 x104) and irradiated EBV‐transformed B‐cells (1 x 104) with abacavir (1,  5,  10,  50,  100µM). The  response was quantified  via both proliferation  and IFN‐γ ELISpot assays as described previously (see 3.3.3.4 and 3.3.3.5).  
3.3.5.4 T­cell receptor Vβ phenotyping T‐cell clones were incubated with 30 different TCR Vβ antibodies in a 96‐well V bottomed plate. All clones were also stained with APC‐labelled CD8 antibody.  T‐cell  clones were  resuspended  in  FACS  buffer  (HBSS  containing  0.5% BSA  and 2mM EDTA)  and  incubated with  the  antibodies  for  20 minutes  in  the  dark  at 4˚C. The different  fluorescent markers meant  that up  to 3 antibodies  could be added to each well  (1 x FITC, 1x PE and 1x APC; all 3µl). The wells were  then washed by centrifuging the plate for 5 minutes (600g, 4˚C). This was repeated a total  of  three  times.  Finally  the  cell  pellets  were  resuspended  in  300µl  FACS 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buffer  and  transferred  to  FACS  tubes  for  analysis  on  the BD  FACS Canto  flow cytometer.   
3.3.5.6 Secretion of cytokines and cytotoxic molecules Secretion of IL‐13, IL5, granzyme B, perforin and Fas ligand was determined by ELISpot  assay.  The  general  protocol  was  as  described  previously  (3.3.3.5). Coating  antibodies  were  used  at  a  final  concentration  of  10µg/ml  (IL‐13) 15µg/ml  (IFN‐γ,  IL‐5,  GrzB)  or  30µg/ml  (Perforin)  depending  on  the  analyte. The detection antibody was used at a concentration of 1µg/ml for all kits. The Fas  ligand  kit  was  obtained  from  a  different  supplier  and  so  a  number  of changes were made to the protocol; coating antibody was diluted 1:100 in PBS, blocking  was  performed  with  2%  (w/v)  skimmed  milk  for  2h,  washes  were performed with  PBS  containing  0.1%  (v/v)  tween‐20,  detection  antibody was diluted 1:100 in PBS containing 1% BSA and incubated for 90 minutes at 37˚C and streptavidin‐ALP was diluted 1:5000 and incubated for 1h at 37˚C.   Secretion of  IL‐2,  IL‐4,  IL‐5,  IL‐9,  IL‐10,  IL‐12,  IL‐13, GMCSF,  IFN‐γ and TNF‐α     was  determined  by  Luminex multiplex  bead  assay.  The  Luminex  assay  allows the  simultaneous  quantification  of  multiple  cytokines  in  the  same  sample (Figure 3.3).   Colour‐coded beads coupled to antibodies directed at each of the target molecules are  incubated with the sample. Each antibody  is coupled to a different  bead  with  a  unique  colour.    A  fluorescently  labelled  reporter,  also specific for the target is later added to quantify the amount of analyte bound to each  bead.  The  Luminex  reader  detects  both  the  colour  of  the  bead  and  the amount of analyte bound. 
Chapter 3 – In vitro assays 
  113 
 Samples comprised cell culture supernatants. Eight T‐cell clones (5 x 104) were incubated  with  and  without  50µM  abacavir  in  the  presence  of  autologous irradiated EBV‐transformed B‐cells (1 x 104). After 48h 100µl supernatant was removed from the well and frozen at ‐80˚C until analysis. On the day of the assay samples were thawed on ice and diluted (1:2, final volume 120µl) with sample buffer. A single vial of standards was reconstituted in 500µl T‐cell medium and diluted as shown in Table 3.4.     
          




















S8  150µl  50µl of S7  (S1:  IL2 = 15,000pg/ml;  IL‐4 = 3500pg/ml;  IL‐5 = 32,000pg/ml;  IL‐9 = 10,000 pg/ml;  IL‐10 = 28,000pg/ml;  IL‐12  =  36,000pg/ml;  IL‐13  =  32,000pg/ml;  GM‐CSF  =  13,000pg/ml;  IFN‐γ  = 30,000pg/ml; TNF‐α = 35,000pg/ml).    The filter plate was prewet with 100µl assay buffer. Magnetic beads were then added to the wells (50µl) and washed twice with wash buffer (100µl). Diluted samples  and  standards  were  then  added  to  the  plate  (50µl)  in  duplicate  and incubated in the dark for 30 minutes on a plate shaker. Detection antibody was diluted 1:10 in detection antibody diluent and added to wells (25µl). The plate was returned to the shaker for a further 30 minutes in the dark. After washing twice  with  wash  buffer,  Streptavidin‐PE  (diluted  1:100  in  assay  buffer)  was added  to wells  (50µl).  The  plate was  returned  to  the  shaker  for  a  further  10 minutes in the dark. Wells were washed three times with wash buffer, the beads were resuspended in 125µl assay buffer and the plate was read. 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3.3.5.7 Statistical analysis The Mann‐Whitney  test was used  to  compare proliferation  in drug  treated vs. control wells. 
3.4 Results 
3.4.1 In vitro enrichment of drug­specific T­cells 
3.4.1.1 Lymphocyte transformation test In  order  to  determine  prior  sensitisation  to  the  drugs  investigated,  the lymphocyte  transformation  test  was  performed.  No  positive  proliferative responses  were  observed  to  either  abacavir  or  ximelagatran  (Figure  3.4).  In contrast robust proliferative responses to tetanus toxoid were observed (SI=12‐94).  
  
Figure  3.4  Representative  lymphocyte  transformation  tests  from  a  HLA‐B*57:01/  HLA‐DRB*07:01 positive volunteer. PBMC were incubated with the drug for 5 days and proliferation determined by [3H]‐thymidine incorporation. A stimulation index of >2 (indicated by the dashed line) were considered a positive result. The stimulation index for TT in this volunteer was 39. 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Figure 3.7  Antigen‐specific  proliferation  of  T‐cells  following  14‐day  enrichment  period. HLA‐DRB*07:01  negative,  HLA‐B*57:01  negative  donors.  Following  14  day  incubation  with  either abacavir,  ximelagatran  or  tetanus  toxoid  T‐cells  were  harvested  and  restimulated  with  the antigen  of  interest.  Proliferation  was  determined  by  [3H]‐thymidine  incorporation.  Data represent mean and standard deviation of triplicate wells.  TT= Tetanus toxoid.  The second endpoint investigated was secretion of interferon‐γ, determined by ELISpot assay.   Figures depict cytokine secretion from lymphocytes expressing both  HLA‐B*57:01  and  HLA‐DRB*07:01  (Figure  3.8),  lymphocytes  with  HLA‐DRB*07:01  but  not  HLA‐B*57:01  (Figure  3.9)  and  lymphocytes  expressing 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neither  allele  (Figure  3.10).  Abacavir  stimulated  increased  secretion  of  IFN‐γ from  lymphocytes  isolated  from  volunteers  005  (SI=2.0;  Figure  3.9)  and  013 (SI=  1.7;  Figure  3.9).  Neither  of  these  volunteers  expressed  HLA‐B*57:01. Ximelagatran did not induce cytokine secretion of greater than 1.2 times greater than background level in lymphocytes from any volunteer.   
 
 






















3.4.2.2 NanoString  The expression of 46 genes was analysed in RNA isolated from the PBMCs of six volunteers  (3  x HLA‐B*57:01  positive,  3  x HLA‐B*57:01  negative).  Due  to  the number  of  samples  each  sample  could  only  be  run  once.    Gene  counts  were therefore averaged and the average fold change was calculated. Tables detailing all of the gene counts and fold changes can be found in the Appendix. The 24h timepoint will be discussed here. A gene count of  less than 20 was considered ‘not expressed’ and was therefore not included in the fold change analysis. 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Figure 3.11 Changes  in gene expression associated with abacavir treatment as determined by the  NanoString  platform.  PBMCs  from  HLA‐B*57:01  positive  or  negative  volunteers  were cultured with abacavir (50µM) for 24h. RNA was subsequently isolated and the expression of a panel  of  46  genes  was  determined.  Data  were  normalised  to  spiked‐in  controls  and  the housekeeping genes GUSB, HPRT and RPL19. Data represent mean + SD from three individuals. Statistical significance was determined by t‐test. 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3.4.3.1 Generation of abacavir­specific T­cell clones PBMC  from  six  volunteers  (3  HLA‐B*57:01  positive,  3  HLA‐B*57:01  negative; Table  3.6)  were  cultured with  abacavir  for  14  days.  Drug‐enriched  CD4+  and CD8+  T‐cells  were  subsequently  isolated,  serially  diluted  and  stimulated  with allogenic irradiated PBMC, IL‐2 and PHA to generate T‐cell clones. Seventy‐four abacavir‐responsive CD8+ clones were generated from 3 volunteers expressing HLA‐B*57:01  (Table  3.3;  Figure  3.14:  0,  9556±9131cpm;  abacavir  [50μM], 33409±26548cpm;  p<0.0001).  Abacavir  stimulated  drug‐specific  T‐cell  clones to  proliferate  and  secrete  interferon‐γ  over  a  range  of  concentrations  of abacavir  (Figure 3.15 A  and B).  In  contrast, when over 400 CD4+  clones were incubated  with  EBV‐transformed  B‐cells  and  abacavir,  specific  reactivity  was not detected (data not shown). 

















Table  3.6  Volunteer  characteristics  and  generation  of  abacavir‐specific  T‐cell  clones.  A lymphocyte transformation test (LTT) was performed in order to rule out any prior sensitivity to the drug. A stimulation index of > 2 was considered a positive result. Seventy‐four CD8+ T‐cell clones were generated by serial dilution in total and used in subsequent mechanistic studies.  
         
ABC‐specific 
clones 







































































Figure 3.15  Abacavir‐specific  proliferation  (A)  and  interferon‐γ  secretion  (B)  of  T‐cell  clones isolated from HLA‐B*57:01 positive drug‐naïve volunteers. Data represent mean and standard deviation of the indicated number of clones. (ns not significant, **p<0.01, ***p<0.001; control vs. treated; Mann‐Whitney test) SFC= spot forming cell.   
  




Figure 3.16  TCR Vβ expression  is polyclonal. Representative  figures of  six T‐cell  clones, with varied  TCR  Vβ  expression  isolated  from  volunteer  024.  Abacavir‐specific  proliferation  as determined by [3H]‐thymidine incorporation is also displayed.   
3.4.3.3 Secretion of cytokines and cytotoxic molecules The  abacavir‐specific  T‐cell  proliferative  response  was  associated  with  high levels of IFN‐γ, IL‐13 and TNF‐α secretion (Table 3.7 [Luminex analysis]; Figure 3.17 [ELISpot]). In contrast, cytokines IL‐4, IL‐5, IL‐9 and IL‐10 were secreted at lower  levels  and  only  by  a  limited  number  of  clones.  T‐cell  activation  was 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Table 3.7  Luminex analysis of  secreted  cytokines and chemokines  from 10 abacavir‐specific T‐cell clones 













Figure  3.19  Abacavir‐specific  secretion  of  cytotoxic molecules  granzyme  B,  perforin and  Fas  ligand  from  T‐cell  clones.  Clones  were  incubated  with  50µM  abacavir  and autologous  antigen‐presenting  cells  in  antibody  coated  filter  plates.  ELISpots  were developed after 48h. Clones were isolated from volunteer 024.   
3.5 Discussion 
T‐cells  are often  implicated  in  the development of  immunological  reactions  to drugs.    The  proliferation  of  drug‐specific  T‐cells  ex  vivo  is  commonly  used  to diagnose drug hypersensitivity reactions and to determine the causative agent where multiple therapies are administered concurrently.  Recently,  abacavir‐specific  T‐cells  have  been  identified  from  drug‐naïve volunteers  expressing  HLA‐B*57:01,  the  HLA  allele  associated  with susceptibility to abacavir hypersensitivity. This was dependent on a 14‐day pre‐
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enrichment period in the presence of IL‐2 (Chessman et al., 2008).  Including a pre‐enrichment step has previously been found to increase the sensitivity of the standard LTT assay when applied to SMX hypersensitive patients (Lavergne et al., 2010). It was also determined that this increase in sensitivity was not due to a  primary  stimulation,  as  drug‐specific  T‐cells were not  detected  in  PBMCs of tolerant or naïve volunteers after following this protocol (Lavergne et al., 2010). It would therefore seem that this pre‐enrichment step results in an expansion of the drug‐specific T‐cells already present in the peripheral blood.  In  this  investigation,  very  limited  proliferative  responses  to  abacavir  were observed in lymphocytes from 2/6 HLA‐B*57:01 positive volunteers. This is in contrast  to  Chessman  et  al.  (2008),  who  were  able  to  detect  drug‐specific responses  in  all  volunteers  expressing  the  risk  allele.  In  that  study  the  T‐cell response was quantified  in terms of  intracellular IFN‐γ staining.  Incorporation of  [3H]‐thymidine  was  chosen  as  an  endpoint  for  this  investigation  as  it commonly  used  to  detect  drug‐specific  T‐cells  in  the  peripheral  blood  of hypersensitive patients (El‐Ghaiesh et al., 2011, Castrejon et al., 2010) and is an accurate measurement of cellular proliferation. However a disadvantage of [3H]‐ thymidine  incorporation  as  a  readout  is  that  it  is  not  able  to  differentiate between  many  cells  proliferating  slightly  and  a  few  cells  undergoing  many divisions.  Each  measurement  is  based  on  the  entire  well.  Flow  cytometry techniques however can measure the response of single cells. Carboxyfluorescin diacetate succinimidyl ester (CFSE) is a fluorescent dye, which is split between daughter cells during each cell division. The subsequent halving of  fluorescent intensity  can  be  quantified  (Lyons,  1999)  (Fulcher  and  Wong,  1999).    A 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particular advantage of this technique is that cell populations e.g CD4+/CD8+ can be analysed separately (Hanafusa et al., 2012). The  cytokine  readout  employed  in  this  investigation  (ELISpot  assay)  did  not detect  any  abacavir‐specific  increase  in  IFN‐γ  secretion  from  lymphocytes expressing  HLA‐B*57:01,  following  the  14‐day  pre‐enrichment.  Though  the ELISpot  has  a  lower  limit  of  detection  (approximately  10  cytokine  secreting cells per 1 million PBMCs), intracellular staining may be more sensitive in cells producing  low  amounts  of  cytokine  (Letsch  and  Scheibenbogen,  2003).    High levels of non‐specific IFN‐γ secretion were detected, possibly due to cells having been incubated with the drug in the presence of IL‐2 for 14 days. Though cells were  washed  prior  to  performing  the  ELISpot,  abacavir  may  induce  danger signalling (Martin et al., 2007) and so therefore the cells could have been in an activated  state  already.  The  addition  of  cytokines  such  as  IL‐15  have  recently been shown to aid the detection of drug/antigen‐specific T‐cells (Zawodniak et al.,  2010),  however  the  day  on  which  they  are  added  can  influence  the  non‐specific activation of T‐cells (Munier et al., 2009).  Much  less  evidence  for  the  involvement  of  T‐cells  in  the  ALT  elevations associated  with  ximelagatran  treatment  exists.  Positive  LTTs  have  been observed in 2/21 patients with ALTs > 4 x upper limit of normal  (maximum SI 3.2  and  2.0  to  melagatran  and  ximelagatran  respectively)(Kindmark  et  al., 2008).  In  this  investigation  a  borderline  positive  proliferative  response  was seen in 1/12 HLA‐DRB*07:01 positive volunteers (SI= 1.9). No responses were detected  by  IFN‐γ  ELISpot.  The  odds  ratio  for  HLA‐DRB*07:01  is  just  4.4 compared to 117 for abacavir indicating that there are likely to be other factors 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accounting  for  individual  susceptibility  (Kindmark  et  al.,  2008,  Mallal  et  al., 2008).   Drug  concentrations  selected  for  the  study were based on  the maximum non‐toxic  stimulatory  concentration.  For  abacavir  this  was  taken  from  a  previous study  (10µg/ml  is  equal  to approximately 35µM)  (Chessman et  al.,  2008). For ximelagatran few long‐term in vitro studies have been performed with primary immune  cells.  The  monocyte‐like  cell  line  THP‐1  showed  some  decrease  in viability following 24h treatment with 100µM ximelagatran (Edling et al., 2008). Hepatocytes however are more tolerant to ximelagatran and a loss in viability is not observed until concentrations exceeding 200µM (Kenne et al., 2008). A dose of 100µM was therefore selected. Due to the cell numbers required melagatran could not be included.     Given  that  the  data  of  Chessman  et  al.  could  not  be  replicated,  a  second approach was adopted, namely the investigation of gene expression. Given that both  abacavir  hypersensitivity  and  flucloxacillin‐induced  liver  injury  are associated with carriage of HLA‐B*57:01 the two drugs could be investigated in the same samples. In this study, the integrity of the isolated RNA was not ideal, however  recruiting  volunteers  again,  repeating  the  incubations  and  then  re‐extracting the RNA was not feasible. When performing microarray analysis high quality RNA is required, generally a RIN >7 is advised (Thompson et al., 2007). Samples were frozen until all of the volunteers had been recruited. It may have been better to have isolated the RNA rapidly and then stored that until all of the samples  had  been  collected.  One  of  the  benefits  of  using  the  NanoString 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platform however  is  that  it  is  relatively  tolerant  to RNA degradation. A recent study directly compared tissue samples that had been either flash frozen (RIN= 4.6‐9.8)  or  formalin‐fixed  and  paraffin‐embedded  (FFPE)(RIN=  1.5‐2.5).  The authors  found  that  there was a good correlation between  the gene expression data obtained from the two sets of samples (Reis et al., 2011). For this reason it was decided to continue with the study.    Following  24  hour  treatment  with  abacavir  a  number  of  genes  showed  an increase  in  expression  that  may  have  been  promising  to  investigate  further (CCL3,  CXCR3,  IL1‐R1,  IL‐6  and  IL‐8).  Though  these  changes  were  not statistically  significant,  a  confirmatory  real‐time  PCR  study  was  designed. Technical  replicates  could be  included  in  the TaqMan  setup and  it was hoped that  this  would  reduce  the  variation  observed.  This  was  not  found  to  be  the case. It would therefore seem that there is significant inter‐individual variation in  the  expression  of  cytokines  and  chemokines.  This  may  be  a  factor  in  the development  of  hypersensitivity  reactions,  however  it  is  unclear  why  this occurs.  Zidek  et  al.  (2007)  found  considerable  variation  in  baseline  levels  of CCL3 in a study investigating the effects of tenofovir treatment. Despite this the authors  were  able  to  obtain  consistent  fold‐change  increases  following  drug treatment. A larger sample size may be required in order to improve the data.         Due to the difficulties in detecting drug‐specific T‐cells by the previous methods T‐cell  cloning  was  attempted.  T‐cell  clones  are  monoclonal  cell  populations derived  from  a  single  T‐cell.  CD4+  and  CD8+  T‐cells  were  separated  prior  to serial dilution, as CD8+ T‐cell  clones are particularly difficult  to  isolate  (Wu et 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al., 2007). Abacavir‐specific T‐cell clones with a clear Th1 cytokine profile were isolated from all three HLA‐B*57:01 positive volunteers included in this part of the  study.  The  varying  number  of  clones  generated  from  each  individual may relate to technical issues; in particular, the extensive handling needed to isolate and culture CD8+ clones (Wu et al., 2007). However, as 45% of individuals who carry the HLA‐B*57:01 allele do not develop hypersensitivity when exposed to abacavir  (Mallal  et  al.,  2008),  it  is  also possible  that  the number of detectable clones is one factor that determines susceptibility. CD4+ clones were generated in  large numbers,  but  abacavir‐specific  responses were not detected, which  is consistent with the class I HLA association.   Volunteers  were  all  LTT  negative  indicating  that  they  were  not  previously sensitised  to  abacavir,  though  given  that  drug‐specific  T‐cell  clones  could  be isolated from the three HLA‐B*57:01 positive volunteers this may suggest that the  frequency  of  drug‐specific  cells  in  the  circulation  is  below  the  limits  of detection of the LTT.   Vβ  expression  was  investigated  both  to  confirm  the  monoclonality  of  T‐cell clones  and  to  investigate  TCR  restriction. When  investigating  carbamazepine‐induced  SJS/TEN,  Ko  et  al.  (2011)  found  that  in  addition  to  HLA‐B*15:02, patients experiencing SJS/TEN also shared a distinct TCRVβ‐11 and TCRVβ‐15 usage. The authors go as  far as  to suggest genotyping  for  this  in  the clinic.    In this  investigation  the TCR‐Vβ  repertoire was heterogeneous as has previously been suggested (Chessman et al., 2008,  Illing et al., 2012b,  Illing et al., 2012a). 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This  would  suggest  that  multiple  epitopes  are  recognised  by  different  T‐cell clones and hence are immunogenic.  Cytotoxic T‐cells are involved in different forms of immunological drug reaction (Kuechler et al., 2004). Following drug‐induced T‐cell receptor triggering, target cell killing might result from increased surface expression of FAS ligand and/or release  of  soluble mediators  such  as  granzymes,  granulysin  and perforin.  FAS ligand  activates  the  apoptotic  cascade  through  ligation  of  FAS  receptors expressed  on  target  cells.  Perforin  disrupts  cell membranes, while  granzymes and  granulysin  induce  apoptosis,  at  least  in  part,  through  direct  activation  of caspases  (granzymes,  caspase  3  and  9;  granulysin,  caspase  7)  (Thomas  et  al., 2001, Saini et al., 2011). The drug‐specific release of Granzyme B from PBMCs can be used to identify patients with drug allergy (Zawodniak et al., 2010). The findings presented here demonstrate  that clones release perforin, granzyme B and  increase  surface  expression  of  FasL  following  activation  with  abacavir. Furthermore,  it was possible  to  group  the  clones  into 3  categories:  (1)  clones secreting effector molecules and displaying increased FAS ligand expression; (2) clones  secreting  effector  molecules;  and  (3)  clones  displaying  increased  FAS ligand  expression.  These  data  support  a  recent  report  describing  distinct granzyme‐containing and FAS ligand‐associated secretory lysosomes in human T‐cells  (Schmidt  et  al.,  2011)  and  suggest  that  lysosomes  are  differentially expressed  in  clones  and/or  differentially  activated  in  response  to  T‐cell receptor signalling. 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Chemically  reactive  metabolites  are  often  implicated  in  the  toxicity  of  drugs. They can have direct  toxic effects  through binding to cellular macromolecules, which may lead to hapten formation.   The major metabolites  formed  in  vivo  following  abacavir  administration  are  a glucuronide and a carboxylic acid, accounting for 36% and 30% of the excreted dose respectively (Figure 4.1)(McDowell et al., 1999). The oxidation of abacavir to  carboxylic  acid  is  thought  to  proceed  via  a  protein‐reactive  aldehyde metabolite (Walsh et al., 2002). As yet this has not been isolated either in vitro or in vivo, due to its apparent instability. Evidence for its formation is based on the observation of an oxime conjugate when methoxylamine is added to in vitro incubations of abacavir and human liver cytosol (Walsh et al., 2002).   The oxidation of abacavir is catalysed by alcohol dehydrogenase (ADH). Walsh 





Figure  4.1  In  vivo  metabolism  of  abacavir  results  in  the  formation  of  two  major metabolites, a carboxylic acid and a glucuronide (McDowell et al., 1999).  The  adduction  reactions  of  a  synthetic  aldehyde  metabolite  were  recently characterised (Charneira et al., 2011).  The mechanism of adduct formation was found  to  be  dependent  on  the  chosen  nucleophile.  Conjugation  to  nitrogen‐containing  nucleophiles  (e.g  valine)  was  found  to  occur  via  Schiff‐base formation  whereas  conjugation  to  sulphur‐containing  nucleophiles  (e.g cysteine) was by 1,4 addition (Charneira et al., 2011)(see 1.8.2 for mechanisms). 
In vitro incubation of the conjugated aldehyde with haemoglobin resulted in the formation of an N‐terminal valine adduct (Charneira et al., 2011). These adducts were  then  used  as  standards  to  determine  whether  similar  adducts  were formed in vivo. When abacavir was administered to rats valine adducts could be detected in 2/6 (1 male, 1 female) animals (Charneira et al., 2012). Cysteine and lysine  adducts  were  not  detected.  It  is  unclear  however  whether  these metabolites  are  immunogenic  or  indeed  formed  in  humans.    Aldehydes  are 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Figure  4.2  Proposed  mechanisms  of  abacavir  oxidation  and  rationale  for  multiple isomeric products observed in vitro. Adapted from (Walsh et al., 2002).   
4.2 Aims 






4.3.1 Chemicals and reagents  Nicotinamide  adenine  dinucleotide  (β‐NAD),  LC‐MS  grade  water  and acetonitrile  were  all  bought  from  Fisher  scientific,  Loughborough,  UK. MultiScreen Solvinert hydrophilic PTFE  filter plates  (0.45µm) were purchased from Merck Millipore, Watford, UK. RNeasy mini kit and RNase‐free DNase kits were purchased from Qiagen, Crawley, UK. The RT² Profiler™ Drug metabolising enzyme PCR array was also purchased from Qiagen.  Abacavir  sulfate  and  carboxylic  acid  were  kind  gifts  from  GlaxoSmithKline. Deuterated abacavir, dihydro abacavir and 1R,4S abacavir were synthesised by Emma  Yang  (Chemistry  department,  University  of  Liverpool).  All  other chemicals and reagents were obtained from Sigma Aldrich, Dorset, UK  
4.3.2 LC­MS/MS conditions Standards  and  samples  were  analysed  on  a  4000  QTRAP  system  (AB  Sciex, Foster City, CA, USA). Chromatographic separation was performed on an Eclipse XBD C18 (2.1x150mm, 5μm) column (Agilent, Cheshire, UK) at 30˚C. An Ultimate 3000  liquid  chromatography  system  (Dionex,  CA,  USA)  was  interfaced  to  the mass spectrometer. Mobile phase A consisted of 10mM ammonium acetate pH 3.8 and mobile phase B  consisted of  acetonitrile. The  compounds were eluted from  the  chromatographic  column  using  a  linear  gradient  (5‐20%  over  20 minutes) with a flow rate of 0.2 ml/min. The mass spectrometer was operated 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Abacavir  287  191  66  27 
Carboxylic acid  301  191  63  29 
2‐chloroadenosine  302  170  68  28  
4.3.3 Abacavir metabolism in human liver cytosol Reactions were performed in 50mM sodium pyrophosphate pH 8.8. Human liver cytosol  (1mg/ml; 500µl) was  incubated with abacavir  (10µM)  in  the presence or  absence of  the  co‐factor NAD  (7.5mM) at 37˚C  for 1,  4 or 20 hours. Where used, 4‐methylpyrazole (4‐MP) was added at the beginning of the reaction at a final  concentration  of  0.6mM. Methoxylamine  was  used  at  a  concentration  of 10mM.  To  stop  the  reaction,  samples  were  placed  on  ice  for  5  minutes.  Ten volumes of  acetonitrile were  added  to  a  100µl  aliquot  of  the  supernatant  and 100µl internal standard (2‐chloroadenosine; 2µM). Samples were vortexed and precipitated protein was removed by centrifugation (13,000g, 15min, 4˚C). The resulting  supernatant was  then  transferred  to  a  clean  tube  and evaporated  to dryness. For mass spectrometric analysis the dried samples were reconstituted in  mobile  phase  (100µl;  10mM  ammonium  acetate  pH3.8  containing  5% 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acetonitrile)  and  filtered  through  a  0.45µm  filter  plate.  Data  was  processed using Analyst software. Relative quantification was based on the peak areas and calculated  with  the  following  equation  %  metabolite  =  metabolite  peak area/total peak areas.   








4.3.5  Absolute  quantification  of  abacavir  turnover  using 
deuterated abacavir as an internal standard. 
 The  initial  method  was  developed  with  2‐chloroadenosine  as  the  internal standard,  based  on  previous  reports  in  the  literature  (Pruvost  et  al.,  2009). During our  investigations however the ionisation of 2‐chloroadenosine proved to be inconsistent between runs. Following the synthesis of deuterated abacavir the  potential  of  using  it  as  a  more  robust  internal  standard  for  absolute quantification was investigated.   The  chromatographic  conditions  and  source  parameters  were  as  previously described  (see  4.3.2).  The  following  criteria  were  used  to  evaluate  the performance of the method: linearity, recovery, matrix effects, sensitivity (LLOD and LLOQ), precision and accuracy. 














S1  4000  8000  200 
S2  2000  4000  200 
S3  1000  2000  200 
S4  500  1000  200 
S5  250  500  200 
S6  100  200  200 
S7  50  100  200 
S8  25  50  200 
S9  10  20  200 
S10  5  10  200  The  standard  curve  was  generated  by  plotting  the  analyte:internal  standard peak  area  ratio  against  the  concentration  of  analyte.  Six  replicates  of  10,  100 and 1000nM abacavir (100µl) were run in order to determine the accuracy and precision of the method and represented the ‘neat’ (100% response) standards when  calculating  recovery  and  matrix  effects  as  described  below.  Standards were chosen to represent high, medium and low range concentrations.   The  limits  of  detection  and  quantification  (LLOD  and  LLOQ)  were  assigned based on a signal to noise ratio of 3:1 and 10:1 respectively. 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4.3.5.2 Recoveries, precision and accuracy To determine the recovery associated with the extraction method, human liver cytosol (1mg/ml; 100µl) was spiked with 10, 100 or 1000nM abacavir (100µl; n=6).  Samples  were  then  extracted  by  the  standard  protocol  as  described previously (see 4.3.2).  The recovery was calculated with the following equation:  Recovery (%) = (peak area of pre‐spiked sample/peak area in neat standard) x 100  Accuracy was  also  determined  by  comparing  the measured  concentration  (as determined  by  integration  with  the  calibration  curve)  to  the  expected concentration:   Accuracy (%) = measured concentration/expected concentration x 100  The  precision  of  the method was  determined  by  calculating  the  coefficient  of variation of the peak areas of the six replicate recovery samples:   Precision (%CV) = standard deviation/average x 100 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4.3.5.3 Matrix effects To  determine  whether  there  were  any  ion  suppression  or  ion  enhancement effects associated with  the experimental matrix, extracted human  liver cytosol was spiked with 100µl of 10, 100 or 1000nM abacavir solution (100µl; n=6).  Matrix effects were calculated with the following equation:  Matrix effect (%) = (peak area of post‐spiked sample/peak area in neat standard) x100 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4.3.5.4 Applications of validated LC­MS/MS method The  LC‐MS/MS  method  was  then  applied  to  the  comparative  metabolism  of abacavir  and  deuterated  abacavir  studies  in  human  liver  cytosol.  Samples prepared  as  described  previously  using  deuterated  abacavir  (Final concentration  of  IS  =  200nM)  or  abacavir  as  the  internal  standard.  Samples were diluted 1:10 prior to analysis to fit the measured concentration within the linear  range  of  the  calibration  curve.  The  formation  of  carboxylic  acid  was expressed as a percentage and determined via the following equation:   % COOH = amount of COOH (nM)/ (amount of ABC (nM)+ amount of COOH) x 100  
4.3.6 Assessment of the metabolising capacity of antigen­
presenting cells Sub‐cellular  fractions  were  generated  from  EBV‐transformed  B‐cells. Approximately  1  x  109  EBV‐transformed  B‐cells  were  pooled  from  6  donors, pelleted,  sonicated  (4  x  15s)  and  centrifuged  (9000g,  20min,  4˚C)  to  remove extracellular membranes. This was termed the S9 fraction. In order to generate a  cytosol  fraction,  this  extract  was  further  centrifuged  (48  000g,  1h,  4˚C)  to remove  the  microsomes.  Protein  content  was  determined  by  the  method  of Bradford et al. (1976). A stock solution of bovine serum albumin was prepared (2mg/ml)  in  distilled  water  and  diluted  to  generate  a  standard  curve  (Table 4.3). 10µl of each standard was added to a 96‐well plate  in duplicate. Samples were analysed at  several different dilutions  (e.g 1:5, 1:10, 1:50, 1:100, 1:250). Bradford reagent was diluted 1:5 in distilled water and added to wells (200µl). 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4.4.1 Chromatographic separation of abacavir standards The chromatographic conditions described  in 4.3.2 yielded good separation of abacavir  (Rt  =  14.98 min),  abacavir  carboxylic  acid  (Rt  =  13.73 min)  and  the internal standard 2‐chloroadenosine (Rt =10.15 min) (Figure 4.4). This method was applied for the following investigations.  
 
Figure  4.4  Chromoatographic  separation  of  standards.  Solution  contained  2µM abacavir, 4µM carboxylic acid and 2µM 2‐chloroadenosine. 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Figure  4.6  Inhibition  of  abacavir  metabolism  by  4‐methylpyrazole.  Abacavir  was incubated with human  liver  cytosol  in  the presence of  the  indicated  concentration 4‐methylpyrazole for 20h. Data represent mean and standard deviation of 3 independent experiments (ns= not significant, *** = p<0.001; control vs. treated; one‐way ANOVA) 
 
4.4.3 Identification of metabolites formed from abacavir 

















Figure 4.10 Metabolism of dihydro abacavir in human liver cytosol. As no standards of dihydro metabolites were  available,  a  precursor  ion  scan was  performed  for  species containing  a  fragment with  a m/z  of  191  (see  Figure  4.8).  A)  Chromatogram Rt  14.8 minutes=  carboxylic  acid;    15.2  minutes  =  dihydro  abacavir  B)  Precursor  ions  m/z 289.5 = dihydro abacavir; 303.1 = corresponding carboxylic acid.   
4.4.4  Absolute  quantification  of  abacavir  turnover  using 
deuterated abacavir as an internal standard. At  the  time  of  the  establishment  of  the  LC‐MS/MS method  2‐chloroadenosine was selected as an  internal standard as  it had been previously reported  in the literature (Pruvost et al., 2009). During the development of the methodology, 2‐chloroadenosine  proved  to  be  an  unsuitable  internal  standard  to  be  used  for absolute quantification due to its poor ionisation properties. As the deuterated 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Figure  4.13  Comparative metabolism  of  abacavir  and  deuterated  abacavir  in  human liver cytosol. Quantification was based on absolute quantification. Human liver cytosol (1mg/ml) was incubated with each of the compounds (10µM) in the presence of the co‐factor NAD for the indicated time‐points. Data represent the mean ± standard deviation of three experiments (*** = p<0.001; one‐way ANOVA) 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4.4.4.4  Investigation  of  abacavir metabolism  in  human  EBV­transformed 











 RNA  isolated  from  EBV‐transformed  B‐cells  was  subjected  to  PCR  array analysis. The genes investigated are listed in Table 4.7, alongside the average Ct values obtained from two replicate samples. The Ct value is an indication of the PCR cycle  at which  the  fluorescent  signal  reaches a  threshold  intensity, hence the lower the number the more abundant the target. Where no amplification of the  target  was  observed  within  the  40  cycles  an  ‘undetermined’  call  was assigned. 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The  formation  of  reactive  metabolites  is  often  associated  with  drug  toxicity. Abacavir  administration  is  associated with  hypersensitivity  reactions  in  up  to 8% of patients undergoing therapy. Previous investigations have suggested the formation of a reactive aldehyde metabolite, which has the potential to bind to proteins  (Walsh  et  al.,  2002,  Charneira  et  al.,  2011)  and  could  lead  to immunogenicity  through a  classical  hapten mechanism.  In order  to determine whether T‐cells  in  in vitro assays are exposed to this metabolite an LC‐MS/MS method was developed to quantify abacavir and its metabolites.      The  LC‐MS/MS  conditions  investigated  yielded  good  chromatographic separation of abacavir and its carboxylic acid metabolite. Firstly the method was applied  to  human  liver  cytosol  given  that  the  metabolism  of  abacavir  has previously  been  characterised  in  this matrix  and  it  provides  a  rich  source  of alcohol dehydrogenase. Abacavir was metabolised to three isomeric carboxylic acids via an aldehyde intermediate that could be trapped with methoxylamine. Formation of  the  carboxylic  acids  could  therefore be used  to  indicate  that  the aldehyde had been produced.  A  number  of  analogues  of  abacavir  were  synthesised  in  order  to  investigate metabolism and the specificity of drug‐responsive T‐cell clones. Modifications to the structure of abacavir may impact upon the stereochemistry of the molecule and  hence  the  direct  interaction  between  abacavir  and  the MHC/TCR  or may alter  the  metabolism  of  the  compound.  The  stereochemistry  of  abacavir  is known to be important for its pharmacological activity (Faletto et al., 1997) and 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so  the  stereoselectivity  of  alcohol  dehydrogenase  was  also  investigated. Pharmaceutical abacavir is a single enantiomer in the 1S,4R configuration. This is  because  the  alternative  1R,4S  configuration  lacks  pharmacological  activity due  to  enantioselectivity  at  the  active  site  of  the  enzyme  adenosine phosphotransferase  (Faletto  et  al.,  1997).  Analysis  of  the  metabolism  of pharmaceutical 1S,4R abacavir and the alternative 1R,4S enantiomeric  form to the corresponding carboxylic acids by human liver cytosol confirmed that both molecules  are  substrates  for  alcohol  dehydrogenase  (Walsh  et  al.,  2002).  This would  indicate  that  any  differences  in  T‐cell  response  would  be  due  to  the altered stereochemistry of the parent drug/metabolites and not due to impaired metabolism (see Chapter 5). Carbovir, the molecule on which abacavir is based is  also  metabolised  by  alcohol  dehydrogenase.  Both  enantiomers  are metabolised in rat liver cytosol but the (+)‐enantiomer (1S,4R) is favoured by 6‐7  fold  (Patanella  and  Walsh,  1992).  Our  investigation  however  was  merely qualitative.  Metabolism  experiments  showed  that  dihydro  abacavir  formed  a  single carboxylic metabolite when  incubated with  human  liver  cytosol.  Double  bond migration  is  involved  in  the  isomerisation  of  abacavir  metabolites  hence  the removal  of  the  double  bond  results  in  the  formation  of  a  single  isomer  of dihydro  carboxylic  acid.  Previously  dihydro  abacavir  has  been  reported  to  be more  susceptible  to  metabolism  but  produce  fewer  non‐extractable  residues than abacavir  (Walsh et  al.,  2002).  It was  this observation  that  implicated  the double bond in the mechanism of protein conjugation. 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In  addition,  deuterated  abacavir  was  synthesised  as  a  potential  tool  for examining  the role of metabolism  in  the abacavir‐specific T‐cell  response. The cleavage  of  carbon‐deuterium  bonds  requires  higher  activation  energy  than carbon‐hydrogen bonds. In preliminary investigations, deuterated abacavir was metabolised  to  three  isomeric  carboxylic  acids  but  at  a  slower  rate  than abacavir. This is termed a kinetic isotope effect. The full characterisation of this effect  requires  further  studies  that  are  outside  the  scope  of  this  thesis.  In particular, calculation of the reaction rate constants.  The availability of deuterated abacavir also presented an opportunity to use  it as  an  internal  standard  in  the  absolute  quantification  of  abacavir  and metabolites  from  in  vitro  incubations.  Isotope‐labelled  internal  standards generally  have  the  same  retention  time  and  ionisation  characteristics  as  the analyte  of  interest  but  can  be  identified  by  their  increased mass.  If  the  signal overlap is kept to a minimum a quantitative method can be established (Atzrodt et al., 2007). Isotope labelled internal standards are also thought to reduce the influence of any matrix effects (Atzrodt et al., 2007). This is because they elute at  the  same  time  as  the  analyte  of  interest  meaning  that  both  the  internal standard and analyte are affected proportionally.   Firstly  quality  control  samples  were  generated  in  order  to  establish  that  the method  could be  reliably used  to quantify  abacavir  and  the  carboxylic  acid  in samples. The calibration curves were linear (R2>0.99) over the ranges examined for abacavir (5‐2000nM) and carboxylic acid (10‐4000nM). The LLOD and LLOQ were 0.075nM and 0.3nM for abacavir and 2.5nM and 10nM for the carboxylic 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acid indicating that the method had the required sensitivity for the samples to be  analysed.  Intra  and  inter day precision  for  abacavir  ranged  from 2  to 15% and  5.5  to  14.9 %  respectively.  Accuracy  was  found  to  be  between  86.6  and 112%. For  abacavir  carboxylic  acid  intra  and  inter day precision  ranged  from 1.5  to  12.7%  and  7.6  to  14%.  Accuracy  was  between  86.4  and  113.3%. Recoveries  ranged  between  86.9‐118.5%  for  abacavir  and  89.1‐122.8%  for carboxylic acid.  Matrix effects generally refer to ion suppression or ion enhancement, which can interfere with the accurate quantitation of the analyte of interest. Matrix effects can be a result of co‐eluting contaminants from the biological matrix (e.g salts, triglycerides, amines), though this is not always the case. Indeed all stages of the sample preparation can influence the ionisation of the sample, even down to the plasticware used (Mei et al., 2003). They can be particularly problematic when complex biological matrices are investigated. In the method developed here no significant  matrix  effects  were  observed.  For  abacavir  matrix  effects  ranged between  93‐110%  and  this was  similar  to  those  calculated  for  the  carboxylic acid  of  between 92  and 113%. Matrix  effects were  particularly  evident  at  the lowest  concentrations  of  both  analytes  though  this  may  be  due  to  the  lower sensitivity of the method at this level.    These fulfilled the criteria provided by the FDA (US Department of Health and Human Services, 2001)  for  the validation of bioanalytical methods. Hence,  the validated  LC‐MS/MS  method  was  considered  reproducible  and  reliable quantification for the studies described in this thesis. 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Once  validated,  the  quantitative  method  was  firstly  applied  to  human  liver cytosol  incubations.  The  metabolic  activity  of  immune  cells  was  then investigated.  Carboxylic  acid  metabolites  were  detected  following  20h incubation of abacavir with an S9 fraction generated from EBV‐transformed B‐cells.  This  was  however  dependent  on  the  concentration  of  samples  prior  to analysis. The protein content was also increased for each incubation due to the suspected  low expression of metabolising enzymes. Oxidative metabolism was also detected in a cytosolic fraction prepared from EBV‐transformed B‐cells.  A  small  amount  of  carboxylic  acid  is  formed,  however  it  is  unclear  what proportion  of  the  aldehyde  this  represents  and  how  much  is  subsequently available to bind to proteins. Recent in vivo studies have characterised abacavir binding  to  haemoglobin  however  it  is  unclear  whether  these  adducts  are capable of  stimulating T‐cells  (Charneira  et  al.,  2012).  It  is  likely  that  these  in 
vivo  adducts  are  formed  as  a  result  of  hepatic  metabolism.  One  of  the  main arguments  for  a  metabolism‐independent  mechanism  of  T‐cell  activation  has been that B and T‐cells do not express class I alcohol dehydrogenase (Adam et al., 2012), however given that oxidative metabolism does indeed occur in these cells  this  may  not  be  important.  In  fact,  the  preliminary  observation  that metabolism  is  not  blocked  by  4‐methylpyrazole  might  indicate  an  as  yet undefined  alcohol  dehydrogenase‐independent  route  of  metabolism.  Further studies are required in order to confirm this.  The  alcohol  dehydrogenase  inhibitor  4‐methylpyrazole  inhibits  class  I  and  II ADH  efficiently.    Class  III  ADH  which  is  widely  expressed  in  many  tissues  is 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however  insensitive  to  4‐methylpyrazole.  It  has  a  rather  different  substrate specificity  to  the  class  I  and  II  ADHs  and  metabolises  ethanol  very  poorly (Wagner et al., 1984). Pyrazole had very little effect on metabolism of ethanol in cytosol  isolated  from  rat  skin  (Lockley  et  al.,  2005).  Similarly  cytosol  isolated from human skin retained 38% of control activity following pyrazole treatment (Cheung et al., 2003). ADH class III has not previously been shown to metabolise abacavir however (Walsh et al., 2002).   Preliminary  gene  expression  analysis  indicates  that  the  RNA  of  a  number  of drug metabolising enzymes is expressed in EBV‐transformed B‐cells. ADH5 was expressed at a high  level as reported previously (Adam et al., 2012). Enzymes expressed at a similar level include a number of aldehyde dehydrogenases, CYPs 1B1,  2C19  and  7B1,  hydroxysteroid  17‐β  dehydrogenase,  esterase  D  and ubiquitin thiolesterases. It is unclear whether any of these have the potential to metabolise  abacavir.  It  would  appear  however  that  a  cytosolic  enzyme  is involved as removal of the microsomes did not prevent abacavir metabolism in B‐cells. This would tend to rule out CYP‐mediated metabolism.   Aldehyde dehydrogenase 1 (ALDH1) is sensitive to disulfiram. Active aldehyde dehydrogenases  are  expressed  in  red  blood  cells  but  also  lymphocytes  and platelets (Helander and Tottmar, 1988). Given that the oxidation of carbovir is partly due  to aldehyde dehydrogenase activity  (Patanella and Walsh, 1992),  it could therefore be predicted that abacavir is similarly metabolised. This enzyme is  likely  to  catalyse  the  oxidation  of  abacavir  aldehyde  to  carboxylic  acid.  In initial  investigations  disulfiram  inhibited  abacavir  metabolism  by 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5.1 Introduction  A  number  of  hypotheses  have  been  proposed  to  explain  the  ability  of  small molecules  such  as  drugs  to  initiate  an  immune  response  against  host  cells. Drugs or drug metabolites may bind covalently  to proteins before being taken up by specialised antigen‐presenting cells. These haptenated proteins are then processed within the cell, and cleaved into peptide fragments which can then be presented  to  T‐cells  via  MHC  molecules  (Park  et  al.,  2001,  Landsteiner  and Jacobs,  1935).  Alternatively  the  p‐i  concept  suggests  that  the  interaction between drug, T‐cell receptor and MHC molecule can be non‐covalent in nature and that direct stimulation of T‐cells occurs, independent of cellular processing (Pichler, 2002). Both of these mechanisms highlight that the unique interaction between  drug,  T‐cell  receptor  and  MHC  molecule  is  a  key  factor  in  the development  of  immune‐mediated  adverse  reactions  to  drugs  and  as  such, genetic associations involving specific HLA alleles may indicate why only small numbers of patients ultimately develop a reaction.  The generation of T‐cell clones allows the study of these mechanisms in vitro. It must however be stressed that these investigations only reveal the mechanisms of activation  in vitro and  in particular  the recall response. Very  little  is known about  the  initial  priming  of  the  response  in  vivo.  These  studies  often  indicate that multiple mechanisms of T‐cell activation can occur simultaneously.  In  the case  of  sulfamethoxazole  (SMX),  distinct  populations  of  T‐cell  clones  can  be generated  that  are  either  parent  drug  specific,  metabolite‐specific  or  cross‐reactive  (Castrejon  et  al.,  2010).  T‐cell  clones  activated  by  the  parent  drug 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• Investigate  the mechanisms  of  antigen  presentation  associated with  T‐cell activation by abacavir  
5.3 Materials and Methods 




T­cell medium was comprised of RPMI 1640 supplemented with 10% human AB serum,  25mM  HEPES,  1000U/ml  penicillin,  0.1mg/ml  streptomycin,  2mM  L‐glutamine and 25µg/ml transferrin.   
Antigen­presenting cell medium was comprised of RPMI 1640 supplemented with 
10% Foetal bovine serum, 25mM HEPES, 1000U/ml penicillin, 0.1mg/ml 
streptomycin and 2mM L-glutamine.   
5.3.3 T­cell cloning T‐cell  clones  used  in  this  chapter  were  generated  according  to  the  methods described previously    (see 3.3.5). Seventy‐four T‐cell clones were available  for investigation (see Table 3.6 and Figure 3.14).  







For  the  ELISpot  assay Multiscreen  filter  plates were  coated with  interferon‐γ antibody (15µg/ml) overnight at 4˚C. Wells were washed with PBS (200µl) and blocked for 30 minutes with T‐cell medium (200µl). T‐cell clones were added to the  plate  along  with  irradiated  autologous  EBV‐transformed  B‐cells  and  the compound  of  interest    (1,  5,  10,  50  and  100µM).  After  48h  the  plate  was developed according to the manufacturers instructions. The wells were washed with  PBS  and  incubated  with  secondary  antibody  (diluted  1:1000  in  PBS containing 0.5% FBS) for 2 hours at room temperature. After washing with PBS, Streptavidin‐ALP    (diluted  1:1000  in  PBS  containing  0.5% FBS) was  added  to wells for one hour. Spots were visualised by the addition of BCIP/NBT substrate (100µl,  15  min).  The  plate  was  counted  on  an  AID  ELISpot  reader  (Cadama Medical, Stourbridge, UK) when thoroughly dried. 
 
5.3.5 Mechanisms of antigen presentation 
5.3.5.1 Fixation of antigen­presenting cells The fixation assay is used to determine the role of intracellular processing in the T‐cell  response.  Autologous  EBV‐transformed  B‐cells  (2  x  106)  were  washed twice in HBSS and resuspended in 1ml HBSS. Glutaraldehyde (12.5µl, 2%) was then added and the cells agitated for 30 seconds. Glycine (1ml, 1M) was quickly added  and  cells  were  agitated  for  a  further  45  seconds.  The  cells  were resuspended  in  10ml  T‐cell  medium  after  extensive  washing  (3  times,  T‐cell medium).  Glutaraldehyde‐fixed  EBV‐transformed  B‐cells    (1x  104,  50µl)  were then  added  to  T‐cell  clones  (5  x  104)  in  the  presence  or  absence  of  abacavir 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(50µM). Cells were  cultured  for 3 days  at 37˚C with  [3H]‐thymidine added  for the final 16h. Proliferation was determined by scintillation counting.  In order to determine the effect of glutaraldehyde fixation on cellular uptake of abacavir  the  intracellular  accumulation  of  abacavir  was  investigated.  EBV‐transformed  B‐cells  (fixed  and  unfixed)(20  x  106;  5ml)  were  incubated  with 10µM abacavir  for 1, 4 and 16 hours. At each  time‐point  cells were harvested centrifuged and the supernatant removed. Cell pellets were resuspended in 5ml water and sonicated (4 x 10 sec). Deuterated abacavir (200nM; 50µl) was used as the internal standard. Acetonitrile (10 volumes) was added and precipitated proteins were removed by centrifugation. Samples were evaporated to dryness and  resuspended  in  50µl  mobile  phase  (10mM  ammounium  acetate,  pH  3.8) prior to LC‐MS/MS analysis (see 4.3.2 for details of LC‐MS/MS conditions).   




5.4.1 Chemical cross­reactivity The specificity of T‐cell clones was determined by both proliferation and IFN‐γ ELISpot  assays.  The  alternative  enantiomer  of  abacavir  (1R,4S  )  did  not stimulate  any  of  the  clones  tested  to  proliferate  (Figure  5.2  A)  or  secrete cytokines  (Figure  5.2B).  Dihydro  abacavir,  which  lacks  a  double  bond  on  the cyclopentane ring, stimulated some clones to proliferate but only at the highest concentrations  (50  and  100µM)(Figure  5.3A  and  B)  and  at  a  decreased magnitude compared to abacavir. Carbovir did not stimulate any of  the clones tested (Figure 5.4). Deuterated abacavir stimulated clones to the same degree as 1S,4R abacavir (Figure 5.5).  
 















Figure  5.5  Cross‐reactivity  of  four  abacavir‐specific  T‐cell  clones  to  deuterated  abacavir was determined by IFN‐γ ELISpot. SFC= spot forming cell. Clones were isolated from volunteer 024.      
5.4.2 Mechanisms of antigen presentation Both processing dependent and independent clones were observed (Figure 5.6A and  B).  However  given  that  MHC  class  I  molecules  are  expressed  by  all nucleated  cells,  the  possibility  of  self‐presentation  was  also  investigated  by omitting the supplementary antigen‐presenting cells. Abacavir stimulated 45% of  the  clones  to  proliferate  and  secrete  IFN‐γ  directly,  in  the  absence  of irradiated  EBV‐transformed  B‐cells  (Figure  5.7A).  The  remaining  clones were activated only in the presence of transformed B‐cells (Figure 5.7B); accordingly, these  clones  were  used  to  probe  mechanisms  of  drug  antigen  presentation 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Figure  5.7  Abacavir‐specific  T‐cell  clones  can  be  activated  in  the  absence  of  supplementary antigen‐presenting cells. T‐cell clones were incubated either with (white bars) or without (grey bars)  the  addition  of  autologous  EBV‐transformed  B‐cells  in  the  presence  of  abacavir. Proliferation  was  determined  by  [3H]‐thymidine  incorporation.  Each  graph  represents  an individual T‐cell clone. Clones were isolated from volunteer 024.   
  















In this chapter, abacavir‐specific T‐cell clones isolated from healthy volunteers expressing  HLA‐B*57:01  were  subjected  to  a  number  of  in  vitro  assays commonly  used  to  determine  chemical  cross‐reactivity  and  the  mechanisms underlying T‐cell activation.  In  order  for  abacavir  to  initiate  a  T‐cell  response,  it  is  possible  that  abacavir binds  directly  to  HLA‐B*57:01  or  an  HLA‐B*57:01  binding  peptide. Alternatively,  abacavir metabolites  could bind  irreversibly  to protein,  forming abacavir‐modified  HLA‐B*57:01  binding  sequences  that  will  be  released through protein processing. With reference to the latter, the identity of proteins modified with  abacavir metabolites,  the  nature  of  the  binding  interaction  and the number of modifications needed to stimulate T‐cells remains unresolved.   Abacavir  analogues  were  synthesised  in  order  to  examine  the  nature  of  the interaction  between  the  drug  and  HLA‐B*57:01.  Chessman  et  al.  (2008) previously  investigated  the  immunogenicity  of  carbovir,  didanosine  and guanosine in PBMCs isolated from hypersensitive patients and found that none of these compounds were able to stimulate abacavir‐specific T‐cells. All of these compounds  lack  the cyclopropyl  ring moiety and hence  this was  implicated  in the immunogenicity of abacavir. In this investigation the alternative enantiomer of  abacavir did not  stimulate any T‐cell  clones and dihydro abacavir was only 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stimulatory  in  certain  clones  and  at  high  concentrations.  Previously  dihydro abacavir  has  been  shown  to  form  fewer  covalent  adducts with  human  serum albumin than abacavir itself (Walsh et al., 2002). This could explain the reduced immunogenicity  of  dihydro  abacavir.  Chemical  restriction  of  the  abacavir‐specific T‐cell response could also be due to the altered stereochemistry of the molecules  impacting  on  the  direct  interaction  with  HLA‐B*57:01.  Deuterated abacavir is metabolised more slowly than abacavir at least in liver preparations (see Chapter 4). The fact that  it still stimulates clones at an equivalent  level to abacavir  itself may  therefore be  interesting. However  it  is  thought  that only a very small number of antigen molecules need to interact with TCRs in order for them to be stimulatory (Brower et al., 1994) and given that incubation times for the various assays can be up to 48 hours it is unclear whether the reduced rate of metabolism is likely to be important.    Omitting antigen‐presenting cells from the assay revealed that some clones did not  require  the  presence  of  supplementary  antigen‐presenting  cells.  This  is consistent with the fact that MHC class I molecules are expressed on almost all nucleated cells.  The role of antigen uptake and processing in the T‐cell response is commonly determined by fixation of antigen‐presenting cells (Schnyder et al., 1997). Glutaraldehyde cross‐links proteins. Cells fixed in this way are unable to process  antigens.  Fixation  does  not  alter  MHC  expression,  presentation  of peptides  that  have  already  been  processed  or  the  direct  interaction  of  drugs with MHC molecules (Zanni et al., 1998, Shimonkevitz et al., 1983). The effect of fixation on drug uptake however has not been studied. Half of the clones tested in this investigation were activated in the presence of fixed antigen‐presenting 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cells. These clones are either able to self‐present or are stimulated by the parent drug  or  a  metabolite  binding  directly  to  an  MHC‐peptide  complex  at  the  cell surface. Vacant MHC molecules are not transported to the cell surface.  Instead they  are  degraded  in  the  cytosol  (Hughes  et  al.,  1997).  Any  cell  surface interaction  would  therefore  be  with  an  occupied  MHC  molecule.  This  might suggest  that  any  bonds  formed  would  be  between  the  drug  and  the  bound peptide.   It  could  be  hypothesised  that  glutaraldehyde  fixation  would  impact  on  the cellular  uptake  of  drugs  through  the  disruption  of  transporters  or  the  cell membrane. However, this was not found to be the case. This is probably due to the fact that abacavir is taken up passively (Mahony et al., 2004). Abacavir is a substrate  for  the  efflux  transporter  P‐glycoprotein  (P‐gp)  (Shaik  et  al.,  2007) which  might  suggest  that  fixation  would  lead  to  increased  accumulation  of abacavir were the transporter to be impaired. This was not observed. Abacavir was  taken up  rapidly by  cells  (both  fixed and unfixed)  and maintained at  this concentration  for  up  to  16  hours.  This  is  in  agreement  with  other  studies  in which  abacavir  can  be  detected  within  the  cell  following  just  a  few  minutes incubation (Mahony et al., 2004) .   Pulsing  of  antigen‐presenting  cells  is  used  to  determine  the  role  of drug/metabolite binding to peptides or the MHC. Following 1 hour or overnight incubation with the drug, antigen‐presenting cells are washed thoroughly prior to co‐incubation with T‐cells. Stable drug‐MHC/peptide complexes are resistant to  washing.  This  interaction  does  not  have  to  be  covalent  in  nature,  indeed 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multiple non‐convalent bonds such as Van der Waals forces or coordinate bonds could be  just as strong as a covalent bond. Pulsing for 1h was not sufficient to stimulate  T‐cell  clones.  As  stated  previously,  abacavir  is  rapidly  taken  up  by antigen‐presenting  cells  meaning  it  would  be  available  to  bind  to  MHC molecules  during  this  time.  These  could  be  vacant  MHC  molecules  or  MHC molecules  already  containing  a  peptide.  In  contrast,  10/19 T‐cell  clones were stimulated  to  proliferate  and/or  secrete  interferon‐γ  by  APCs  pulsed  with abacavir for 16 hours. The time‐dependency of the APC pulsing T‐cell response is  difficult  to  reconcile  with  a  direct  interaction  of  abacavir  with  surface  or endogenous  MHC  molecules,  as  abacavir  is  present  within  the  cell  at  similar levels at both of these time‐points. Interestingly, 16 hours is the time required for abacavir metabolites  to be generated  in APCs  (see Chapter 4) However,  in the absence of a specific inhibitor to block abacavir metabolism in immune cells, its  role  in  the  T‐cell  response  is  difficult  to  prove.    Fixation  of  APCs  prior  to pulsing  with  abacavir  indicates  that  functional  APCs  are  required  and  that processing mechanisms are important in the pulsed response. This could be the processing of self‐peptides or haptenated peptides.  Our findings must be discussed in the context of recent findings by a number of groups that have shown that abacavir binds to endogenous MHC molecules and alters  the  repertoire  of  peptides  displayed  on  the  cell  surface  (Illing  et  al., 2012a, Norcross et al., 2012, Ostrov et al., 2012) (discussed in Chapter 6). The processing  of  self‐peptides  is  likely  to  be  an  important  step  in  immune recognition by this mechanism.  
Chapter 5 – Abacavir‐specific T‐cell clones 
  209 




Final discussion  Adverse  drug  reactions  (ADRs)  are  a  serious  health  problem  and  a  frequent cause of drug withdrawals. Type B off‐target reactions are particularly difficult to  predict  and  affect  only  a  small  number  of  susceptible  individuals. Many  of these reactions have an immune aetiology.   Most  experimental work  to  date  has  focussed  on  the  characterisation  of  cells isolated from hypersensitive patents and in this way much can be learned about the cellular phenotype and cytokine profile of drug‐reactive cells. Drug‐specific cytotoxic T‐cells  can often be  identified and  this may give an  indication of  the cause  of  cellular  damage. Multiple mechanisms  of  T‐cell  activation  have  been hypothesised  (see 1.5)  and evidence  supporting  each of  these  can be  inferred from the characteristics of T‐cell clones isolated from hypersensitive patients. It is still difficult to interpret how this relates to the  in vivo situation however as experimental findings are based on a recall response. In addition to traditional proliferative responses measured in the standard LTT assay, cytokine secretion as  determined  by  ELISpot  is  increasingly  used  to  characterise  drug hypersensitivity (Rozieres et al., 2009). This is   particularly useful where CD8+ T‐cells are involved in the reaction and may indeed improve the sensitivity of in 
vitro assays.   The  emergence  of  a  variety  of  highly  specific  HLA  associations  has  however both provided a means through which to predict at‐risk patients and also shed further  light  on  the  underlying  mechanisms.  A  diverse  array  of  adverse 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reactions have now been reported to be associated with possession of a specific HLA  molecule  and  both  skin  and  liver  reactions  are  represented.  Given  that specific  HLA  molecules  may  have  a  functional  role  in  antigen  presentation, future work  to understand  the mechanisms  involved must be performed with cells  from  a  known  genetic  background.  A  cohort  of  400  volunteers  was therefore established in order to investigate these associations in vitro.   The association between HLA‐B*57:01 and abacavir hypersensitivity represents a  prime  example  of  how pharmacogenomics  can be  effectively  translated  into the  clinic.  Genotyping  prior  to  prescription  has  been  introduced  on  a  global scale, effectively reducing the incidence of the reaction (Hughes et al., 2004). A total  of  26  individuals  expressing  HLA‐B*57:01 were  identified  in  our  cohort and cells from these volunteers were used in in vitro assays.   Drug‐specific  T‐cells  are  often  implicated  in  the  pathogenesis  of  drug hypersensitivity reactions. An important breakthrough however came with the detection  of  drug‐reactive  T‐cells  isolated  from  healthy  volunteers  that  have never been exposed to abacavir (Chessman et al., 2008). A similar phenomenon has also  recently been observed with carbamazepine and HLA‐B*15:02  (Ko et al.,  2011).  Our  attempts  however  to  replicate  these  findings  were  largely unsuccessful  (Chapter  3).  This  may  be  due  to  technical  difficulties  or  the alternative readouts examined. Abacavir‐specific T‐cell clones however could be generated  from all HLA‐B*57:01 volunteers  tested. This may  indicate  that  the number of drug‐reactive  cells was  too  low  to detect by either proliferation or 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cytokine ELISpot directly. It was only through analysing single cell populations that robust responses were observed.   Traditionally  T‐cell  responses  detected  by  either  LTT  or  ELISpot  assay  have been  attributed  to  the  expansion  of  a  memory  cell  population  following  the initial  priming  of  the  immune  response  in  vivo.  Could  these  cells  therefore  be from a cross‐reactive population? The cross‐reacting antigen would need to be prevalent in a number of different populations and uniquely restricted by HLA‐B*57:01. It may however explain why only a proportion of patients expressing HLA‐B*57:01  develop  a  hypersensitivity  reaction  when  exposed  to  abacavir; perhaps  they  must  also  have  previously  encountered  a  cross‐reacting  viral peptide.  Interestingly,  HLA‐B*57:01  restricted  CD8+  T‐cells  are  more  cross‐reactive to point mutants of viral peptides than T‐cells restricted by other HLA alleles (Kosmrlj et al., 2010). This is thought to be because HLA‐B*57:01 binds fewer self‐peptides than other alleles and therefore encounters fewer peptide‐TCR  sequences  during  thymic  development.  Precursor  frequencies  are  also predicted  to  be  higher  in  a HLA‐B*57:01  restricted  repertoire  (Kosmrlj  et  al., 2010). Possession of the HLA‐B*57:01 allele is protective against HIV infection (Migueles  et  al.,  2000),  possibly  because  mutations  in  the  HIV  virus  do  not impact upon immune recognition. Nevertheless,  it  was  found  that  the  abacavir‐specific  T‐cell  clones  that  were isolated  in  the present  study were highly  specific  in a  chemical  sense and not activated by various analogues of abacavir (Chapter 5). This may  indicate  that there  is more  to  the  interaction  than a  simple  fit  of  the molecule  in  a  specific 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TCR. The specificity appears to reside at  least  in part, within the HLA‐B*57:01 molecule itself, as previously reported (Chessman et al., 2008).   Chessman et al. (2008) previously investigated the immunogenicity of carbovir, didanosine and guanosine  in PBMCs  isolated from hypersensitive patients and found that none of these compounds were able to stimulate abacavir‐specific T‐cells.  All  of  these  compounds  lack  the  cyclopropyl  ring moiety  and hence  this was  implicated  in  the  immunogenicity  of  abacavir.  In  this  investigation  the alternative  enantiomer  of  abacavir  did  not  stimulate  any  T‐cell  clones  and dihydro  abacavir  was  only  stimulatory  in  certain  clones  and  at  high concentrations.  Previously  dihydro  abacavir  has  been  shown  to  form  fewer covalent adducts with human serum albumin than abacavir itself (Walsh et al., 2002).  This  could  explain  the  reduced  immunogenicity  of  dihydro  abacavir. Chemical restriction of the abacavir‐specific T‐cell response could also be due to the altered stereochemistry of the molecules impacting on the direct interaction with  HLA‐B*57:01.  Deuterated  abacavir  is  metabolised  more  slowly  than abacavir  at  least  in  liver  preparations  (see  Chapter  4).  The  fact  that  it  still stimulates clones at an equivalent level to abacavir itself may therefore relate to the  direct  (metabolism  independent)  activation  of  T‐cells.  Alternatively,  the levels  of  metabolism  seen  with  deuterated  abacavir  might  be  sufficient  to activate the T‐cell response.  Alongside  the  T‐cell  assays,  metabolic  investigations  were  also  performed. Chemically  reactive metabolites  are  often  implicated  in  drug  hypersensitivity reactions. In order to make any conclusions regarding the mechanisms of T‐cell activation  it  is  therefore  important  to  understand which  chemical  entities  the 
Chapter 6 – Final discussion 
  214 
cells  are  exposed  to.  The  oxidation  of  abacavir  to  a  stable  carboxylic  acid metabolite proceeds via a reactive aldehyde (Walsh et al., 2002). This has been found to covalently bind  to proteins both  in vitro  and  in vivo  (Charneira et al., 2011,  Charneira  et  al.,  2012).  Whether  these  modified  proteins  are immunogenic is unclear.  In  this  investigation  EBV‐transformed  B‐cells  were  found  to  be metabolically active. This is important as these cells represent the only source of metabolising enzymes  in  the  in  vitro  assays.    Metabolites  were  formed  in  low  amounts; nonetheless this indicates that cells are exposed to the reactive aldehyde during 
in vitro assays. Of course  the major site of metabolism  in vivo  is  the  liver.  It  is difficult  to  suggest  therefore  what  contribution  abacavir  metabolism  plays  in 
vivo  versus  in  vitro.  Reactive  metabolites  formed  hepatically  are  unlikely  to reach distant sites unchanged. Instead they are likely to bind to proteins in the vicinity  in  which  they  are  formed.  These  modified  proteins  could  then potentially circulate in the blood to other sites. However, if that were the case it is difficult to conceive why certain organs are targeted.     The major chemical entity present in our  in vitro assays is however the parent drug.  There  have  been  considerable  advances  with  regard  to  understanding how abacavir can interact with HLA‐B*57:01 directly. A number of groups have all  independently  proposed  a  novel mechanism  of  drug  interaction with  HLA molecules  (Ostrov  et  al.,  2012,  Norcross  et  al.,  2012,  Illing  et  al.,  2012a).  The central  feature  of  each  of  these  studies  is  that  T‐cell  activation  occurs independently  of  either  drug  bioactivation  or  hapten  formation.  Due  to  the 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groundbreaking  nature  of  these  findings  each  of  the  papers will  be  discussed here.  
“Abacavir  induces  loading  of  novel  self­peptides  into  HLA­B*57:01:  an 
autoimmune  model  for  HLA­associated  drug  hypersensitivity”  (Norcross  et  al. 2012)  In this investigation the authors attempted to define the influence of abacavir on peptide  binding  to HLA‐B*57:01.  Firstly,  the  authors  determined  the  effect  of abacavir on the strength of peptide binding to soluble HLA‐B*57:01 molecules (sHLA‐B*57:01). A fluorescently labelled self‐peptide was incubated with sHLA‐B*57:01  in  the  presence  and  absence  of  abacavir.  Abacavir  enhanced  the binding  of  the  peptide  in  a  concentration‐dependent  manner.  Neither didanosine  (another  NRTI)  nor  flucloxacillin  (an  antibiotic  causing  DILI  in patients expressing HLA‐B*57:01) had this effect. The authors suggest that this may represent a physiological interaction as the increase in peptide affinity was observed at doses as  low as 10µM. Soluble HLA‐B*57:01 molecules were  then cultured  in  the presence or absence of  abacavir  and  the bound peptides were analysed  by  mass  spectrometry.  Peptides  common  to  both  treated  and untreated  samples  contained  the  expected  HLA‐B*57:01‐binding  P2  and  C terminal  (PΩ)  anchor  residues.  These  included  alanine,  threonine or  serine  at P2  and  tryptophan,  tyrosine  or  phenylalanine  at  PΩ.  Following  abacavir treatment,  eluted  peptides  showed  an  increased  preference  for  isoleucine  or leucine at PΩ. No changes to the P2 residue were observed.   Next,  the authors investigated whether  these  peptides would  only  bind  to  sHLA‐B*57:01  in  the 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presence of the drug. This was not the case. It is unclear however whether this could  have  been  due  to  the  use  of  soluble  HLA  molecules.  The  authors  also suggested  that  abacavir  metabolites  might  bind  in  a  similar  way  to  abacavir itself and hence have a similar effect.            
“Immune self­reactivity triggered by drug­modified HLA­peptide repertoire” (Illing et al. 2012)  In this paper, the ability of a number of different HLA alleles to present abacavir to T‐cells was assessed. In addition to alleles previously investigated (Chessman et  al.,  2008)  the  authors  looked  at  HLA‐B*57:11  which  contains  Ile94Thr, Ile95Leu and Val97Trp mutations located within the C/E pocket. This allele was not  able  to  present  abacavir  to  T‐cells,  further  highlighting  the  importance  of specific  amino  acid  residues  located  within  the  binding  groove  of  the  HLA molecule.  The  effect  of  abacavir  treatment  on  the  peptides  eluted  from  cell  lines expressing  HLA‐B*57:01  and  HLA‐B*57:03  was  then  investigated.  HPLC fractions  of  peptides  eluted  from  cells  expressing  HLA‐B*57:01  but  not  HLA‐B*57:03 contained unmodified abacavir, indicating that the drug was associated with  the  eluted peptides. No metabolites were observed, however  as we have seen,  in some cell types metabolites are formed in very low amounts that may be  below  the  quantitative  limit  of  the  assay.  Following  drug  treatment  the characteristics  of  peptides  eluted  from  cells  expressing  HLA‐B*57:01  was 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altered. Peptides displayed an increased preference for isoleucine or leucine at PΩ.    No  effect  on  the  PΩ  residue was  observed  in  peptides  eluted  from  cells expressing HLA‐B*57:03 or HLA‐B*58:01 following drug treatment.    In  order  to  determine  the  biological  importance  of  these  observations,  the authors  generated  T‐cell  lines  from  HLA‐B*57:01  positive  volunteers.  TAP‐deficient  antigen‐presenting  cells  were  only  able  to  induce  a  T‐cell  response when  endogenous  peptides  were  supplied  in  addition  to  abacavir.  Abacavir alone was not stimulatory. This indicates the importance of antigen processing. The  authors  however  did  not  mention  whether  the  peptides  alone  i.e.  in  the absence  of  abacavir,  were  stimulatory.  This  peptide‐specific  response  led  the authors to investigate to TCR‐Vβ repertoire of responding cells. Because T‐cells were  exposed  to  a  number  of  different  peptide  epitopes  it  could  be  expected that  TCR‐Vβ  useage  would  be  polyclonal.  This  was  indeed  the  case  and  is  in agreement with data obtained from T‐cell clones, presented in Chapter 3.  A  key  aspect  of  this work was  the  elucidation  of  a  crystal  structure  of  a  self‐peptide  bound  to  HLA‐B*57:01  in  the  presence  of  abacavir.  This  structure revealed that residues previously identified as being crucial for the presentation of  abacavir  to  T‐cells  formed  direct  interactions  with  abacavir.  In  particular, Ser116  and  Asp114  were  found  to  form  hydrogen  bonds  with  the  abacavir molecule. Extensive bonds were identified between abacavir and HLA‐B*57:01, yet relatively few contacts were made between abacavir and the bound peptide. 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The  authors  also  attempted  to  apply  these  findings  to  the  interaction  of carbamazepine and HLA‐B*15:02. Fewer alterations  in peptide sequence were observed  and  these  were  confined  to  non‐anchor  positions.  The  authors however suggest that the presence of altered peptides indicates that the model is applicable to multiple forms of drug hypersensitivity.    
“Drug  hypersensitivity  caused  by  alteration  of  the  MHC­presented  self­peptide 
repertoire” (Ostrov et al. 2012)  Prior  to  performing  cellular  assays,  the  authors  utilised  computer  modelling techniques based on peptide libraries to screen HLA‐B*57:01 binding peptides and predict how abacavir could influence peptide binding. This model predicted that the affinity of peptides containing a valine, alanine or isoleucine PΩ residue would be increased in the presence of abacavir. This is slightly different to the findings  of  the  previous  papers.  Two  peptides  were  then  synthesised  which differed only at the PΩ residue. These peptides were termed pep‐V (containing a valine  residue) and pep‐W (containing a  tryptophan  residue). Based on  the  in 
silico modelling it was expected that pep‐V would only bind to HLA‐B*57:01 in the  presence  of  abacavir.  Indeed  the  binding  affinity  of  pep‐V  increased  in  a concentration  dependent  manner.  Molecular  modelling  suggested  a  potential binding  site  for  abacavir  located within  the  F  pocket  of HLA‐B*57:01  close  to Ser116. In order to investigate this further, a crystal structure of HLA‐B*57:01 and  pep‐V  in  the  presence  of  abacavir  was  solved.    In  agreement  with  the previous  study,  abacavir  was  found  to  make  extensive  contacts  with  HLA‐
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Figure  6.1  The  altered  peptide  repertoire  model.  A  non‐covalent  association  of abacavir and HLA‐B*57:01 leads to the loading of an altered set of peptides.    Our data would fit with these findings, at least for some clones. Where antigen processing  is  important  in  the  T‐cell  response  this  could  represent  the involvement  of  endogenous  self‐peptides  as  described  above  or  haptenated proteins  formed  following  drug  metabolism.  It  is  unclear  currently  how  to differentiate  between  these  mechanisms  in  vitro  as  an  altered  self‐peptide binding  to  HLA‐B*57:01  in  the  presence  of  abacavir  could  be  mimicking  a peptide modified covalently with the drug or indeed vice versa.  Other clones however were activated even when antigen‐presenting cells fixed with glutaraldehyde were used. This may be more  in  line with recent  findings from  Adam  et  al.  (2012).  A  population  of  T‐cell  clones  isolated  from  HLA‐B*57:01  positive  healthy  volunteers  was  identified  that  could  be  activated 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extremely  rapidly  (<200s)  following drug  treatment. Clearly,  the  speed of  this activation would not allow any role for metabolism or processing of haptenated proteins.   The  use  of  abacavir  analogues  has  highlighted  the  chemical  restriction  of  the abacavir‐specific  T‐cell  response.  Molecular  modelling  techniques  could  be utilised  in  order  to  explore  whether  this  restriction  is  based  on  the  direct interaction of  each of  these  compounds with HLA‐B*57:01.  In  silico modelling could also be used to identify chemical structures that do not interact with HLA‐B*57:01  with  such  high  affinity.  In  collaboration  with  The  Department  of Chemistry  at  the  University  of  Liverpool  we  are  currently  adopting  this approach.  Novel  analogues  of  abacavir  will  be  synthesized  based  on  their interaction  (or  lack  of)  with  HLA‐B*57:01  and  used  in  (1)  T‐cell  assays  to measure  immunogenicity,  (2)  metabolic  screens  and  (3)  functional  assays  to measure anti‐viral activity.  The  field of drug hypersensitivity research has advanced greatly over  the past four  years.  HLA  associations  have  been  observed  for  many  adverse  drug reactions and evidence  is building  that some of  these associations may have a functional consequence (Chessman et al., 2008, Ko et al., 2011).  As yet however few  of  these  associations  have  been  translated  into  a  clinical  setting  (Phillips and Mallal,  2009).  Further work  is  required  in order  to  establish whether  the functional  relevance  of  HLA  associations  is  applicable  to  other  types  of  drug hypersensitivity  or  whether  current  findings  are  unusual  to  the  drugs investigated  so  far.  The  strength  of  the  association may  also  be  an  important 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factor  and weak  associations with highly prevalent  alleles may not  yield  such impressive results.   In  addition,  emerging  evidence  for  the  involvement  of  T‐cells  in  DILI  is  a significant  breakthrough  (Monshi  et  al.,  2013).  Flucloxacillin‐specific  T‐cell clones  were  generated  from  5/6  patients  investigated  in  the  study,  enabling phenotypic  and  mechanistic  investigations  to  be  performed.  A  possible explanation  for  the  liver‐specific  effects  of  flucloxacillin  may  also  have  been uncovered,  in  that T‐cell  clones were  found  to express a variety of  chemokine receptors (e.g CCR4 and CCR9) which are associated with T‐cell migration to the liver.  Furthermore  T‐cell  clones were  also  generated  from  healthy  volunteers expressing the relevant risk allele (HLA‐B*57:01). In contrast to work described with  both  abacavir  and  carbamazepine,  this  was  dependent  on  including  an initial priming stage using autologous dendritic cells as antigen‐presenting cells. The  increased  antigen‐presenting  capability  of  dendritic  cells  appears  to  give the  method  greater  sensitivity  and  may  therefore  allow  the  investigation  of other drugs associated with DILI (Faulkner et al., 2012).      Abacavir  hypersensitivity  represents  an  area  in  which  novel  methodologies have  been  applied  to  interrogate  the  interaction  between  drugs,  proteins  and cells.  T‐cell  clones  isolated  from  volunteers  expressing  HLA‐B*57:01  have proven to be an incredibly useful tool in examining the mechanisms of antigen presentation  and  cytotoxicity  relevant  to  the  drug  reaction.    The  interaction between abacavir and the HLA molecule is highly specific and seemingly minor alterations  to  both  the  drug  molecule  and  the  amino  acids  within  the  HLA 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Tables  A1­A5  The  frequency  of  HLA  alleles  among  volunteers recruited to the cohort established in Chapter 2   








A*010103  0.001  0.3  0  1 
A*0101g  0.162  34.8  9  125 
A*0106  0.001  0.3  0  1 
A*020118  0.001  0.3  0  1 
A*0201g  0.199  45.7  23  153 
A*0202  0.005  1.0  0  4 
A*0205  0.005  1.0  0  4 
A*0205g  0.005  1.0  0  4 
A*0206g  0.004  0.8  0  3 
A*0207g  0.004  0.8  0  3 
A*0211g  0.004  0.8  0  3 
A*022001  0.001  0.3  0  1 
A*0222g  0.001  0.3  0  1 
A*0224  0.001  0.3  0  1 
A*030103  0.001  0.3  0  1 
A*0301g  0.108  23.1  6  83 
A*0302  0.003  0.5  0  2 
A*1101g  0.073  16.1  6  56 
A*1102  0.003  0.5  0  2 
A*2301g  0.018  3.6  0  14 
A*2402g  0.084  16.9  0  65 
A*2403g  0.001  0.3  0  1 
A*2410  0.001  0.3  0  1 
A*250101  0.008  1.6  0  6 
A*2501g  0.012  2.3  0  9 
A*2601g  0.026  5.2  0  20 
A*2901g  0.004  0.8  0  3 
A*290201  0.027  5.5  0  21 
A*3001g  0.005  1.0  0  4 
A*3002  0.008  1.6  0  6 
A*3101g  0.030  6.0  0  23 
A*3201  0.025  4.9  0  19 
A*3301  0.001  0.3  0  1 
A*330101  0.003  0.5  0  2 
A*3303g  0.010  2.3  1  8 
A*3601  0.001  0.3  0  1 
A*6601  0.001  0.3  0  1 
A*6601g  0.003  0.5  0  2 
A*6801  0.005  1.0  0  4 
A*6801g  0.016  3.1  0  12 
A*6802  0.001  0.3  0  1 
A*680201  0.005  1.3  1  4 








B*0702g  0.134  24.4  9  85 
B*070503  0.001  0.3  0  1 
B*0705g  0.006  1.3  0  5 
B*080104  0.004  0.8  0  3 
B*0801g  0.122  23.6  3  88 
B*1301  0.003  0.5  0  2 
B*130101  0.001  0.3  0  1 
B*1302  0.004  0.8  0  3 
B*130201  0.003  0.5  0  2 
B*1401  0.009  1.8  0  7 
B*140201  0.023  4.7  0  18 
B*150102  0.003  0.5  0  2 
B*1501g  0.053  10.4  1  39 
B*1502  0.010  1.8  1  6 
B*1503g  0.003  0.5  0  2 
B*1505  0.001  0.3  0  1 
B*1507  0.003  0.5  0  2 
B*151101  0.001  0.3  0  1 
B*1513  0.003  0.5  0  2 
B*1516  0.001  0.3  0  1 
B*1517  0.004  0.8  0  3 
B*1518  0.005  1.0  0  4 
B*152501  0.003  0.5  0  2 
B*1801g  0.035  7.0  0  27 
B*1802  0.001  0.3  0  1 
B*2702  0.003  0.5  0  2 
B*2705g  0.044  8.6  1  32 
B*2707  0.001  0.3  0  1 
B*3501g  0.030  6.0  0  23 
B*350201  0.004  0.8  0  3 
B*3503g  0.016  3.1  0  12 
B*3505  0.001  0.3  0  1 
B*350801  0.003  0.5  0  2 
B*370101  0.021  4.2  0  16 
B*380101  0.009  1.8  0  7 
B*3901g  0.006  1.3  0  5 
B*3905  0.001  0.3  0  1 
B*390602  0.001  0.3  0  1 
B*400103  0.001  0.3  0  1 
B*4001g  0.055  10.4  2  38 
B*4002g  0.006  1.3  0  5 
B*4006  0.010  2.1  0  8 
B*400601  0.005  1.0  0  4 
B*4101  0.003  0.5  0  2 
B*410201  0.001  0.3  0  1 







B*4403  0.047  9.1  1  34 
B*440302  0.009  1.8  0  7 
B*4404  0.001  0.3  0  1 
B*4405  0.001  0.3  0  1 
B*4501g  0.004  0.8  0  3 
B*460101  0.001  0.3  0  1 
B*4601g  0.003  0.5  0  2 
B*4701  0.003  0.5  0  2 
B*470101  0.001  0.3  0  1 
B*4801g  0.001  0.3  0  1 
B*4901  0.003  0.5  0  2 
B*490101  0.004  0.8  0  3 
B*5001  0.016  3.1  0  12 
B*5002  0.001  0.3  0  1 
B*5101g  0.048  9.4  1  35 
B*520102  0.001  0.3  0  1 
B*5201g  0.019  3.6  1  13 
B*530101  0.009  1.8  0  7 
B*5401  0.001  0.3  0  1 
B*5401g  0.001  0.3  0  1 
B*5501  0.022  4.4  0  17 
B*550201  0.003  0.5  0  2 
B*5601  0.004  0.8  0  3 
B*5601g  0.005  1.0  0  4 
B*570101  0.035  6.8  1  25 
B*570301  0.003  0.5  0  2 
B*5801g  0.008  1.6  0  6 
B*7301  0.001  0.3  0  1 








C*0102  0.021  3.9  1  14 
C*0102g  0.027  5.5  0  21 
C*020202  0.035  7.0  0  27 
C*0302  0.008  1.3  1  4 
C*030304  0.001  0.3  0  1 
C*0303g  0.061  11.9  1  45 
C*0304  0.065  12.5  2  46 
C*0401g  0.070  13.2  3  48 
C*0403  0.004  0.8  0  3 
C*0501g  0.084  16.1  3  59 
C*0602  0.083  16.1  2  60 
C*0701g  0.166  30.9  9  110 
C*0702g  0.152  27.5  11  95 
C*0704g  0.013  2.6  0  10 
C*0726  0.001  0.3  0  1 
C*080101  0.005  1.0  0  4 
C*0801g  0.009  1.6  1  5 
C*0802  0.030  6.0  0  23 
C*080301  0.001  0.3  0  1 
C*0804  0.001  0.3  0  1 
C*1202  0.018  3.4  1  12 
C*1203  0.043  8.6  0  33 
C*140201  0.010  2.1  0  8 
C*1502g  0.040  8.1  0  31 
C*1505  0.005  1.0  0  4 
C*160101  0.036  7.3  0  28 
C*1602  0.004  0.8  0  3 
C*1701g  0.003  0.5  0  2 








DRB1*010101  0.076  14.3  3  52 
DRB1*010201  0.008  1.6  0  6 
DRB1*0103  0.014  2.9  0  11 
DRB1*030101  0.128  23.9  6  86 
DRB1*0306  0.001  0.3  0  1 
DRB1*040101  0.098  18.2  5  65 
DRB1*0402  0.009  1.8  0  7 
DRB1*040301  0.016  3.1  0  12 
DRB1*0404  0.043  8.6  0  33 
DRB1*040501  0.009  1.6  1  5 
DRB1*0406  0.001  0.3  0  1 
DRB1*040701  0.009  1.8  0  7 
DRB1*0408  0.004  0.8  0  3 
DRB1*070101  0.145  26.2  10  91 
DRB1*0801  0.012  2.3  0  9 
DRB1*080302  0.004  0.8  0  3 
DRB1*090102  0.022  3.9  2  13 
DRB1*100101  0.009  1.8  0  7 
DRB1*1101  0.023  4.4  1  16 
DRB1*110101  0.012  2.3  0  9 
DRB1*110201  0.003  0.5  0  2 
DRB1*1103  0.007  1.3  0  5 
DRB1*110401  0.010  2.1  0  8 
DRB1*110601  0.004  0.8  0  3 
DRB1*111402  0.001  0.3  0  1 
DRB1*1201g  0.010  2.1  0  8 
DRB1*120201  0.012  2.3  0  9 
DRB1*130101  0.043  8.6  0  33 
DRB1*130201  0.038  7.0  2  25 
DRB1*130301  0.005  1.0  0  4 
DRB1*130501  0.003  0.5  0  2 
DRB1*1401g  0.022  3.9  2  13 
DRB1*1404  0.013  2.3  1  8 
DRB1*140501  0.001  0.3  0  1 
DRB1*1501  0.001  0.3  0  1 
DRB1*150101  0.156  28.6  10  100 
DRB1*150201  0.016  3.1  0  12 
DRB1*150202  0.001  0.3  0  1 
DRB1*1503  0.001  0.3  0  1 
DRB1*150301  0.001  0.3  0  1 
DRB1*160101  0.007  1.3  0  5 








DQB1*050101  0.001  0.3  0  1 
DQB1*0201g  0.239  42.3  21  142 
DQB1*0301g  0.155  28.1  11  97 
DQB1*030201  0.112  20.8  6  74 
DQB1*030302  0.060  11.4  2  42 
DQB1*0304  0.003  0.5  0  2 
DQB1*030501  0.001  0.3  0  1 
DQB1*0401  0.005  0.8  1  2 
DQB1*0402  0.014  2.9  0  11 
DQB1*050101  0.105  19.5  6  69 
DQB1*050201  0.013  2.6  0  10 
DQB1*050301  0.035  6.5  2  23 
DQB1*0504  0.001  0.3  0  1 
DQB1*0601  0.030  6.0  0  23 
DQB1*060201  0.138  25.5  8  90 
DQB1*060301  0.049  9.9  0  38 
DQB1*0604g  0.023  4.7  0  18 
DQB1*060801  0.001  0.3  0  1 






Gene Average SD Average SD change Average SD Average SD change
CCL11 nd - nd - - nd - nd - -
CCL3 nd - nd - - nd - nd - -
CCL4 134 108 98 75 -1.36 563 664 182 177 -3.10
CCL5 1101 1064 1095 1073 -1.01 707 321 502 262 -1.41
CCL7 nd - nd - - nd - nd - -
CCR1 156 25 80 40 -1.96 40 45 18 16 -2.19
CCR2 nd - nd - - nd - nd - -
CCR3 nd - nd - - nd - nd - -
CCR4 nd - nd - - nd - nd - -
CCR5 34 40 nd - - nd - nd - -
CD4 91 28 128 82 1.41 58 53 47 42 -1.23
CD40 109 129 46 35 -2.37 nd - nd - -
CD40LG nd - nd - - nd - nd - -
CD80 nd - nd - - nd - nd - -
CSF2 nd - nd - - nd - nd - -
CTLA4 48 15 42 25 -1.15 61 48 51 42 -1.18
CX3CL1 nd - nd - - nd - nd - -
CXCR3 120 138 75 79 -1.60 60 45 43 34 -1.42
CXCR4 5553 4741 4774 2996 -1.16 3489 3526 4156 4275 1.19
GATA3 nd - nd - - nd - nd - -
GUSB 70 26 83 46 1.19 43 48 44 49 1.02
HPRT1 104 84 81 48 -1.29 46 49 57 59 1.23
ICOS nd - nd - - nd - nd - -
IFNG nd - nd - - nd - nd - -
IL10 nd - nd - - nd - nd - -
IL12A nd - nd - - nd - nd - -
IL12B nd - nd - - nd - nd - -
IL12RB2 nd - nd - - nd - nd - -
IL13 nd - nd - - nd - nd - -
IL15 nd - nd - - nd - nd - -
IL17A nd - nd - - nd - nd - -
IL18 nd - nd - - nd - nd - -
IL18R1 45 30 35 5 -1.29 57 74 50 62 -1.13
IL1R1 nd - nd - - nd - nd - -
IL2 nd - nd - - nd - nd - -
IL4 nd - nd - - nd - nd - -
IL4R 457 416 342 240 -1.34 367 482 343 430 -1.07
IL5 nd - nd - - nd - nd - -
IL6 nd - nd - - 31 41 48 65 1.55
IL7 nd - nd - - nd - nd - -
IL8 5521 2957 4067 2057 -1.36 5909 6958 5258 6382 -1.12
IL9 nd - nd - - nd - nd - -
INHBA nd - nd - - nd - nd - -
LAG3 nd - nd - - nd - nd - -
RPL19 13266 6354 13869 7420 1.05 9887 8528 7777 7078 -1.27
TNFRSF9 nd - nd - - nd - nd - -
Control Abacavir







Gene Average SD Average SD change Average SD Average SD change
CCL11 nd - nd - - nd - nd - -
CCL3 nd - nd - - nd - nd - -
CCL4 134 108 98 75 -1.36 563 664 182 177 -3.10
CCL5 1101 1064 1095 1073 -1.01 707 321 502 262 -1.41
CCL7 nd - nd - - nd - nd - -
CCR1 156 25 80 40 -1.96 40 45 18 16 -2.19
CCR2 nd - nd - - nd - nd - -
CCR3 nd - nd - - nd - nd - -
CCR4 nd - nd - - nd - nd - -
CCR5 34 40 nd - - nd - nd - -
CD4 91 28 128 82 1.41 58 53 47 42 -1.23
CD40 109 129 46 35 -2.37 nd - nd - -
CD40LG nd - nd - - nd - nd - -
CD80 nd - nd - - nd - nd - -
CSF2 nd - nd - - nd - nd - -
CTLA4 48 15 42 25 -1.15 61 48 51 42 -1.18
CX3CL1 nd - nd - - nd - nd - -
CXCR3 120 138 75 79 -1.60 60 45 43 34 -1.42
CXCR4 5553 4741 4774 2996 -1.16 3489 3526 4156 4275 1.19
GATA3 nd - nd - - nd - nd - -
GUSB 70 26 83 46 1.19 43 48 44 49 1.02
HPRT1 104 84 81 48 -1.29 46 49 57 59 1.23
ICOS nd - nd - - nd - nd - -
IFNG nd - nd - - nd - nd - -
IL10 nd - nd - - nd - nd - -
IL12A nd - nd - - nd - nd - -
IL12B nd - nd - - nd - nd - -
IL12RB2 nd - nd - - nd - nd - -
IL13 nd - nd - - nd - nd - -
IL15 nd - nd - - nd - nd - -
IL17A nd - nd - - nd - nd - -
IL18 nd - nd - - nd - nd - -
IL18R1 45 30 35 5 -1.29 57 74 50 62 -1.13
IL1R1 nd - nd - - nd - nd - -
IL2 nd - nd - - nd - nd - -
IL4 nd - nd - - nd - nd - -
IL4R 457 416 342 240 -1.34 367 482 343 430 -1.07
IL5 nd - nd - - nd - nd - -
IL6 nd - nd - - 31 41 48 65 1.55
IL7 nd - nd - - nd - nd - -
IL8 5521 2957 4067 2057 -1.36 5909 6958 5258 6382 -1.12
IL9 nd - nd - - nd - nd - -
INHBA nd - nd - - nd - nd - -
LAG3 nd - nd - - nd - nd - -
RPL19 13266 6354 13869 7420 1.05 9887 8528 7777 7078 -1.27
TNFRSF9 nd - nd - - nd - nd - -
Control Abacavir







Gene Average SD Average SD change Average SD Average SD change
CCL11 nd - nd - - nd - nd - -
CCL3 nd - nd - - nd - nd - -
CCL4 134 108 217 241 1.62 563 664 405.1 501 -1.39
CCL5 1101 1064 964 902 -1.10 707 321 507.4 187 -1.39
CCL7 nd - nd - - nd - nd - -
CCR1 156 25 50 17 -3.11 40 45 25.5 23 -1.56
CCR2 nd - nd - - nd - nd - -
CCR3 nd - nd - - nd - nd - -
CCR4 nd - nd - - nd - nd - -
CCR5 34 40 nd - - nd - nd - -
CD4 91 28 147 116 1.61 58 53 57.5 43 -1.01
CD40 109 129 23 14 -4.73 nd - nd - -
CD40LG nd - nd - - nd - nd - -
CD80 nd - nd - - nd - nd - -
CSF2 nd - nd - - nd - nd - -
CTLA4 48 15 57 36 1.17 61 48 54.9 50 -1.10
CX3CL1 nd - nd - - nd - nd - -
CXCR3 120 138 72 38 -1.66 60 45 47.1 32 -1.28
CXCR4 5553 4741 2441 756 -2.28 3489 3526 2326.2 2754 -1.50
GATA3 nd - nd - - nd - nd - -
GUSB 70 26 135 126 1.95 43 48 51.4 55 1.19
HPRT1 104 84 46 11 -2.29 46 49 44.5 48 -1.04
ICOS nd - nd - - nd - nd - -
IFNG nd - nd - - nd - nd - -
IL10 nd - nd - - nd - nd - -
IL12A nd - nd - - nd - nd - -
IL12B nd - nd - - nd - nd - -
IL12RB2 nd - nd - - nd - nd - -
IL13 nd - nd - - nd - nd - -
IL15 nd - nd - - nd - nd - -
IL17A nd - nd - - nd - nd - -
IL18 nd - nd - - nd - nd - -
IL18R1 45 30 36 11 -1.24 57 74 45.4 55 -1.25
IL1R1 nd - nd - - nd - nd - -
IL2 nd - nd - - nd - nd - -
IL4 nd - nd - - nd - nd - -
IL4R 457 416 273 142 -1.68 367 482 354.4 476 -1.04
IL5 nd - nd - - nd - nd - -
IL6 nd - nd - - 31 41 38.3 59 1.24
IL7 nd - nd - - nd - nd - -
IL8 5521 2957 2967 1882 -1.86 5909 6958 4289.6 4693 -1.38
IL9 nd - nd - - nd - nd - -
INHBA nd - nd - - nd - nd - -
LAG3 nd - nd - - nd - nd - -
RPL19 13266 6354 16976 10744 1.28 9887 8528 8501.7 7824 -1.16
TNFRSF9 nd - nd - - nd - nd - -
B*57:01 Positive B*57:01 Negative







Gene Average SD Average SD change Average SD Average SD change
CCL11 nd - nd - - nd - nd - -
CCL3 nd - nd - - nd - nd - -
CCL4 134 108 162 108 1.22 563 664 619 761 1.10
CCL5 1101 1064 983 1064 -1.12 707 321 538 333 -1.31
CCL7 nd - nd - - nd - nd - -
CCR1 156 25 146 25 -1.07 40 45 45 57 1.13
CCR2 nd - nd - - nd - nd - -
CCR3 nd - nd - - nd - nd - -
CCR4 nd - nd - - nd - nd - -
CCR5 34 40 nd - - nd - nd - -
CD4 91 28 91 28 -1.00 58 53 59 57 1.02
CD40 109 129 33 129 -3.29 nd - nd - -
CD40LG nd - nd - - nd - nd - -
CD80 nd - nd - - nd - nd - -
CSF2 nd - nd - - nd - nd - -
CTLA4 48 15 51 15 1.05 61 48 63 61 1.03
CX3CL1 nd - nd - - nd - nd - -
CXCR3 120 138 73 138 -1.64 60 45 60 62 1.00
CXCR4 5553 4741 3131 4741 -1.77 3489 3526 3203 3283 -1.10
GATA3 nd - nd - - nd - nd - -
GUSB 70 26 71 26 1.02 43 48 42 48 -1.03
HPRT1 104 84 100 84 -1.04 46 49 54 54 1.16
ICOS nd - nd - - nd - nd - -
IFNG nd - nd - - nd - nd - -
IL10 nd - nd - - nd - nd - -
IL12A nd - nd - - nd - nd - -
IL12B nd - nd - - nd - nd - -
IL12RB2 nd - nd - - nd - nd - -
IL13 nd - nd - - nd - nd - -
IL15 nd - nd - - nd - nd - -
IL17A nd - nd - - nd - nd - -
IL18 nd - nd - - nd - nd - -
IL18R1 45 30 49 30 1.08 57 74 54 75 -1.06
IL1R1 nd - nd - - nd - nd - -
IL2 nd - nd - - nd - nd - -
IL4 nd - nd - - nd - nd - -
IL4R 457 416 207 416 -2.20 367 482 341 442 -1.08
IL5 nd - nd - - nd - nd - -
IL6 nd - nd - - 31 41 36 54 1.17
IL7 nd - nd - - nd - nd - -
IL8 5521 2957 4720 2957 -1.17 5909 6958 6704 8421 1.13
IL9 nd - nd - - nd - nd - -
INHBA nd - nd - - nd - nd - -
LAG3 nd - nd - - nd - nd - -
RPL19 13266 6354 13123 6354 -1.01 9887 8528 9042 7614 -1.09
TNFRSF9 nd - nd - - nd - nd - -
B*57:01 Positive B*57:01 Negative






Gene Average SD Average SD change Average SD Average SD change
CCL11 nd - nd - - nd - nd - -
CCL3 455 28 1757 36 3.86 28 34 36 49 1.30
CCL4 1107 267 1805 236 1.63 267 69 236 163 -1.13
CCL5 939 600 972 562 1.04 600 494 562 412 -1.07
CCL7 327 23 208 36 -1.57 nd - nd - -
CCR1 235 44 137 48 -1.72 44 43 48 44 1.09
CCR2 nd - nd - - nd - nd - -
CCR3 nd - nd - - nd - nd - -
CCR4 nd - nd - - nd - nd - -
CCR5 74 19 61 12 -1.21 nd - nd - -
CD4 71 37 47 36 -1.50 37 46 36 37 -1.01
CD40 68 30 106 19 1.56 nd - nd - -
CD40LG nd - nd - - nd - nd - -
CD80 nd - nd - - nd - nd - -
CSF2 nd - nd - - nd - nd - -
CTLA4 98 67 137 79 1.41 67 64 79 78 1.18
CX3CL1 nd - nd - - nd - nd - -
CXCR3 41 41 101 38 2.46 41 33 38 36 -1.07
CXCR4 2100 1897 3258 1781 1.55 1897 1560 1781 1534 -1.06
GATA3 nd - nd - - nd - nd - -
GUSB 87 48 106 46 1.22 48 52 46 48 -1.04
HPRT1 100 55 86 60 -1.17 55 52 60 58 1.09
ICOS 40 21 31 16 -1.28 nd - nd - -
IFNG nd - nd - - nd - nd - -
IL10 nd - nd - - nd - nd - -
IL12A nd - nd - - nd - nd - -
IL12B nd - nd - - nd - nd - -
IL12RB2 nd - nd - - nd - nd - -
IL13 nd - nd - - nd - nd - -
IL15 nd - nd - - nd - nd - -
IL17A nd - nd - - nd - nd - -
IL18 nd - nd - - nd - nd - -
IL18R1 47 44 66 50 1.40 44 61 50 63 1.15
IL1R1 35 15 112 15 3.20 nd - nd - -
IL2 nd - nd - - nd - nd - -
IL4 nd - nd - - nd - nd - -
IL4R 130 102 213 79 1.64 102 92 79 82 -1.30
IL5 nd - nd - - nd - nd - -
IL6 156 28 1497 84 9.60 28 45 84 139 2.98
IL7 nd - nd - - nd - nd - -
IL8 11475 2634 42123 4215 3.67 2634 2646 4215 3453 1.60
IL9 nd - nd - - nd - nd - -
INHBA nd - nd - - nd - nd - -
LAG3 nd - nd - - nd - nd - -
RPL19 10791 7279 10990 7206 1.02 7279 7620 7206 7517 -1.01
TNFRSF9 nd - nd - - nd - nd - -
B*57:01 Positive B*57:01 Negative






Gene Average SD Average SD change Average SD Average SD change
CCL11 nd - nd - - nd - nd - -
CCL3 455 28 134 102 -3.39 28 34 63 62 2.26
CCL4 1107 267 1437 2002 1.30 267 69 489 272 1.83
CCL5 939 600 824 498 -1.14 600 494 568 253 -1.06
CCL7 327 23 102 140 -3.19 nd - nd - -
CCR1 235 44 87 70 -2.70 44 43 28 3 -1.56
CCR2 nd - nd - - nd - nd - -
CCR3 nd - nd - - nd - nd - -
CCR4 nd - nd - - nd - nd - -
CCR5 74 19 92 118 1.25 nd - nd - -
CD4 71 37 46 22 -1.53 37 46 31 38 -1.19
CD40 68 30 22 13 -3.12 nd - nd - -
CD40LG nd - nd - - nd - nd - -
CD80 nd - nd - - nd - nd - -
CSF2 nd - nd - - nd - nd - -
CTLA4 98 67 134 36 1.38 67 64 54 68 -1.26
CX3CL1 nd - nd - - nd - nd - -
CXCR3 41 41 48 31 1.17 41 33 34 16 -1.21
CXCR4 2100 1897 2926 3759 1.39 1897 1560 927 712 -2.05
GATA3 nd - nd - - nd - nd - -
GUSB 87 48 74 31 -1.16 48 52 45 49 -1.06
HPRT1 100 55 115 102 1.14 55 52 52 38 -1.05
ICOS 40 21 41 55 1.02 nd - nd - -
IFNG nd - nd - - nd - nd - -
IL10 nd - nd - - nd - nd - -
IL12A nd - nd - - nd - nd - -
IL12B nd - nd - - nd - nd - -
IL12RB2 nd - nd - - nd - nd - -
IL13 nd - nd - - nd - nd - -
IL15 nd - nd - - nd - nd - -
IL17A nd - nd - - nd - nd - -
IL18 nd - nd - - nd - nd - -
IL18R1 47 44 79 68 1.68 44 61 36 37 -1.20
IL1R1 35 15 66 80 1.87 nd - nd - -
IL2 nd - nd - - nd - nd - -
IL4 nd - nd - - nd - nd - -
IL4R 130 102 150 133 1.15 102 92 52 48 -1.98
IL5 nd - nd - - nd - nd - -
IL6 156 28 211 351 1.35 28 45 118 191 4.18
IL7 nd - nd - - nd - nd - -
IL8 11475 2634 16269 13533 1.42 2634 2646 4918 4653 1.87
IL9 nd - nd - - nd - nd - -
INHBA nd - nd - - nd - nd - -
LAG3 nd - nd - - nd - nd - -
RPL19 10791 7279 11686 4656 1.08 7279 7620 8439 10365 1.16
TNFRSF9 nd - nd - - nd - nd - -
B*57:01 Positive B*57:01 Negative






Gene Average SD Average SD change Average SD Average SD change
CCL11 nd - nd - - nd - nd - -
CCL3 455 28 645 576 1.42 28 34 117 64 4.21
CCL4 1107 267 1773 1188 1.60 267 69 1488 1732 5.57
CCL5 939 600 633 427 -1.48 600 494 444 287 -1.35
CCL7 327 23 383 117 1.17 nd - 232 179 -
CCR1 235 44 261 176 1.11 44 43 74 67 1.68
CCR2 nd - nd - - nd - nd - -
CCR3 nd - nd - - nd - nd - -
CCR4 nd - nd - - nd - nd - -
CCR5 74 19 173 169 2.35 nd - nd - -
CD4 71 37 36 15 -1.97 nd - nd - -
CD40 68 30 124 29 1.82 nd - 43 10 -
CD40LG nd - nd - - nd - nd - -
CD80 nd - nd - - nd - nd - -
CSF2 nd - nd - - nd - nd - -
CTLA4 98 67 136 59 1.39 67 64 66 73 -1.01
CX3CL1 nd - nd - - nd - nd - -
CXCR3 41 41 58 41 1.41 41 33 38 34 -1.06
CXCR4 2100 1897 1677 1764 -1.25 1897 1560 841 257 0.44
GATA3 nd - nd - - nd - nd - -
GUSB 87 48 75 44 -1.16 48 52 55 75 1.15
HPRT1 100 55 135 98 1.35 55 52 47 22 0.86
ICOS 40 21 37 43 -1.08 nd - nd - -
IFNG nd - nd - - nd - nd - -
IL10 nd - nd - - nd - nd - -
IL12A nd - nd - - nd - nd - -
IL12B nd - nd - - nd - nd - -
IL12RB2 nd - nd - - nd - nd - -
IL13 nd - nd - - nd - nd - -
IL15 nd - nd - - nd - nd - -
IL17A nd - nd - - nd - nd - -
IL18 nd - nd - - nd - nd - -
IL18R1 47 44 70 66 1.48 44 61 40 42 0.92
IL1R1 35 15 39 53 1.11 nd - nd - -
IL2 nd - nd - - nd - nd - -
IL4 nd - nd - - nd - nd - -
IL4R 130 102 260 227 2.00 102 92 117 105 1.14
IL5 nd - nd - - nd - nd - -
IL6 156 28 386 381 2.47 28 45 65 54 2.29
IL7 nd - nd - - nd - nd - -
IL8 11475 2634 15481 17044 1.35 2634 2646 3079 2771 1.17
IL9 nd - nd - - nd - nd - -
INHBA nd - nd - - nd - 58 70 -
LAG3 nd - nd - - nd - 34 28 -
RPL19 10791 7279 9307 3426 -1.16 7279 7620 8648 9415 1.19
TNFRSF9 nd - nd - - nd - nd - -
B*57:01 Positive B*57:01 Negative






Gene Average SD Average SD change Average SD Average SD change
CCL11 nd - nd - - nd - nd - -
CCL3 57 64 88 78 1.53 nd - nd - -
CCL4 324 212 516 488 1.59 413 532 353 462 -1.17
CCL5 520 366 652 571 1.26 541 380 504 378 -1.07
CCL7 nd - nd - - nd - nd - -
CCR1 51 42 43 11 -1.18 nd - nd - -
CCR2 nd - nd - - nd - nd - -
CCR3 nd - nd - - nd - nd - -
CCR4 nd - nd - - nd - nd - -
CCR5 42 60 27 29 -1.54 nd - nd - -
CD4 78 45 70 39 -1.12 63 77 46 57 -1.37
CD40 53 18 53 19 -1.01 nd - nd - -
CD40LG nd - nd - - nd - nd - -
CD80 nd - nd - - nd - nd - -
CSF2 nd - nd - - nd - nd - -
CTLA4 84 21 102 26 1.21 41 51 39 41 -1.06
CX3CL1 nd - nd - - nd - nd - -
CXCR3 45 16 48 17 1.06 30 30 23 21 -1.30
CXCR4 1841 1607 1834 1496 1.00 601 229 730 410 1.21
GATA3 nd - nd - - nd - nd - -
GUSB 83 27 76 32 -1.01 62 81 56 69 -1.12
HPRT1 98 79 97 71 -1.01 37 15 41 18 1.10
ICOS nd - nd - - nd - nd - -
IFNG nd - nd - - nd - nd - -
IL10 nd - nd - - nd - nd - -
IL12A nd - nd - - nd - nd - -
IL12B nd - nd - - nd - nd - -
IL12RB2 nd - nd - - nd - nd - -
IL13 nd - nd - - nd - nd - -
IL15 nd - nd - - nd - nd - -
IL17A nd - nd - - nd - nd - -
IL18 nd - nd - - nd - nd - -
IL18R1 56 57 81 87 1.43 nd - nd - -
IL1R1 nd - nd - - nd - nd - -
IL2 nd - nd - - nd - nd - -
IL4 nd - nd - - nd - nd - -
IL4R 210 74 184 60 -1.14 84 69 70 69 -1.21
IL5 nd - nd - - nd - nd - -
IL6 nd - nd - - nd - nd - -
IL7 nd - nd - - nd - nd - -
IL8 3013 2583 3524 2081 1.17 819 945 957 1033 1.17
IL9 nd - nd - - nd - nd - -
INHBA nd - nd - - nd - nd - -
LAG3 nd - nd - - nd - nd - -
RPL19 11803 6376 12823 6747 1.09 9705 11841 9767 12299 1.01
TNFRSF9 nd - nd - - nd - nd - -
B*57:01 Positive B*57:01 Negative






Gene Average SD Average SD change Average SD Average SD change
CCL11 nd - nd - - nd - nd - -
CCL3 57 64 60 52 1.04 nd - nd - 1.79
CCL4 324 212 279 264 -1.16 413 532 282 230 -1.46
CCL5 520 366 613 509 1.18 541 380 503 298 -1.07
CCL7 nd - nd - - nd - nd - -
CCR1 51 42 91 103 1.80 nd - nd - -
CCR2 nd - nd - - nd - nd - -
CCR3 nd - nd - - nd - nd - -
CCR4 nd - nd - - nd - nd - -
CCR5 42 60 36 27 -1.19 nd - nd - -
CD4 78 45 56 41 -1.41 63 77 34 50 -1.83
CD40 53 18 nd - - nd - nd - -
CD40LG nd - nd - - nd - nd - -
CD80 nd - nd - - nd - nd - -
CSF2 nd - nd - - nd - nd - -
CTLA4 84 21 75 52 -1.13 41 51 37 42 -1.10
CX3CL1 nd - nd - - nd - nd - -
CXCR3 45 16 nd - - 30 30 nd - -
CXCR4 1841 1607 1653 1491 -1.11 601 229 521 266 -1.15
GATA3 nd - nd - - nd - nd - -
GUSB 83 27 68 39 -1.21 62 81 41 46 -1.52
HPRT1 98 79 110 75 1.13 37 15 45 29 1.20
ICOS nd - nd - - nd - nd - -
IFNG nd - nd - - nd - nd - -
IL10 nd - nd - - nd - nd - -
IL12A nd - nd - - nd - nd - -
IL12B nd - nd - - nd - nd - -
IL12RB2 nd - nd - - nd - nd - -
IL13 nd - nd - - nd - nd - -
IL15 nd - nd - - nd - nd - -
IL17A nd - nd - - nd - nd - -
IL18 nd - nd - - nd - nd - -
IL18R1 56 57 73 64 1.30 nd - nd - -
IL1R1 nd - nd - - nd - nd - -
IL2 nd - nd - - nd - nd - -
IL4 nd - nd - - nd - nd - -
IL4R 210 74 102 75 -2.07 84 69 43 5 -1.98
IL5 nd - nd - - nd - nd - -
IL6 nd - nd - - nd - nd - -
IL7 nd - nd - - nd - nd - -
IL8 3013 2583 6714 9810 2.23 819 945 2846 2238 3.48
IL9 nd - nd - - nd - nd - -
INHBA nd - nd - - nd - nd - -
LAG3 nd - nd - - nd - nd - -
RPL19 11803 6376 14638 7301 1.24 9705 11841 11175 13855 1.15
TNFRSF9 nd - nd - - nd - nd - -
B*57:01 Positive B*57:01 Negative






Gene Average SD Average SD change Average SD Average SD change
CCL11 nd - nd - - nd - nd - -
CCL3 57 64 154 129 2.69 nd - 63 40 -
CCL4 324 212 468 327 1.44 413 532 466 508 1.13
CCL5 520 366 434 356 -1.20 541 380 332 210 -1.63
CCL7 nd - nd - - nd - nd - -
CCR1 51 42 215 18 4.24 nd - nd - -
CCR2 nd - nd - - nd - nd - -
CCR3 nd - nd - - nd - nd - -
CCR4 nd - nd - - nd - nd - -
CCR5 42 60 135 151 3.18 nd - nd - -
CD4 78 45 122 82 1.55 63 77 80 115 1.28
CD40 53 18 143 34 2.67 nd - nd - -
CD40LG nd - nd - - nd - nd - -
CD80 nd - nd - - nd - nd - -
CSF2 nd - nd - - nd - nd - -
CTLA4 84 21 93 39 1.10 41 51 71 55 1.73
CX3CL1 nd - nd - - nd - nd - -
CXCR3 45 16 33 20 -1.36 30 30 29 24 -1.02
CXCR4 1841 1607 1339 769 -1.37 601 229 425 155 0.71
GATA3 nd - nd - - nd - nd - -
GUSB 83 27 84 51 1.02 62 81 49 60 -1.26
HPRT1 98 79 124 76 1.26 37 15 51 37 1.37
ICOS nd - nd - - nd - nd - -
IFNG nd - nd - - nd - nd - -
IL10 nd - nd - - nd - nd - -
IL12A nd - nd - - nd - nd - -
IL12B nd - nd - - nd - nd - -
IL12RB2 nd - nd - - nd - nd - -
IL13 nd - nd - - nd - nd - -
IL15 nd - nd - - nd - nd - -
IL17A nd - nd - - nd - nd - -
IL18 nd - nd - - nd - nd - -
IL18R1 56 57 62 53 1.09 nd - nd - -
IL1R1 nd - nd - - nd - nd - -
IL2 nd - nd - - nd - nd - -
IL4 nd - nd - - nd - nd - -
IL4R 210 74 237 99 1.13 84 69 86 43 1.02
IL5 nd - nd - - nd - nd - -
IL6 nd - nd - - nd - nd - -
IL7 nd - nd - - nd - nd - -
IL8 3013 2583 2020 1609 -1.49 819 945 621 645 -1.32
IL9 nd - nd - - nd - nd - -
INHBA nd - nd - - nd - nd - -
LAG3 nd - nd - - nd - nd - -
RPL19 11803 6376 9117 4351 -1.29 9705 11841 7909 8555 -1.23
TNFRSF9 nd - nd - - nd - nd - -
B*57:01 Positive B*57:01 Negative
Control Tetanus Control Tetanus
